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ABSTRACT
Humans have exploited plant alkaloids as medicines since at least the Neolithic
Era. Today, alkaloids such as vinblastine (isolated from Catharanthus roseus) and
morphine (isolated from Papaver somniferum) are prescribed to treat various cancers and
relieve pain, respectively. Despite this storied use and palpable presence in the current
pharmacopeia, relatively little is known about the biosynthesis, regulation and transport
of these molecules.
For example, monoterpene indole alkaloid (MIA) biosynthesis, a set of metabolic
pathways that produces hundreds of bioactive natural products, has not been fully
elucidated in any organism. Here we examine the biosynthesis of secologanin, which
contributes the monoterpene moiety to all MIAs. Specifically, we excavate C. roseus
transcriptomic datasets to identify 1 0-hydroxygeraniol oxidoreductase, a missing step in
secologanin biosynthesis. 10-hydroxygeraniol oxidoreductase catalyzes the oxidation of
both hydroxyl moieties of 10-hydroxygeraniol to form 10-oxogeranial, which is the
substrate for iridoid synthase, the reductive cyclase that assembles the characteristic
iridoid scaffold.
Despite having an incomplete understanding of MIA biosynthesis, several
engineering strategies have been successfully deployed to incorporate halogenation into
the MIA machinery and yield halogenated alkaloids. Although alkaloids and plant natural
products have been used to treat various diseases, these compounds have not evolved
specifically to do so. Therefore, these compounds frequently require editing to effectively
tune their biological and pharmacological activities. We also describe efforts to
reengineer tryptophan halogenase RebH to preferentially install chlorine onto tryptamine,
the direct indole precursor for the MIAs. After reengineering RebH, we then over-
expressed the tryptamine-specific mutant RebH Y455W and flavin reductase RebF in C.
roseus and observed the de novo biosynthesis of a chlorinated unnatural natural product
12-chloro- 19,20-dihydroakuammicine.
Lastly, we describe the serendipitous discovery of a P. somniferum codeine-O-
demethylase mutant that selectively demethylates codeine, a benzylisoquinoline alkaloid
involved in morphine biosynthesis, instead of both codeine and thebaine. This mutant
may selectively disable a redundant route in the biosynthesis of morphine that has been
associated with poor seed and licit opium quality.
Thesis Advisor: Sarah E. O'Connor
Title: Professor, The John Innes Centre and the University of East Anglia
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Introduction: Recent Progress in the Metabolic Engineering of Alkaloids
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I. Introduction
Medicinal plants and the natural products derived from them have been
exploited for thousands of years. For example, opium poppy has been employed
both as an anaesthetic and a conduit to the spiritual world since at least the
Neolithic Era.1'2 Independently, the blue petals of some periwinkle varieties are
said to invoke a sense of calm in Hoodoo practices (traditional African-American
folk magic), while the leaves are believed to strengthen conjugal vows if sewn
into a couple's mattress.2
The alkaloids themselves-isolated from poppy, periwinkle and other
medicinal plants-have a particularly long and storied narrative as well. This
history is highlighted in the life of Cleopatra, who used alkaloid-containing
extracts from belladonna (Italian for 'beautiful woman') to dilate her pupils so as
to increase her beauty and thereby disarm her enemies.3 Far from being
confined to ancient chronicles, the alkaloids retain a palpable presence in today's
clinics. For example, optometrists still apply eye drops containing the alkaloid
atropine, an active component of belladonna, to dilate the pupil during routine
eye exams.3
It is unsurprising that most alkaloids are bioactive given that evolutionary
processes select for the biosynthesis of products that confer an advantage to the
producing organism. Despite the rich ethnopharmacological tradition and high
usage of alkaloids in the modern era, relatively little is known about the
biosynthesis, regulation and transport of these molecules. Access to these potent
pharmaceuticals frequently pivots upon isolation from their native producers;
20
isolation typically requires laborious separation techniques that often result in low
yields. Lacking a more sophisticated understanding of alkaloid biosynthesis
significantly impedes our ability to co-opt nature's machinery in order to
overproduce-that is, to metabolically engineer-these valuable compounds.
Notably, many drug screening efforts exclude plant natural products
because of their high production costs and instead screen larger numbers of
simpler synthetic molecules, which can be produced inexpensively and in fewer
chemical steps.4 Typically these high throughput screens are enriched with
aromatic, sp 2 -rich compounds that are obtained from commercial vendor
libraries.5 While these compounds have been useful for certain targets such as
kinase inihibition, this area of chemical space is not always ideal for drug-like
molecules.4'5 In contrast, natural products and compounds inspired by natural
products occupy a 'privileged' drug-like space, and comprise nearly half of all
FDA approved drugs.5 7 Importantly, natural products nearly always have more
chiral carbons-a metric of complexity-than compounds typically found in
commercial vendor libraries.5 Given that natural products have specifically
evolved to bind to cellular targets and exhibit some bioactivity that is beneficial to
the host organism, it is hardly surprising that natural products are enriched for
bioactivity, while relatively flat compounds uninspired by natural product
structures typically fail pharmaceutical screens.8
Given the successes of getting natural products through the drug pipeline,
we contend that more natural products-including plant alkaloids-should be
included in drug screens. Plant natural products have a high success rate as
21
candidates and leads.6'7 While the chemical syntheses of plant natural products,
particularly the alkaloids, are dramatically improving,9 many syntheses are still
too lengthy for commercial production or require industrially impractical
separation steps. Therefore, alternative production platforms must be developed,
evaluated and instituted. An increasing body of work enlists microbes as well as
cell and tissue cultures to produce these valuable plant-derived products.7
Biological systems have the potential to be scalable and selective, while
simultaneously being more environmentally friendly and-importantly-less
expensive than synthetic reactions.7
In this chapter, we highlight recent metabolic engineering efforts designed
to improve production of selected plant-derived alkaloids. We focus on the
monoterpene indole alkaloids (MIAs), the benzylisoquinoline alkaloids (BlAs) and
the glucosinolates. Though not classically classified as alkaloids, the
glucosinolates are nitrogen-containing compounds that have been the subject of
a compelling body of research that will inform the forward engineering of all plant
natural products. In total, these three classes of plant-derived nitrogen-containing
natural products have been the subject of recent research efforts aimed at
discovering and manipulating cellular activities, which include enzymatic function,
metabolite transport and regulatory control. Ultimately this work may lead to
biotechnologically useful enzymes and new drug candidates. Throughout this
chapter, we also highlight the challenges that arise in attempting to chart the
underexplored landscape of plant biosynthesis. Lastly, the chapter concludes by
contextualizing the scope of this thesis.
22
11. The Monoterpene Indole Alkaloids
A. Introduction
The monoterpene indole alkaloids (MIAs) have garnered interest over the
past few decades largely because of vinblastine 8 and vincristine 9, two potent
and widely prescribed anti-cancer agents that are currently produced solely
through harvest from the leaves of mature periwinkle plants (Catharanthus
roseus). 0 The concentrations of vinblastine and vincristine per gram of dry leaf
material are approximately 0.01% and 0.003%, respectively, and are greatly
dependent upon plant growth conditions." Their low yields and lengthy
production timeline have elicited intense efforts to engineer higher titers of these
medicinally important MIAs.
The MIAs are encountered most commonly in the Apocynaceae,
Loganiaceae and Rubiaceae families.12 Most MIAs are built from the secoiridoid
secologanin 3 and the indole-containing molecule tryptamine 2 (Figure 1a) [9].
Strictosidine synthase (STS) condenses these two molecules via a Pictet-
Spengler condensation that forms strictosidine 4, The P-carboline backbone that
is formed via STS exhibits over 25 unique activities, highlighting the 'privileged'
status of this class of compounds. 7,13
Strictosidine 4-the central precursor in MIA metabolism-is believed to
ultimately succumb to either of two chemical fates.1 4'15 If the plant is not under
herbivore attack, strictosidine 4 is deglucosylated and rearranged into the over
3000 MIAs found in nature.15 Madagascar periwinkle contains a subset of
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approximately 130 MIAs. Alternatively, if the plant is under herbivore attack, the
strictosidine 4 pool (estimated to be approximately 10 mM in periwinkle leaf
epidermal cells hormonally treated to mimic herbivore attack) can be directed to
the nucleus for mass deglucosylation, leading to a reactive dialdehyde species
capable of cross-linking proteins. This mechanism has been dubbed the
strictosidine nuclear 'bomb' in reference to the 'mustard oil bomb' mechanism of
glucosinolate biosynthesis (see below).15 Importantly, many of the MIA
metabolites themselves have also been implicated in plant defense strategies. 6
B. Obtaining the Building Blocks for Metabolic Engineering Efforts-A Case Study
on the Discovery of P450s Involved in MIA biosynthesis
The enzymatic pathways leading to the MIAs have not yet been fully
elucidated in any organism. These uncharacterized biochemical steps may utilize
novel chemistries or possess informative and interesting specificities that enable
the enzymes to be employed in various synthetic metabolic pathway designs.17,18
Notably, many plants-including MIA producers-are predicted to contain a high
percentage of cytochromes P450 (P450s). Some estimates place P450s at
approximately 1 % of representative plant genomes,19 over 5-fold higher than the
proportion of P450s found in the human genome.2 0 By using molecular oxygen to
tailor hydrocarbon skeletons, P450s facilitate a panel of difficult chemical
transformations and are consequently utilized in many alkaloid biosynthetic
pathways.18
24
P450s have also been successfully engineered for biotechnological
purposes.221 Various technologies, such as nanodiscs,2 and N-terminus
reengineering efforts21 have improved the expression of membrane-bound
P450s, making this class of enzymes accessible to a full suite of biochemical and
biophysical characterization techniques. Given the high sequence similarity of
P450s, identifying a P450 that facilitates a specific biochemical reaction within a
biosynthetic pathway remains a challenge. This has greatly slowed the discovery
and characterization of new P450s within the plant kingdom. However, Giddings
et al. recently used co-expression analysis to identify P450s with expression
profiles similar to known MIA biosynthetic genes.1 7 By functionally assaying these
candidates in Saccharomyces cerevisiae, Giddings et al. discovered one P450
(CYP71BJ1) that hydroxylated the 19 position of either lochnericine or
tabersonine 7, an intermediate that is positioned at a metabolic branch point.1 7
Hydroxylation of tabersonine 7 at the 16 position commits the intermediate to
vindoline and vinblastine 8 biosynthesis, whereas hydroxylation at the 19 position
commits the molecule to 19-0-acetylh6rhammericine formation.1 7 Controlling this
switch may be important in engineering efforts designed to improve the titres of
vindoline and vinblastine 8. Moreover, similar strategies must be employed to
find other missing pathway steps in MIA biosynthesis (Chapter 2) and other
natural product pathways.
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Figure 1.1: (A) The monoterpene indole alkaloid (MIA) pathway. TDC,
tryptophan decarboxylase; STS, strictosidine synthase; Gic, glucose. (B)
Introduction of halogenation into the MIA pathway. RebH and PyrH are both
flavin-dependent halogenases from actinomycetes species; STSvm,
strictosidine synthase Val214Met mutant. (C) Reengineering of halogenase to
preferentially chlorinate tryptamine 2 over the natural substrate tryptophan
1 (Chapter 3).
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C. Engineering 'Unnatural' Natural Products
Plant alkaloids often require modification to improve their pharmacological
properties prior to human consumption. Halogenation, particularly fluorination
and chlorination, is a pervasive modification in successful pharmaceutical
candidates.23 24 Halogens often confer the potency of a drug, alter its
pharmacokinetics or function as site-specific handles for subsequent
modification. 2 Halogens can be introduced into MIA pathways by a number of
methods. One particular example employed mutasynthesis, a process whereby
natural biosynthesis is first blocked by genetic silencing of the natural precursor,
and then rescued by feeding with structural analogs of the precursor.26 In this
case, in conjunction with the RNAi-mediated knockdown of tryptophan
decarboxylase (TDC), unnatural tryptamine 2 analogs were added to a
chemically 'silent'-non-alkaloid producing-background and fluorinated MIA
analogs were observed.26 In a separate engineering strategy, strictosidine
synthase (STS)-the enzyme situated at the first committed step of MIA
biosynthesis-was engineered to accept an expanded range of halogenated
tryptamine 2 precursors; 27 the utility of this enzyme was demonstrated in planta
by feeding previously unaccepted unnatural precursors to C. roseus hairy roots.28
Finally, Runguphan et al. interfaced RebH and PyrH-two tryptophan
halogenases isolated from soil-dwelling actinomycetes species-with the MIA
metabolism of periwinkle to produce halogenated natural products de novo [24]
(Figure 1 b). However, the lines overexpressing both RebH and RebF also
displayed a brown and slow growth morphology. 29 Runguphan et al.
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hypothesized that this morphology was the result of the accumulation of 7-
chlorotryptan la, an analog of primary metabolite L-tryptophan 1 that is
somewhat structurally similar to 4-chloroindole-3-acetic acid, an auxin known to
be involved in regulating plant growth. 29
To circumnavigate this problem, Glenn et al. employed structure-guided
protein design to engineer a halogenase that preferentially chlorinated tryptamine
2, a more direct MIA precursor (Figure 1C) (Chapter 3).30 Microgram per gram
fresh weight quantities of 12-chloro-19,20-dihydroakuamicine 5a were observed
with this strategy, but neither 7-chlorotryptophan la nor 7-chlorotryptamine 2a
accumulated in planta, indicating the chlorinated precursor was being effectively
shuttled into MIA metabolism [25]. Engineering halogenation into MIA
metabolism highlights an important need to interface specialized metabolism with
primary carbon and nitrogen metabolism.
I1. The benzylisoquinoline alkaloids
A. Introduction
Benzylisoquinoline alkaloids (BlAs) are found mainly in the Papaveraceae,
Ranunculaceae, Berberidaceae and Menispermaceae plant families.
Approximately 2500 BIAs have been isolated to date.31 This class of compounds
has been used throughout human history and contains pharmaceuticals that are
still widely used today, including the narcotic and analgesic morphine 28, the
cough suppressant codeine 26, the muscle relaxant papaverine, and the anti-
microbial agents sanguinarine 19 and berberine 29. All known BIAs, like the
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MIAs, are derived from a single intermediate, which, for this class of compounds,
is norcoclaurine 13. Norcoclaurine synthase (NCS) catalyzes the Pictet-Spengler
condensation between dopamine 11 and 4-hydroxyphenylacetaldehyde 12 to
yield the central intermediate, norcoclaurine 13.
Notably, the biosynthetic pathways of several benzylisoquinoline
alkaloids-morphine 28, sanguinarine 19 and berberine 29-have been fully
elucidated at the genetic level, which has enabled sophisticated metabolic
engineering approaches. The application of metabolic engineering strategies for
BIAs has focused predominantly on improving the yields of specific alkaloid
compounds that exhibit medicinal value (Table 1.1).
B. Enzyme Discovery and Engineering in BIA Pathways
Several outstanding efforts in enzyme discovery have been reported for
BIA biosynthetic pathways. In a recent effort, Hagel et al. characterized two 0-
demethylases that are involved in morphine biosynthesis, completing the
characterization of the morphinan pathway (Figure 2B).3 This work also clearly
highlighted how co-expression analysis can be used to discover enzymes with
unprecedented catalytic function. These enzymes offer the first examples of non-
heme iron(II) oxoglutarate dioxygenases capable of catalyzing O-demethylation.
Codeine-0-demethylase (CODM) regioselectively demethylates codeine 26 and
thebaine 22 at the 3-position, while thebaine-6-0-demethylase (T60DM)
demethylates thebaine 22 and oripavine 24 at the 6-position. Swapping amino
acid regions between the two demethylases resulted in a CODM mutant that
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selectively demethylates codeine (Figure 2B) (Chapter 4).33 This mutant-which
effectively sidesteps oripavine 24 production by committing thebaine 22 to just
one of two possible routes-could potentially impact titers of codeine 26 and
morphine 28 in subsequent metabolic engineering efforts. Collectively, these
studies highlight how characterizing individual pathways steps and understanding
their specificity and selectivity can both inform and enable metabolic engineering
efforts.
While transcript analysis has proven to be spectacularly successful in
elucidating the demethylases of morphine 28 biosynthesis, Winzer et al. provide
a rare example of gene clustering in a BIA pathway. 34 The authors describe a 10-
gene cluster in the poppy genome that putatively encodes the entire biosynthetic
pathway of the BIA noscapine 15. This is the first gene cluster discovered for an
alkaloid pathway, and it is the largest plant gene cluster discovered to date. The
authors further successfully silenced six of the ten proposed genes using VIGS to
validate their role in noscapine 15 biosynthesis.34 This study indicates that
genomic data, in addition to expression data, can be used to decipher alkaloid
pathways in plants.
C. Engineering in Native Hosts
In one of the earliest attempts to engineer BIA-producing plants, RNA
interference (RNAi) was used to silence the expression of codeinone reductase
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in the opium poppy.35 COR, the penultimate enzyme of morphine biosynthesis,
converts codeinone 25 to codeine 26 (Figure 2b). While one might anticipate that
the silencing of COR would lead to elevated levels of codeinone 25, the study
found instead that COR-silenced plants accumulated reticuline 14-an
intermediate seven steps upstream of codeinone 25-at the expense of
morphine 28, codeine 26, oripavine 24 and thebaine 22. A feedback mechanism
was proposed as an explanation for the elevated levels of reticuline 14, though
testing this hypothesis has yielded conflicting results.35
Other early attempts to improve the yields of BIA alkaloids include the
overexpression of berberine bridge enzyme (BBE) in Eschscholzia califomica
root cultures. This effort resulted in elevated levels of downstream alkaloids and
decreased levels of amino acids, though notably levels of tyrosine 10-the amino
acid employed in BIA synthesis-were unaltered. 6 Conversely, the antisense
suppression of BBE expression led to the effective silencing of BIA production
and increased cellular amino acid levels, though, again, tyrosine 10 levels went
largely unchanged (less than two-fold higher than in control lines).37 Nonetheless,
these two studies highlight how perturbations in alkaloid metabolism can impact
primary metabolism.6' 37 More recent studies suggest, however, that the RNAi
suppression of BBE in E. californica leads to increased accumulations of (S)-
reticuline 14 instead of various canonical amino acids.38 These contradictory
results are surprisingly common in the metabolic engineering of alkaloids in
plants and cell cultures and provide us with the impetus to understand these
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pathways in greater detail, paying specific attention to their biochemical and
molecular regulatory elements.
D. Reconstituting BIA Biosynthesis into Microbial Systems
Many pathways in BIA biosynthesis are fully characterized, which opens
the possibility of transplanting entire alkaloid pathways into microbial hosts.
Though relatively difficult, the reconstitution of entire metabolic pathways into
microbial hosts confers a number of advantages, including rapid biomass
accumulation, facile purification and access to the host of tools available for
workhorse organisms like E. coli and S. cerevisiae. A number of recent reports
have successfully reconstituted portions of BIA pathways into S. cerevisiae, E.
coli and combinations thereof in co-culture systems.3 9-41 For example, Hawkins et
al. were able to produce reticuline 14 as well as sanginarine/berberine-type and
morphinan-type BIAs in yeast by over-expressing genes from mixed plant
sources and human. 40 Notably, they were also able to tune enzyme expression
levels through use of a glucocorticoid-inducible promoter and in situ promoter
titration. 5 This level of tuning enables maximal pathway flux and minimal enzyme
expression. The expression system is nominally taxed under these conditions,
since valuable cellular resources are not used on the biosynthesis of
supernumerary proteins and nucleic acids.
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IV. The Glucosinolates
A. Introduction
The glucosinolates are not classified as alkaloids, although, along with the
alkaloids, these compounds are amino acid-derived, nitrogen-containing small
molecules of plant origin. The glucosinolates are included in this chapter because
the recent and creative metabolic engineering studies performed on this class of
compounds will undoubtedly inform the forward engineering of all plant natural
products, particularly the alkaloids, which also contain nitrogen. Glucosinolates
are sulfur- and nitrogen-containing compounds that are derived from glucose and
various amino acids (Figure 3A).42 They are found in cruciferous vegetables (the
Brassicaceae plant family) and have been shown to possess a range of
bioactivities.42 The glucosinolates occupy an essential space in the chemical
ecology of their host organisms by attracting specialist crucifer pollinators and
insects and deterring predatory herbivores.43 Specifically, crucifers employ
myrosinases (hydrolases) to cleave the glucose moiety of glucosinolates in
response to predation and herbivory (Figure 3B).44 The myrosinases and
glucosinolates are physically segregated within the plant, coming into contact
only upon disruption of the plant tissue (Figure 3B). 44 Upon hydrolysis, the
resultant unstable aglycone intermediate spontaneously rearranges into the
corresponding isothiocyanate via a Lossen-type rearrangement.44 The three
known types of specifier proteins, Thiocyanate-Forming Proteins (TFPs), Nitrile-
Forming Proteins (NFPs) and Epithiospecifier Proteins (ESPs)-which can be
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found in planta or in various specialist insects-can redirect glucosinolate
hydrolysis from isothiocynate products toward thiocyanate, simple nitrile and
epithionitrile products, respectively (Figure 3B).44 Notably, many specifiers can
direct glucosinolate hydrolysis to more than one product.44 Early workers on this
plant defense and pollination system dubbed it 'The Mustard Oil Bomb'.43 To
date, over 120 glucosinolates have been identified. 45
B. Improving Yields in Non-Native Hosts
The reconstitution of entire metabolic pathways into heterologous plant
hosts requires the use of efficient and facile 'gene stacking' methodologies. A
spectacularly successful example is the engineering of benzylglucosinolate
biosynthesis into Nicotiana benthamiana. Benzylglucosinolate was reconstituted
in N. benthamiana using a transient expression system. In this study, Geu-Flores
et al. identified a y-glutamyl peptidase bottleneck, suggesting that reduced sulfur
is incorporated into glucosinolates via glutathione conjugation (Figure 3A).42 The
co-expression of this peptidase augmented the yield of benzylglucosinolate 5.7-
fold, indicating how consideration of primary metabolite resources can impact
natural product yield.42
In a separate metabolite analysis, Moldrup et al. monitored the
accumulation of desulfobenzylglucosinolate, the penultimate product in the
benzylglucosinolate pathway.46 Directing sulfur from primary to secondary
metabolism through the co-expression of adenosine 5-phosphosulfate kinase-
which provides the 3'-phosphoadenosine-5'-phosphosulfate (PAPS) co-
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-substrate necessary for the final step of benzylglucosinolate biosynthesis
(Figure 3A)-in the N. benthamiana expression system alleviated the subsequent
bottleneck and increased the benzylglucosinolate yield by 16-fold.46
In yeast, Mikkelsen et al. were able to reconstitute the biosynthesis of
indolylglucosinolate.45 This example was a proof-of-concept study for a
technology that enables the stacking of large numbers of genes, a requirement
for total pathway reconstitution. Notably, the benzylglucosinolate biosynthetic
pathway has also been stably transformed into Nicotiana tabacum, another non-
cruciferous plant, which does not normally produce glucosinolates.47 This
reengineered plant has been shown to attract the diamondback moth (Plutella
xylostella) and encourage oviposition (the deposition of eggs), highlighting its
potential utility as a dead-end trap crop to deter predatory insects and prevent
billion-dollar damages to cruciferous crops worldwide.47
Forward engineering in non-native hosts is particularly attractive if the
product distribution converges to one or a few products. This obviates the need
for taxing and costly separation procedures and can allow for rapid biomass
accumulation. Moreover, forward engineering can increase product gains, as the
engineering takes place in a nearly or completely chemically silent background.
In contrast, over-expressing or silencing single genes in the context of normal
plant primary and secondary metabolism typically does not significantly alter the
product profile.
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V. Scope of Thesis
This thesis-Understanding and Manipulating Alkaloid Biosynthesis-
commences with an effort to identify 10-hydroxygeraniol oxidoreductase activity
in Madagascar periwinkle (Chapter 2). 10-hydroxygeraniol oxidoreductase is an
enzyme involved in the biosynthesis of secologanin, the terpenoid precursor for
all MIAs. A high proportion of genes in the C. roseus transciptomic datasets are
predicted to facilitate oxidation or reduction steps, making the discovery of the
physiologically relevant enzymes(s) involved in this transformation difficult.
Despite having an incomplete understanding of MIA biosynthesis, the
pathway has still been amenable to various engineering strategies, most notably
incorporation of halogens. Chapter 3 discusses our efforts to engineer
halogenation into periwinkle by redesigning RebH, a tryptophan halogenase, to
preferentially chlorinate tryptamine, a direct MIA precursor. We subsequently
incorporated this reengineered halogenase into alkaloid biosynthesis and
observed the de novo biosynthesis of a halogenated 'unnatural' natural product.
The final research chapter (Chapter 4) explores mixing-and-matching
closely related protein sequences in benzylisoquinoline alkaloid biosynthesis to
generate an enzyme with novel activity. Specifically, we systematically swapped
residues from PsT60DM-a dioxygenase that demethylates the 6 position of
oripavine and thebaine-into PsCODM, a dioxygenase that demethylates the 3
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position of thebaines and codeine. The resulting enzyme was a PsCODM mutant
that was specific for codeine. This switch in selectivity does not readily correlate
with the substrate specificity of the parent enzymes. This chapter highlights the
difficulty of rationally redesigning enzymes. Nonetheless, because the mutant is
specific for codeine, it could presumably be used in reconstitution efforts to
disable a redundant route in morphine biosynthesis.
The thesis closes with major conclusions of the work discussed within this
text followed by the grand challenges and future work of the field (Chapter 5).
From folk magic to clinics, plant-derived natural products have an exciting and
storied past and hopefully a rich and expansive future.
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Chapter 2
Discovery of 10-hydroxygeraniol Oxidoreductase Activity in C. roseus
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I. Introduction
The iridoids constitute a sizable class of natural products and boast an
equally impressive repertoire of biological activities (Figure 2.1).12 Despite their
utility as both pharmaceuticals and pest repellents, many steps of iridoid
biosynthesis are unknown.' 2 The enzymatic reactions within this pathway have
both captivated and challenged scientists for decades. Ultimately, understanding
this pathway could potentially decrypt novel enzymatic function. Moreover,
understanding iridoid biosynthesis will aid in the production of these valuable fine
chemicals in tractable heterologous hosts.
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Figure 2.1: Structures of three representative plant iridoids. Glc, glucose.
Iridoids are composed of a bicyclic 10-carbon skeleton that is derived from
the condensation of dimethylallyl pyrophosphate (DMAPP) 4 and isopentyl
pyrophosphate (IPP) 5.2 Subsequently, geraniol synthase dephosphorylates this
10-carbon unit-geranyl pyrophosphate 6-to form geraniol 7.3 In the first
committed step of iridoid terpene biosynthesis, geraniol 10-hydroxylase
(G1OH)-a cytochrome P450-hydroxylates geraniol 7 at position 10, forming
1 0-hydroxygeraniol 8.4
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The pathway from 10-hydroxygeraniol 8 to secologanin 15, the direct
precursor to monoterpene indole alkaloid formation, contains approximately eight
steps, at least three of which are unknown (Figure 2.2).2 Namely, the enzyme(s)
that facilitates oxidation of the di-alcohol 10-hydroxygeraniol 8 to the di-aldehyde
10-oxogeranial 9 is unknown.2 However, alcohol dehydrogenases are known to
catalyze the oxidation of alcohols and are therefore strongly implicated in this
transformation. Likewise, the enzyme(s) that facilitates conversion of nepetalactol
10 to 7-deoxyloganic acid aglycone 12 is unknown.2 Notably, this conversion
may require as many as three unique enzymes. The first predicted step in this
conversion-a hydroxylation reaction-is likely cytochrome P450-dependent.
The oxidation of the resultant alcohol 11 to the carboxylic acid 12 may employ
the same cytochrome P450 or require separate dehydrogenases. Namely, a
dehydrogenase may convert the alcohol 11 to an aldehyde, then the aldehyde to
the carboxylic acid. Alternatively, a dedicated alcohol dehydrogenase may
convert the alcohol 11 to an aldehyde, and a disparate aldehyde dehydrogenase
may convert the resulting aldehyde to the carboxylic acid 12. Finally, the enzyme
responsible for the glucosylation of the 7-deoxyloganin aglycone 13 is unknown,
though a glucosyl transferase is strongly implicated in this transformation.2
Importantly, it is perfectly feasible to imagine that the glucosyl transferase could
also act on nepetalactol 10 or any intermediate prior to acid formation.
Intriguingly, the glucosylation of nepetalactol 10 directly-prior to P450
oxidation-would prove strongly redolent of flavonoid biosynthesis.5 While some
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substrate specificity studies have been performed with crude plant lysates, the
order of these reactions has not yet been established definitively.6
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Figure 2.2: The proposed biosynthesis of iridoid secologanin 16. From 10
hydroxygeraniol 8 to secologanin 16, a direct monoterpene indole alkaloid
precursor, at least three enzymatic steps are unknown. Glc, glucose; OPP,
pyrophosphate.
As outlined above, chemical logic allows us to sensibly hypothesize the
enzyme class responsible for each unknown pathway step. Further, advances in
sequencing technologies and statistical methods equip us to identify and assess
the biological function of candidate genes of interest. This chapter focuses on the
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discovery and characterization of 10-hydroxygeraniol oxidoreductase, the
enzyme that catalyzes the conversion of 1 0-hydroxygeraniol 8 to 1 0-oxogeranial
9. This enzyme acts on the substrate positioned at the seat of iridoid biosynthesis
and produces the substrate for iridoid synthase, a reductive cyclase that
assembles the bicyclic iridoid scaffold.
Previous attempts to identify the 10-hydroxygeraniol oxidoreductase were
confined to protein isolation from iridoid-containing plants.' 8  Specifically,
Hallahan et al. demonstrated that oxidoreductase activity found in Nepeta
racemosa (catmint) leaf extracts converted 10-hydroxygeraniol 8 to 10-
oxogeranial 9 in an NADP*-dependent fashion (NAD' is not accepted). The
enzyme of interest-a heterodimer comprised of one 40 kDa subunit and one 42
kDa subunit-was purified 1150-fold, though not to apparent homogeneity.
Consequently, no protein sequence is reported.7
In a separate study, Ikeda et al. purified to apparent homogeneity a 44-
kDa oxidoreductase from Rauwolfia serpentina cell cultures that converted 10-
hydroxygeraniol 8 to 10-oxogeranial 9.8 This enzyme was shown to be NADP'-
dependent (while NAD+ is not accepted) and, based on atomic absorption
spectroscopy, to bind zinc ions. Moreover, in contrast to previously characterized
alcohol dehydrogenases from higher plants, this enzyme appears to function as a
monomer based on gel filtration chromatography and SDS PAGE analysis.
Strikingly, the first 21 residues of alcohol dehydrogenases isolated from maize,
pea and Arabidopsis exhibit high sequence homology, with 13 of the N-terminal
residues conserved.8 However, the N-terminus of the purified protein from R.
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serpentina-N H2-NQQXXTKVTKMVYKLVLVNTY-did not display significant
homology to previously characterized alcohol dehydrogenases or to proteins
registered in the Protein Data Bank. To the best of our knowledge, the 10-
hydroxygeraniol oxidoreductase gene from R. serpentina has not been cloned,
and the full sequence has not been reported.
While previous studies relied upon protein isolation-an arduous, but
state-of-the-art technique when sequence data is unavailable-we trawled
recently acquired C. roseus transcriptomic datasets in this study to 'fish out'
genes of interest.9 Specifically, we selected genes of interest by employing the
'guilt-by-association' principle, whereby uncharacterized, but functionally
annotated genes are baited with genes of known function-in this case, genes
known to be involved in C. roseus iridoid biosynthesis.110 Genes functionally
predicted to catalyze alcohol dehydrogenation that also cluster with known iridoid
biosynthetic genes in hierarchical clustering algorithms are assigned as prime
10-hydroxygeraniol oxidoreductase candidates. These candidates are
subsequently assessed for length completeness, cloned from the complementary
DNA (cDNA) of C. roseus, expressed heterologously, then assayed for the
desired activity. Importantly, the N-terminus of the oxidoreductase isolated from
R. serpentina displays no significant sequence homology to any transcripts in the
C. roseus assemblies or to genes registered within the Plant Genomic Database.
Efficiently mining large datasets for genes of interest is currently a major
challenge in the field of plant enzyme discovery." In the most recent C. roseus
transcriptomic assembly, approximately 1.2% (about 400) of the gene transcripts
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(0.6% heme-dependent and 0.6% non-heme-dependent) are functionally
predicted to facilitate redox reactions!-a figure that undergirds terrestrial plants'
expansive oxidoreductive landscape. Notably, however, the 'guilt-by-association'
principle has been successfully employed previously with C. roseus
transcriptomic data sets to bait the genes of missing pathway steps, including the
reductive cyclase responsible for iridoid scaffold assembly.' 0 This chapter
describes our efforts to excavate C. roseus transcriptomic datasets to unearth
the alcohol dehydrogenase(s) responsible for the oxidation of 10-hydroxygeraniol
8 to 10-oxogeranial 9, a missing step in iridoid biosynthesis.
II. Results and Discussion
The oxidation of the di-alcohol 10-hydroxygeraniol 8 to the di-aldehyde 10-
oxogeranial 9 strongly invokes catalysis via an alcohol dehydrogenase.
Therefore, in a principle known as 'guilt-by-association,' we mined C. roseus
transcriptome assemblies for alcohol dehydrogenases with similar expression
patterns to known genes in iridoid biosynthesis.
The most recent C. roseus transcriptome assembly contains
approximately 33,000 transcripts.9 To facilitate the mining process, we employed
various transcript filtering conditions. For example, Dr. Fernando Geu-Flores
filtered the data set based on gene expression in leaves and methyl jasmonate
elicitation. Genes either not expressed or only poorly expressed [fragments per
kilobase of exon per million (FPKM) values < 2] in leaves can be discarded, as
iridoid biosynthesis is known to occur in leaves. We postulate that 10-
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hydroxgeraniol oxidoreductase expression is high in leaves. Similarly, methyl
jasmonate is known to upregulate iridoid biosynthesis.12 Therefore, genes non-
elicited by methyl jasmonate may also be discarded. Approximately 4,500
transcripts remain after these constraints are enforced.
Additionally, in three separate filters, I retained only the 5000 most highly
expressed genes in C. roseus immature leaves, mature leaves and hairy roots,
respectively. Because iridoid-containing molecules are isolated from each of
these three tissues, we conjecture that iriodoid biosynthetic genes should be
highly expressed in these tissues as well. Transcripts with FPKM values less
than zero in each of these tissue samples were discarded.
We then employed hierarchical clustering analyses on each of the four
filtered assemblies to correlate gene expression levels across the 17 different
tissue samples. Transcripts were imported into Multiple Experiment Viewer 4_7,
then clustered using the hierarchical clustering algorithm based on Pearson
Correlation as the distance metric and average linkage clustering as the linkage
selection method. A representative cluster (cluster based on both high leaf
expression and methyl jasmonate elicitation) is shown below (Figure 2.3).
In addition to hierarchical clustering, we also treated the data with another
type of analysis called mutual ranking analysis. Using a preliminary transcriptome
dataset (C. roseus transcriptome assembly 1), Geu-Flores et al. generated a
mutual ranking list based on gene expression likeness to geraniol 10-
hydroxylase, the enzyme directly upstream of 1 0-hydroxygeraniol
oxidoreductase.' Specifically, Geu-Flores et al. calculated the Pearson
52
Correlation Coefficients (PCCs) for each contig that passed the methyl
jasmonate elicitation and high leaf expression filters. Genes were ranked in
descending order according to their PCCs for geraniol 10-hydroxylase. This list is
the forward ranking list. To obtain the reverse ranking list, Geu-Flores et aL.
computed the PCCs for the 200 best-correlated contigs in the forward list against
each other. The mutual rank (Table 2.1) is the square root of the forward and
reverse product:
Equation 2.1: Mutual Rank = [(forward rank)(reverse rank)]112
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ID Mut Rank PCC Rev Rank Fwd Rank MRV Annotation Comments
2665_iso=1 1 0.989099123 2 1 1.414 p450 Cytochrome P450
9933 iso=1 2 0.974834433 3 2 2.449 ---
34690_iso=1 3 0.972471793 3 3 3 --- ---
9710_iso=1 4 0.965799646 4 4 4 p450 Cytochrome P450
13334_iso=1 5 0.964354354 5 5 5 GcpE 4-hydroxy-3-methylbut-2-en-1-y diphosphate synthase, bacterial-type
729 iso=1 6 0.957657585 4 10 6.325 --- Iridoid Synthase
42065 iso=1 7 0.962529328 7 6 6.481 --- ---
17224 iso=1 8 0.9620476 6 7 6.481 DXP redisom 1-deoxy-D-xylulose 5-phosphate reductoisomerase, C-terminal5089_Iso=1 9 0.955826582 5 11 7.416 ADH zincN Candidate 5743
15157_iso=2 10 0.959631421 7 8 7.483 MTHFR Methylenetetrahydrofolate reductase
37738_iso=3 11 0.953962234 5 12 7.746
12882_iso=1 12 0.9340208 3 20 7.746 UDPGT UDP-glucuronosyl/UDP-glucosyltransferase
17468 iso=1 13 0.958511244 8 9 8.485 zf-Dof Zinc finger, Dof-type
18942 iso=1 14 0.947575109 8 13 10.2 polyprenyl-sy Polyprenyl synthetase
36044 iso=1 15 0.942874239 9 15 11.62 DUF581 Protein of unknown function DUF581
39905 iso=1 16 0.945957994 13 14 13.49 --- _ ---
2437 iso=1 17 0.933503619 9 21 13.75 YgbB 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase, core3272_iso=1 18 0.929045736 8 26 14.42 GcpE 4-hydroxy-3-methylbut-2-en-1-yi diphosphate synthase, bacterial-type
7526_iso=1 19 0.916690108 6 37 14.9 --- ---
3938_iso=1 20 0.94046914 15 17 15.97 GHMP kinase. GHMP kinase, C-terminal
1136_iso=1 21 0.921921584 9 33 17.23 Aldedh Aldehyde dehydrogenase
43316 iso=1 22 0.936586676 19 18 18.49 --- _ ---
9680_iso=2 23 0.887353468 4 98 19.8 HLH Helix-loop-helix DNA-binding domain
8952 iso=1 24 0.907762934 7 57 19.97 --- ---
31515_iso=1 25 0.941437245 32 16 22.63 LRRNT_2 Leucine-rich repeat-containing N-terminal domain, type 2
Table 2.1 The top 25 contigs from a mutual rank with Geraniol 10-hydroxylase. Candidate 5743 ranks 9th and is shown in red.ID, transcript number in C. roseus transcriptome dataset 1; Mut Rank, Mutual Rank; PCC, Pearson Correlation Coefficient; Rev,Reverse; Fwd, Forward; MRV, Mutual Ranking Value.
After selecting alcohol dehydrogenases from each of these analyses, we
then assessed each candidate for length by comparing the longest open reading
frame across all C. roseus assembly data with the top-ranking BLAST (Basic
Local Alignment Search Tool) hit. Partial length genes were discarded. Next, we
assessed each gene for its predicted sub-cellular localization by submitting
sequences to the TargetP 1.1 server. 3 Genes strongly (i.e. confidence level 1)
predicted to localize to the chloroplast, mitochondria or endoplasmic reticulum
(ER) were discarded, as all early iridoid biosynthetic steps are cytosolic, including
the characterized steps directly before (i.e. G10H) and after (i.e. iridoid synthase)
10-hydroxygeraniol oxidoreductase. Notably, the P450-dependent enzyme G10H
is anchored to the ER membrane, but catalysis occurs within the cytoplasm.
Eight candidates were retained after all constraints were enforced; the
filter(s) and hierarchical cluster(s) in which the candidates appear are shown in
Table 2.2. Table 2.2 also displays the mutual rank order, if the candidate
appeared on the mutual ranking list. Candidate 5743 had a mutual rank of 9,
making it the highest-ranking candidate on the mutual ranking list.
Candidate Me3a+Leaf Immat. Leaf Hairy Root Root Mutual Rank Cytosol
1786 X X X Not Found X
26 X X X 103 X
4319 X X Not Found
5743 X X X X 9
7220 X Not Found X
8694 165
2041 X 91
580 X X X X Not Found X
Table 2.2: Candidate filter summary. 'X' signifies that the candidate passed the
filter restraints and was identified in the corresponding cluster. Geraniol 10-
hydroxylase mutual rank is provided if the candidate is found on the list. Meja,
methyl jasmonate; Immat., immature.
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Notably, four of the final eight candidates are predicted with varying
confidence levels to localize to the ER, according to TargetP 1.1 (Table 2.3). The
candidates were retained, however, because the signal peptide predictor SignalP
4.1 server failed to identify any regions likely to function as signal peptides for
any of these candidates.1 4 Moreover, none of the candidates are strongly
predicted to localize to the ER. Significantly, Candidate 5743 is one of the
candidates predicted, albeit with low confidence (i.e. confidence level 5), to enter
the secretory pathway and localize to the ER. We postulate that the high cysteine
content (15 cysteine residues in the 378-residue primary structure) likely
relegates this candidate to the ER in the prediction algorithm. Notably, however,
Ikeda et al. indirectly implicated sulfhydryl groups in 10-hydroxygeraniol
oxidoreductase catalysis by incubating the oxidase from R. serpentina with a
thiol-reactive Michael acceptor (i.e. N-ethyl maleimide) and observing significant
activity attenuation.8 Therefore, Candidate 5743-which co-expresses well with
known iridoid biosynthetic genes, according to both hierarchical clustering
analyses and mutual ranking-was retained in the screen even though the
prediction algorithms suggested it was unlikely to localize to the cytosol.
Candidate Chloroplast Mitochondria ER Other Confidence
1786 0.193 0.130 0.122 0.519 4
26 0.180 0.165 0.035 0.406 4
4319 0.102 0.023 0.850 0.042 2
5743 0.589 0.028 0.607 0.063 5
7220 0.197 0.261 0.024 0.557 4
8694 0.140 0.038 0.321 0.645 4
2041 0.268 0.078 0.278 0.092 5
580 0.009 0.326 0.159 0.606 4
Table 2.3: TargetP1.1 localization prediction. Strongest predictions are
highlighted in yellow. High confidence = 1; low confidence = 5. Confidence
values reflect the difference between the two highest predictions.
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Faced with cloning multiple genes, we employed USER cloning, a ligation-
free, cassette-based expression method. Each gene, except for Candidate 580,
which could not be cloned from C. roseus cDNA, was successfully cloned into
the USER cassette (gene and protein sequences are provided in Appendix A). All
candidate expression trials were run in RosettaTM 2 E. coli, a host strain
optimized for rapid and robust eukaryotic protein expression. Proteins were
expressed and purified with an N-terminal histidine tag (His6). Five of the seven
cloned candidates-candidates 1786, 26, 4319, 5743 and 7220-expressed well
Theoretical Predicted
Candidate Mass (kDa) pI Expression?
1786 40.7 5.27 yes
26 32.5 5.22 yes
4319 40.0 7.63 yes
5743 40.4 6.27 yes
7220 33.4 5.71 yes
8694 42.9 5.76 no/poor
2041 42.9 6.57 no/poor
Table 2.4: Summary of data from candidate expression in Rosetta 2 cells. Five of
the 7 cloned candidates expressed robustly. Theoretical masses listed are the
predicted average masses using the ExPASy server.
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(Table 2.4; Figure 2.4) and were subsequently assayed for 1 0-oxogeranial 9
formation from 1 0-hydroxygeraniol 8.
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Figure 2.4: SDS PAGE gels of candidate expression and purification. A.
Expression of Candidates 1786, 26 and 4319. Each of these candidates
expressed well. B. Expression of Candidate 5743. C. The expression trials of
Candidates 7220 and 8694. Candidate 7220 expressed well under the
conditions highlighted in the method section, whereas Candidate 8604 did
not. D. Expression trial of Candidate 2041. Candidate 2041 did not express
well under the conditions of the screen (methods section). Red boxes
highlight the fractions that were pooled, concentrated and buffer exchanged
into 20 mM MOPS (pH 7.0) for subsequent assay.
Each of the five well-expressed candidates was screened for 10-
oxogeranial 9 formation by both thin layer chromatography (TLC) and gas
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chromatography - mass spectrometry (GC-MS). Positive hits-candidates that
produced 10-oxogeranial 9-were further assessed with a battery of controls to
test for zinc and cofactor (NAD+ or NADP+) dependence (Appendix A). Namely,
we conducted the following control experiments on positive hits: (1) no enzyme
controls, where enzyme was omitted from the assay; (2) no NAD' or NADP+
controls, where these cofactors were omitted from the assay; (3) no zinc controls,
where no ZnCl 2 was added to the assay mixture; and (4) chelator controls, where
1 mM EDTA (ethylene diamine tetraacetic acid) was added to the assay and
ZnCl 2 was omitted. The summary of those experiments is shown below in Table
2.5; the TLC controls and all GC-MS data are supplied in Appendix A.
I Candidate Screen I TIC I Ic~uc 
15743 EDTA + No Zinc Yes Yes Yes Yes
INo NAD(P)+ Controls No No No No
No Enzyme Controls No No No No
Table 2.5: Summary of the candidate screen with TLC and GC-MS. 'Yes' indicates that
10-oxogeranial 9 formation was observed. 'No' indicates that 10-oxogeranial 9
formation was not observed. 'N/A' indicates that the candidate was not screened
under said conditions (No controls with Candidate 26 were conducted on TLC
because product formation was not observed via TLC.) Experiments for each
candidate are grouped.
The TLC screen identified two candidates-Candidates 1786 and 5743-
that can utilize either NAD+ or NADP+ to form 1 0-oxogeranial 9, based on co-
migration with an authentic standard (Figure 2.5). To confirm 10-oxogeranial 9
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formation via TLC, we also performed a coupled assay with a representative
positive hit (Candidate 5743 with NAD+) and iridoid synthase, the enzyme directly
downstream of 10-hydroxygeranial oxidoreductase. In aqueous media,
nepetalactol 10-the iridoid synthase product-forms a range of hydrates, which
most standard TLC stains fail to detect readily. Therefore, we monitored 10-
oxogeranial disappearance rather than nepetalactol 10 formation. The spot that
co-elutes with 10-oxogeranial 9 was metabolized in the coupled assay, whereas
the same spot was retained in the control experiment with only Candidate 5743
and NAD+, confirming 1 0-oxogeranial 9 formation (Figure 2.6).
A. Candidates with NAD+
Candiates
4M Produc
*w Substae
Homnhs: EtOk (1:1)
B. Candidates with NADP+
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E Product
Hemms: EtOAc (1:1)
Figure 2.5: TLC screens of candidates with (A) NAD+ and (B) NADP+. Candidates
1786 and 5743 accept both NAD+ and NADP+ to form 10-oxogeranial, the
authentic standard of which is on the right of both sets of TLCs. TLC plates are
stained with anisaldehyde.
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Figure 2.6: Coupled assay with Candidate 5743 (NAD+) and iridoid synthase. In
the presence of iridoid synthase and NADPH (right), the spot that co-migrates
with 10-oxogeranial 9 (middle) disappears. The 10-oxogeranial standard is
shown on the left. The iridoid synthase product, nepetalactol 10, forms a range of
hydrates in aqueous media, which are not readily detected by anisaldehyde.
For both Candidate 1786 and Candidate 5743, product formation occurs only in
the presence of the enzyme and NAD+ or NADP+. Product formation was still
observed when zinc was omitted from the assay, suggesting that either Zn2+ is
unnecessary for catalysis, or more likely that the enzyme co-purifies with metal
bound during expression in LB media supplemented with 100 pM ZnC 2.
PredZinc, a zinc binding predction server with 75% accuracy for known zinc-
binding proteins, predicts zinc-binding sites at positions C43, H64, C94, C97 and
C100 for Candidate 1786 and positions C51, H72, C102, C105 and C108 for
Candidate 5743.17
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Intriguingly, the addition of EDTA to the assay mixture in conjunction with
the omission of ZnCl2 only quelled product formation with Candidate 1786 when
NADP+ was employed, suggesting Zn2+ binds more weakly with this co-factor.
The addition of chelator EDTA did not disrupt product formation for Candidate
1786 with NAD+ or for Candidate 5743 with either NAD+ or NADP*.
We also confirmed 10-oxogeranial 9 formation with GC-MS, specifically by
co-elution with an authentic standard and spectral similarity to the standard's
fragmentation pattern. Representative traces of positive hits are shown in Figure
2.7; all other traces are provided in Appendix A.
The GC-MS results were in good agreement with the TLC results, except
GC-MS-a more sensitive technique than TLC-identified an additional positive
hit. Specifically, GC-MS identified that Candidate 26 exclusively employs NADP+
to form 10-oxogeranial (NAD* is not accepted). Candidate 26 also forms product
when zinc is omitted from the assay and when the EDTA is added to the assay
and zinc is omitted. Again, these results suggest that either the candidate does
not require Zn2+ for catalysis or more likely that the enzyme co-purifies with metal
bound during protein expression LB media supplemented with 100 pM ZnCl2.
PredZinc predicted no zinc-binding residues for Candidate 26.16 Intriguingly,
however, Candidate 26 is the only candidate that accepts NADP+ exclusively,
which is in agreement with previously reported 10-hydroxygeraniol
oxidoreductase activities purified from other plants. 7,8
62
2
A. 10-
2
61 14LLiJ
~ *;~
I
5.2
L
4.2
___ U* If t
10-hydrxygeraniol A
I-oxogeranialA
CandidateCandidats 574- Nc
xogeranial Authentic Standard
B. Candidate 5743 - NADP+
JP2 J!
Uthnftic Standard
uthenlic Standard
to 5743 - NADP*
NAD(P)* Control
10.50 10.55 10.60 10.65 10.70 10.75 10.80 10.865 10.90 10.96 11.00 11
Time (minutes)
Figure 2.7: Gas Chromatography - Mass Spectroscopy (GC-MS) chromatograms and spectra of a representative
positive hit (Candidate 5743 with NADP+ - Blue). Candidate 5743 with NADP+, shown in blue, co-elutes with an
authentic standard of 10-oxogeranial (Black). The GC spectra of both the authentic standard of 10-oxogeranial
(black) and Candidate 5743 with NADP+ (blue) are shown in insets A and B. Magnified spectra are provided in
Appendix A. The fragmented ions are identical in the assay and the authentic standard, which confirms 10-
oxogeranial 9 formation in the assay. Notably, 10-oxogeranial 9 is not formed in the control lacking NAD(P)+ (shown
in red). The enzymatic substrate, 10-hydroxygeraniol 8 is shown in green.
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Having confirmed product formation via GC-MS, we have successfully
identified three candidates (Candidates 1786, 26 and 5743) that may prove
useful in reconstituting iridoid biosynthesis, most notably secologanin
biosynthesis, for biotechnological purposes. Importantly, preliminary experiments
suggest that candidate 5743 functions well in efforts to reconstitute nepetalactol
(Sherden and O'Connor, unpublished). However, we also aim to understand the
physiological relevance of these candidates. A silencing effect-whereby the
candidate gene is knocked down and a distinct metabolic phenotype emerges-
would physiologically validate or revoke candidates in this screen, proving or
disproving their relevancy to iridoid biosynthesis in C roseus.
Assuming no functional redundancy, silencing the 10-hydroxygeraniol
oxidoreductase could result in the accumulation of substrate, 10-hydroxygeraniol
8, and a decrease in downstream iridoids and iridoid-derived alkaloids. It is
important to note, however, that the plant could potentially derivatize 10-
hydroxygeraniol 8 to prevent its accumulation. In this case, we would not observe
an accumulation of 10-hydroxygeraniol 8, but would still expect a decrease in
downstream iridoid or monoterpene indole alkaloid production. We can use
Virus-Induced Gene Silencing (VIGS) to test this hypothesis. VIGS utilizes the
tobacco rattle virus platform, a bipartite vector system that hijacks the plant's own
defense system to degrade the cognate mRNA of interest and thereby potentially
induce a transient gene silencing effect.1 7 Importantly, VIGS has been shown to
be effective in C. roseus for a number of genes involved in monoterpene indole
alkaloid biosynthesis.17
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Here, 478-base pair regions in both candidates 1786 and 5743 were
targeted for knockdown (candidate 26 was not prepared in time for the first round
of VIGS experiments and will be assessed at a later date). The region to be
silenced is cloned and inserted into vector pTRV2 (tobacco rattle virus). To
facilitate the cloning, inserts were flanked with adapters compatible with the
pTRV2 USER cassette described in Geu-Flores et al.1 The metabolic profiles of
these silenced lines remain to be measured. Additionally, quantitative PCR must
also confirm that the gene candidates are in fact silenced. These experiments
are ongoing.
In addition to understanding the physiological relevance of these
candidates, we also wish to understand why the enzyme-which produces a
presumably toxic dialdehyde intermediate capable of cross-linking proteins-
evolved in the first place. The answer is as yet unknown. Speculation leads us to
ask if the 1 0-hydroxygeraniol oxidoreductase and iridoid synthase rapidly co-
evolved and if a protein-protein interaction is required to shuttle the dialdehyde
product into nepetalactol 10 formation in order to prevent cell damage by the
highly reactive aldehyde.
1I. Future Work
We have successfully mined C. roseus transcriptomic datasets for an
enzyme that catalyzes a missing step in iridoid biosynthesis. Specifically, using
hierarchical clustering algorithms and the mutual ranking list of G1QH-the
enzyme directly upstream of 10-hydroxygeraniol oxidoreductase-we identified
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three enzymes with 10-hydroxygeraniol oxidoreductase activity. While we believe
these candidates could prove to be promising for a number of biotechnology
applications, most notably the reconstitution of secologanin biosynthesis, a
number of experiments remain to be completed in the full characterization of
these candidates. First, a number of peaks in addition to the substrate and
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Figure 2.8: The two possible routes from 10-hydroxygeraniol 8 to 10-
oxogeranial 9. The possible intermediate 10-hydroxygeranial 18 is known to
isomerize at the 2,3-double in aqueous solution. Similarly, the enzymatic
product 10-oxogeranial 9 is known to isomerize at the 2,3-double bond in
aqueous solution. The isomers of the potential intermediate at the product
could account for four peaks on a representative GC-MS chromatogram
(Candidate 1786 with NAD+).
product are found on GC-MS chromatograms; these must be properly
characterized. Co-injecting authentic standards of the intermediates will aid in
peak identification. Dr. Nathaniel Sherden is synthesizing and characterizing
both possible enzymatic intermediates, 1 0-oxogeraniol 17 and 10-
hydroxygeranial 18 (Figure 2.8). The intermediate 10-hydroxygeranial 18 is
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Figure 2.9: Representative trace (Candidate 1786 with NAD+) illustrating multiple peaks in addition to the substrate(not highlighted, 10-hydroxygeraniol 8) and product (orange, 10-oxogeranial 9) peak. Peak 1 (blue) and Peak 4(orange, 10-oxogeranial) have similar GC spectra, suggesting they could be isomers of each other. Likewise, Peak 2(red) and Peak 5 (green) have similar GC spectra, which suggests they could be isomers of each other. Both 10-
oxogeranial 9 and potential intermediate 10-hydroxygeranial 17 are known to isomerize in aqueous solution.
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known to isomerize at the 2,3-double bond in aqueous solution and could
account for two peaks observed in the Candidate 1786 with NAD chromatogram,
for example (Figure 2.9).18 Peaks 2 and 5 have similar fragmentation patterns,
suggesting that they are related (red and green insets, respectively) and could be
isomers of 10-hydroxygeranial 18. An authentic standard of 10-hydroxygeranial
18 will confirm this assignment. Similarly, the enzymatic product 10-oxogeranial 9
is also isomerically unstable at the 2,3-double bond, which could potentially
explain the presence of Peak 1.19 Peak 1 (blue inset) has a similar fragmentation
pattern to 10-oxogeranial 9 (orange inset, Peak 4, E isomer at the 2,3-double
bond), suggesting the peaks are related. These assignments would account for
all 5 major peaks in the assay with Candidate 1786 and NAD+ (Figure 2.9).
Similar assignments must be made for all other positive hits in the screen as well.
After identifying the enzymatic intermediate(s), steady state kinetic
parameters will be measured via spectrophotometry of the NADP+ absorbance
(increase in absorbance at 340 nm) for 1 0-hydroxygeraniol 8 and a number of
commercially available substrate analogs, including geraniol 7, nerol 19,
citronellol 20 and linalool 21. These compounds were selected for their structural
similarity to the native substrate, 10-hydroxygeraniol 8. Notably, linalool 21
cannot undergo dehydrogenation because the alcohol is tertiary. However, it is
possible that linalool 21 may function as a competitive alcohol dehydrogenase
inhibitor by binding, but not being converted to product.
Understanding the substrate scope of these enzymes will inform future
biotechnological applications. To understand the physiological relevance of these
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candidates, however, the metabolic and gene expression profiles of the VIGS
experiments must be thoroughly analyzed. These experiments are underway.
OH
GeranikO Nerol Cronllai Unalool
7 19 20 21(both isomers) (both isomers) (both isomers)
Figure 2.10: Substrate analogs to test with 10-hydroxygeraniol oxidoreductase.
Analogs were chosen based on structural similarity to 10-hydroxygernaiol 8.
Linalool 21 possesses only a tertiary alcohol that cannot be oxidized to the
corresponding aldehyde. Importantly, 21 may function as an inhibitor.
IV. Conclusions
In this chapter, I have described how we employed 'guilt-by-association'
through the use of hierarchical clustering to discover enzymes with 10-
hydroxygeraniol oxidoreductase activity. 10-hydroxygeraniol reductase is a
missing enzyme in C. roseus iridoid biosynthesis and as such has never been
cloned and characterized. This discovery will aid in biotechnological efforts to
reconstitute iridoid biosynthesis in tractable heterologous hosts. Three
candidates from our screen-Candidates 1786, 5743 and 26-were able to
oxidize both hydroxyl moieties of 10-hydroxygeraniol. Interestingly, Candidates
1786 and 5743 can utilize both NADP+ and NAD+, whereas candidate 26 uses
NADP+ exclusively. Interestingly, in both N. racemosa and R. serpentina-the
two plants in the literature with partially characterized 10-hydroxgeraniol
oxidoreductases-the enzyme exclusively accepts NADP+. 7'8
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For all three candidates, in assays to test Zn2+ dependency, ZnCl 2 was
omitted from the reaction. However, product formation was still observed,
suggesting that either Zn2+ is unnecessary for catalysis or more likely that the
enzyme co-purifies with metal bound during expression in LB media
supplemented with 100 pM ZnC12. Intriguingly, the addition of EDTA to the assay
mixture in conjunction with the omission of ZnCl2 only quelled product formation
in the assay with Candidate 1786 and NADP+, suggesting Zn2+ binds more
weakly in these conditions. The zinc-binding prediction server ZincPred predicted
zinc-binding sites for both Candidate 1786 and Candidate 5743 (bolded,
underlined and in red font in Appendix A; listed in Results and Discussion), but
did not identify any zinc-binding residues for Candidate 26.16 More complete
characterizations of these enzymes are underway.
Though the discovery of these enzymes is poised to aid in various
biotechnological endeavors, most importantly, the heterologous reconstitution of
secologanin, the physiological relevance of the three active enzymes is yet to be
determined. We have elected to study the candidates' physiological relevance
using VIGS; these experiments are currently underway. Theoretically, three
outcomes are plausible: (1) These candidates could be physiologically irrelevant,
meaning no silencing effect is observed at the metabolite or transcript levels; (2)
one (or more) candidate could be physiologically relevant, but functional
redundancy mutes any silencing effect at the metabolite level (candidates could
potentially be knocked down combinatorially to address this issue); or (3) one (or
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more) could be physiologically relevant, and that relevancy is displayed in both
the gene expression profile and metabolic profile.
V. Methods
A. Gene Cloning
The cassette-consisting of GFP flanked on either side by Pac sites,
variable nucleotide regions (which enable directional cloning) and Nt.BbvCl
sites-was generated according to Nour-Eldin et al. then inserted into the BamHl
and Hindill sites of pET28a (Figure 2.11; Page 29).15 Candidates were cloned
from C. roseus cDNA with X7 phusion polymerase ® and primer annealing
temperatures of 55 0C and flanked with the corresponding USER adapters.
Primers to amplify each candidate are listed in Table 6.2. The linearized vector
(digested with Pac and Nt.BbvCl) was incubated with gel purified and USER-
digested 10-hydroxygeraniol oxidoreductase candidate genes prior to
am
1500 bp E
500 bp
1 2 3 4 5 6 7
Lane Candidate Base Pair Count
1 1786 1131
2 26 900
3 4319 1098
4 5743 1137
6 8694 1164
7 2041 1170
Figure 2.12: USER cloning PCR-purified inserts and expected base pair counts.
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transformation into chemically competent Top 10 ® cells (Figure 2.12). Plasmids
were then isolated and sequenced to check for the correct insert sequence prior
to transformation into chemically competent RosettaM 2 cells for expression. All
candidates were cloned successfully except candidate 580 (Figure 2.12).
Primer Name Sequence (5'-3')
1786_sense GGCCTTAAQQ CAGATCATAACTTGCAAGGCTGTGG
1786_antisense GGTTTAAU TCACAATGTGATGAGAACCTTCACGC
26_sense GGCCTTAAUG GCCGCCATGGGTACC
26_antisense GGTTTAAU TCATTCAAACGATGACTCCTCGCTG
4319_sense GGCCTTAAUG GCCAGAAAATCACCAGAAGATGAACAT
4319_antisense GGTTTAAU TCACACCTCTGATGGAAGAGTGAG
5743_sense GGCCTTAAU ACCAAGACCAATTCCCCTGC
5743_antisense GGTTTAAU TTAGAACTTGATAACAACTTTGACACAATCAG
7220_sense GGCCTTAAUG GAGATTAATGTTGAAGTTGCTCCAGTAAG
7220_antisense GGTTTAAU TCAAAACTCGGATAGTTTTGTCTGATCAAAGT
8694_sense GGCCTTAAUQ ACGTCGTCATCCTCGCCGTC
8694_antisense GGTTTAAU TTACTCTTGAGAAGCCCCATATCTGC
2041_sense GGCCTTAAUG GGATACTACCATTATTATATTAGACAACCACTC
2041_antisense GGTTTAAU TCAACATCTGCAACTATGTTGTGCTTCG
580_sense GGCCTTAAUG CATCTGCAGCACCCCATCCG
580_antisense GGTTTAAUTCATTCCTCAAATTTCAATGTATTTCCAATGTCAAT
Table 2.6: Primers used to amplify candidates in this study for expression with
pET28a in Rosetta 2 cells. Sense and antisense adaptors for the pET28a USER
cassette are shown in red and green, respectively. Black letters represent gene-
specific sequences. The underlined portion of the sense primers shows the start
codon.
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A.
Nt.BbvCI Paci Pacl Nt.BbvCl
GCTGAGGCCTTAAJTAPG TTAATAAACIICAGC
CGACI|CCGGAA TAATT 'AA AATTTGGAGTCG
SET28a USER Casette
(7 o Into BanHI and Hindlil sites)
Paci
Nt.BbvCI
digestion
GCTGAGGCCTTAAT-3' TCAGC
CGACT 3'-TAATTTGGAGTCG
C.
5'-GCCCTTAAUG CANDIAEATTAAACC
CGGGAATTAC C UAATTTGG-5'
USER
digestion
GCANDIDATE ATTAAACC3'
3'CGGGAATTAC
1. Incubation
2. Transformation
GCTGAGGCCTTAATGCANDIDATE ATTAAACCTCAGC
CGACTCCGGAATTAC TAATTTGGAGTCG
pET28a with candidate
Figure 2.11. Scheme for USER cloning. Adapted from Nour-Eldin.(A) pET28a USER cassette, cloned into the BamHI
and Hindlil sites. Digestion with Pac and Nt.BbvCl results in directional overhang adaptors. B.'CANDIDATE'
amplified with uracil-containing adaptors that are complementary to the overhangs of the USER cassette (shown in
A). Digestion with USER enzyme removes the uracil residues and allows short fragments to dissociate. C. After
incubating the linearized cassette and the USER enzyme-digested candidate at 37 *C for 15 minutes and at room
temperature for 15 minutes, the plasmid can be directly transformed into E. coli without prior ligation.
B.
B. Protein Expression
All candidates were cloned into pET28a and in frame with an N-terminal
His6 tag. Cultures were seeded from a single colony harboring the gene of
interest; colonies were grown overnight at 37 *C and shaking at 200 rpm in LB
media supplemented with kanamycin and chloriamphenicol. Ten milliliters of the
seed culture were added to 500 mL of LB media supplemented with kanamycin
and chloramphenicol and shaken at 200 rpm at 37 0C until the optical density at
600 nm (OD6oo) reached 0.5-0.7. After reaching the appropriate OD600 , the
cultures were incubated at room temperature for 1 hour. Subsequently, the LB
media was supplemented with IPTG to a final concentration of 0.1 mg/mL to
induce expression and 100 pM ZnC2 to potentially aid in protein folding.
Candidates were expressed at 18 0C for 16 hours.
Cells were then spun down at 8000 rpm for 20 minutes. The cells were
then resuspended in chilled PBS buffer [50 mM KH 2 PO 4 (pH 8), 300 mM NaCl,
10 mM imidazole,10 mM dithiothreitol and 10% glyercol] and subjected to
sonication (1 second on and 4 seconds off for 1.5 minutes; 60% intensity). The
cellular refuse was spun down at 18000 rpm for 1 hour. The supernatant was
incubated with 600 pL of Ni-NTA resin for 2.5 hours at 4 OC. The enzyme was
eluted with stepwise fractions of increasing imidazole concentrations (25 mM, 50
mM, 100 mM, 150 mM and 300 mM).
Imidazole fractions were then subjected to SDS PAGE. Fractions shown
to contain protein (red boxes, Figure 2.4) at the correct molecular weight were
pooled and concentrated to 1 mL using a 10 kDa molecular weight cutoff Amicon
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@ centrifugal filter (15 mL). Concentrated samples were then buffered
exchanged three times with 20 mM MOPS and immediately stored at -20 0C in
single-thaw aliquots.
C. Thin Layer Chromatography (TLC) Assays
Assays for oxidase activity that were monitored by TLC contained the
following components: 700 pM 10-hydroxygeraniol, 9 mM NAD(P)+, 100 PM
ZnC 2, 100 mM phosphate (pH 7.2), 3 pM enzyme (concentration based on
Bradford Assay and the protein's predicted average molecular weight on the
ExPASy server).19 Distilled and deionized water was added to a final volume of
100 pL in each reaction. The reactions were run at 30 *C for approximately 16
hours. To quench the reactions and extract the product mixtures, 90 pL of the
assay mixture were added to 200 pL of dichloromethane in a glass vial and
mixed thoroughly with a syringe. After the phases settled, approximately 100 pL
of the dichloromethane layer were recovered. Samples were then concentrated
to approximately 15 ptL under vacuum. To screen for product formation,
approximately 5 pL of the sample or control were spotted onto thin layer
chromatography (TLC) plates and run in hexanes: ethyl acetate (1:1). All plates
were stained with anisaldehyde and analyzed for product formation (Appendix A).
D. Gas Chromatrography - Mass Spectrometry (GC-MS) Assays
Assays were set up with the following components: 700 jM 10-
hydroxygeraniol, 9 mM NAD(P), 100 pM ZnC 2, 100 mM Phosphate (pH 7.2), 3
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pM Enzyme (based on Bradford Assay and the protein's predicted average
molecular weight on the ExPASy server).1 9 Deionized and distilled water was
added to a final volume of 100 tL in each reaction. The reactions were run at 30
0C for approximately 16 hours. To quench the reactions and extract the product
mixtures, 90 pL of the assay mixture were added to 400 tL of dichloromethane
(in a glass vial) and mixed thoroughly with a glass syringe. After the phases
settled, approximately 300 pL of the dichloromethane layer were recovered.
Samples were concentrated to dryness under vacuum then re-suspended with
dichloromethane to exactly 50 pL in glass vial inserts.
GC-MS analyses were carried out using an Agilent 6890N GC system that
was connected to an Agilent 5973 MS detector. The separations were per-
formed on a Zebron ZB-5 HT column (30 m X 0.25 mm X 0.10 mm) using
helium as the carrier gas at a rate of 1 mL min~' (linear velocity of 37 cm s-) and
an injector temperature of 220 OC. The program initiated with an isothermal
phase at 60 0C for 5 minutes, followed by a 20 0C min-' gradient up to 150 C, a
45 0C min' gradient up to 280 OC, then a 4-min isothermal phase at 280 OC. The
total run time was 16.39 min. GC-MS chromatograms and product spectra are
shown in Appendix A.
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E. Virus-Induced Gene Silencing (VIGS)
478-base pair regions from Candidates 1786 and 5743 were cloned using
the following primer pairs:
Primer Sequence (5'-3')
1786_VIGSSense GGCGCGAUTCCTCAAGAATGTCTTCCGCCAAAG
1786_VIGSAntisense GGTTGCGAUATTCAAGAGCTTCATTAACCAAGTCAGG
5743_VIGSSense GGCGCGAUTGCTCCTTCTGTCATCACTTGCAAAG
5743_VIGSAntisense GGTTGCGAUTGGATCTACCTTCACTGCATAAGCTG
Table 2.7: Primers used to amplify 478-base pair regions of open reading frames
from Candidates 1786 and 5743. Red and green show the sense and antisense
adapters for the pTRV2 cassette. Black represents gene specific sequences.
pTRV2 vectors harboring the inserts of interest were subjected to sequencing
prior to being transformed into electrocompetent Agrobacterium tumefacians
(strain Gv3101). The agrobacterium was prepared and handled according to
Liscombe et al. Colony PCR (using primers shown in Table 2.6) was performed
on overnight cultures to ensure that the agrobacterium retained the plasmid
(Figure 2.13).18
Subsequently, cultures harboring pTRV1 and pTRV2 with the region to be
silenced were pelleted and resuspended in inoculation solution (10 mM MES, 20
pM acetosyringone, 10 mM MgC 2) to a final OD600 of 0.7. pTRV1 and pTRV2
harboring the insert of interest were mixed in a 1:1 ratio (according to OD6oo) and
incubated at 30 *C with shaking for 4 hours. Eight-week-old C. roseus plants
(Little Bright Eyes)-grown in a walk-in growth chamber at 26 *C and a
photoperiod of 16 hours light and 8 hours dark-were inoculated via pinching just
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1500 bp
500 bp
Figure 2.13: Colony PCR of Candidates 1786 and 5743 (in duplicate) after
Agrobacterium tumefacians (Gv3 101) harboring the construct containing the
478-base pair insert had been cultured overnight. This experiment was
conducted to ensure the A. tumefacians retained the construct prior to plant
inoculation.
below the apical meristem. Eight plants were inoculated with each construct
harboring regions from either Candidate 1786 or Candidate 5743. Silenced
magnesium chelatase-which displays a leaf yellowing phenotype resulting from
the disruption of photosynthesis-was used as a silencing marker proxy.
Additionally, an empty vector was also infiltrated to enable comparison of
silencing due to the insert alone. Eight plants were inoculated with each of the
magnesium chelatase and empty vector control constructs as well.
VI. Appendix A Contents
Appendix A, affixed to the end of this thesis, contains gene and protein
sequences for each of the 7 cloned candidates, TLC controls and all GC-MS
spectra.
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Chapter 3
Reengineering a Tryptophan Halogenase to Preferentially Chlorinate a Direct
Alkaloid Precursor
Part of this chapter is published as a communication in
Glenn WS, Nims E and O'Connor SE. J Am Chem Soc. 2011 Dec
7; 133(48):19346-9
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I. Introduction
Though natural products have been used to treat human disease for
thousands of years, they have not evolved specifically to do so. Therefore, before
reaching the clinic, these co-opted natural products frequently require structural
modification-an exigent enterprise given their often awe-inspiring complexity. 1-4
Installing halogens regioselectively onto natural products can generate
compounds with novel or improved properties. What is more, a significant
fraction (roughly 25%) of pharmaceuticals in the clinic contains halogens.24
Notably, several classes of halogenases have been discovered and
characterized, which enables environmentally friendly halogenation; however,
applications are limited because of the oftentimes narrow substrate specificity of
these enzymes.5 Importantly, it has been demonstrated across different classes
of natural products that incorporating simple precursor analogs into biosynthetic
pathways is an effective strategy to produce complex natural products that are
modified in a site-specific manner.6-9 Therefore, we reasoned that enzymatically
generating a modified precursor in situ would enable de novo production of
complex natural products that are site-specifically modified.
This chapter describes strategies to interface RebH-a halogenase that
regioselectively installs chlorine atoms onto the 7 position of tryptophan 1-with
monoterpene indole alkaloid (MIA) metabolism to yield chlorinated alkaloids de
novo. MIA biosynthesis commences with the decarboxylation of L-Tryptophan 1
by tryptophan decarboxylase to yield tryptamine 2 (Figure 1A),10 which
condenses with secologanin 3 via a Pictet-Spengler-type reaction mechanism
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A. Scheme of Monoterpene Indole Alkaloid Biosynthesis
JO 2H - H / \ H N
i% A/ N 2  N ~OGc -QPN HH .c
N H LL,OGc NH Tryptamine MeO 2C H CO 2Me
L-Tryptophan 2 MeO 2C Strictosidine 19,20-dihydroakuammicine
1 Secologanin 4
3
B. In planta rexpression of RebHiF - Runguphan et al.14
N
..CO 2H
i~e\ N~j9, / NH2  \
RebF N2eb  PP Bottleneck N NH_2CI H C1 H CI H C0 2MG
7-Chlorotryptophan 7-chlorotryptamine 12-choro
lb 2b 19,20-dihydroakuammicine5b
Figure 3.1: A. Scheme of MIA biosynthesis. Tryptophan decarboxylase (TDC)
decarboxylates L-Tryptophan 1 to form tryptamine 2, which condenses with
secologanin via a Pictet-Spenglerase-type mechanism to form strictosidine 4, the central
MIA intermediate. 19, 20-dihydroakuammicine is a MIA found in Madagascar periwinkle
that harbors opiate activity. B. Runguphan et al. expressed RebH/F in planta and
observed the de novo production of chlorinated alkaloid 12-chloro-19,20-
dihydroakuammicine at 25 [tg/g fresh weight. However, 7-Chlorotryptophan lb
accumulated at 50 [tg/g fresh weight because of the TDC bottleneck.
to form strictosidine 4, which is the central intermediate in the biosynthesis of
over 3000 MIAs, including 19,20-dihydroakuammicine 5, a strychnos-type MIA
with opiate activity (Figure 1A). Previously, Runguphan et al. integrated RebH
and its partner flavin reductase RebF into the metabolism of C. roseus
(Madagascar periwinkle), a plant that produces a subset of approximately 130
MIAs (Figure 1 B). 13 ,14 RebH and RebF generate 7-chlorotryptophan, which
endogenous tryptophan decarboxylase decarboxylates to form 7-
chlorotryptamine 2b. 7-chlorotryptamine 2b-a modified direct MIA precursor-is
then incorporated into MIA metabolism, generating a chlorinated MIA, namely 12-
chloro-19,20-dihydroakuammicine 6b. However, in addition to accumulating 12-
chloro-19,20-dihydroakuammicine 5b, a halogenated "unnatural" natural product,
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the resulting tissue cultures also accumulated substantial levels of 7-
chlorotryptophan 1b (Figure 1B). 1 4 Tryptophan decarboxylase, the enzyme
that converts L-Tryptophan 1 to tryptamine 2, accepts 7-chlorotryptophan lb
at only 3% of the efficiency of the native substrate L-Tryptophan 1, thereby
creating a metabolic bottleneck .4
This bottleneck is undesirable because 7-chlorotryptophan lb could be
shuttled into the production of the more valuable halogenated alkaloid final
product 12-chloro-19,20-dihydroakuammicine 5b. Moreover, L-Tryptophan 1 is
an essential metabolite that is involved in many central metabolic processes,
including protein biosynthesis and, in the case of plants, auxin (growth hormone)
biosynthesis. The accumulation of a halogenated primary metabolite seemingly
has adverse effects on the growth rate of the tissues, perhaps because it is
incorporated into protein or auxin biosynthesis. In contrast, chlorinated
tryptamine analogs can be fed to seedlings and hairy roots at concentrations up
to 1 mM without adverse effects.8
We hypothesized that this bottleneck could be alleviated in two ways: (1)
over-express the endogenous periwinkle tryptophan decarboxylase to increase
the conversion of 7-chlorotryptophan lb to 7-chlorotryptamine 2b (Figure 3.2A);
and (2) reengineer the halogenation machinery, namely RebH, to preferentially
chlorinate a substrate downstream of the decarboxylase bottleneck (Figure
3.2B). Here we demonstrate that while over-expressing tryptophan
decarboxylase failed to fracture the metabolic bottleneck (Figure 3.2A),
reengineering RebH to install chlorine preferentially onto tryptamine 2
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successfully circumvented the bottleneck altogether (Figure 3.2B). To validate
the function of this engineered enzyme in vivo, we transformed the tryptamine-
specific RebH mutant (Y455W) into the alkaloid-producing plant Madagascar
A. Strategy I to alleviate TDC bottleneck - Overexpress TDC
SCO 2H 2H
C 2H N H T DC WN H 2N RebF NNH P Over- I C H C 2MCI H Express
L-Tryptophan 7-Chiorotryptophan 7-chorotryptamine 12-choro-1 lb 2b 19,20-dhydroakuammcine
5b
B. Strategy 2 to alleviate TDC bottleneck - Reengineer RebH
"CO 2HN
/) ~ V\ \ H R NH2  \
N7 N . 7 RebF N 
-- NH H CI H CI H CO 2Me
12-chioro-L-Tryptophan Tryptamine 7-chlorotryptamine 19,20-dihydroakuammicine1 2 2b 5b
Figure 3.2: A. Strategy 1 to alleviate the TDC bottleneck by over-expressing TDC
in planta. B. Strategy 2 to alleviate the TDC entails reengineering RebH to
preferentially chlorinate tryptamine 2, which is downstream of the bottleneck.
periwinkle. Despite having an incomplete understanding of MIA biosynthesis at
the genetic level, we observed the de novo production of the halogenated
alkaloid 12-chloro-19,20-dihydroakuammicine 5b. In comparison with cultures
harboring wild-type RebH and RebF, tissue cultures containing mutant RebH
Y455W and RebF also accumulate microgram per gram fresh-weight quantities
of 12-chloro-19,20-dihydroakuammicine 5b but, in contrast, do not accumulate 7-
chlorotryptophan 1b, demonstrating the selectivity and potential utility of this
mutant in metabolic engineering applications.
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1I. Results and Discussion
We initially hypothesized that the over-expression of tryptophan
decarboxylase in periwinkle would increase the conversion of 7-chlorotryptophan
Ib to 7-chlorotryptamine 2b and thereby alleviate the bottleneck (Figure 3.2A).
However, all efforts at the constitutive over-expression of tryptophan
decarboxylase, RebH and RebF in periwinkle resulted in plant tissue that failed to
survive selection (Figure 3.3A). Additionally, tissues transformed with only
tryptophan decarboxylase also failed to survive selection and could not be
Figure 3.3: A. Madagascar periwinkle hairy roots over-expressing RebH, RebF
and TDC on Gamborg's B5 media after 21 days. B. Periwinkle hairy roots on
Gamborgs B5 media after 21 days over-expressing TDC only. Both sets of
roots failed to survive selection. Roots only over-expressing TDC could not be
rescued by being placed on media supplemented with tryptophan.
rescued through transfer to growth medium supplemented with 500 pM L-
Tryptophan 1 (Figure 3.3B). The apparent lethality of tryptophan decarboxylase
over-expression suggests, perhaps unsurprisingly, that disrupting the flux of L-
Tryptophan I is detrimental to plant survival.
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The alternative strategy-bypassing the tryptophan decarboxylase
bottleneck-hinges upon our ability to reengineer substrate specificity. Two
strategies are plausible, namely reengineering tryptophan decarboxylase to
selectively decarboxylate 7-chlorotryptophan 1b or reengineering RebH to
selectively chlorinate a downstream intermediate. Because the structure of
tryptophan decarboxylase is unknown and the structure of RebH is known1 we
elected to focus our efforts solely on the halogenase. Enzyme engineering efforts
are substantially enhanced when the protein structure is known and the
mechanism is well understood. Then, the enzyme can be subjected to structure-
guided techniques, such as domain swapping and site-directed mutagenesis,
which create smaller protein libraries that are enriched for functional mutants.
RebH, a structurally characterized enzyme whose mechanism is well understood,
is a prime candidate with which to undertake various enzyme engineering efforts
for these reasons.
With various enzyme engineering strategies in hand, we can begin to
envision ways to engineer halogenases to accept non-native substrates for
various metabolic engineering and biocatalysis efforts. Specifically, we
envisioned reengineering the halogenase to preferentially chlorinate tryptamine
2, a downstream biosynthetic intermediate that is the direct precursor to MIA
biosynthesis and removed from primary metabolism (Figure 3.2B). We targeted
tryptamine, specifically, because chlorinated tryptamine analogs have been
shown to be non-toxic in feeding experiments with seedlings and hairy roots,
even when concentrations were as high as 1 mM.
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To reengineer RebH for tryptamine 2 selectivity, we examined the crystal
structure of RebH complexed with L-Tryptophan I (PDB entry 2E4G) and
proposed 17 mutations to the active site, specifically targeting residues proximal
to the carboxylate moiety of the native substrate L-Tryptophan I (Figure 3.3).15
We employed LC-MS to monitor mutant activity for both Tryptophan I and
tryptamine 2. Gratifyingly, one RebH mutant, RebH Y455W, preferentially
L-Trp Y455
152
Figure 3.4: Tryptophan 1 complexed with RebH (2E4G). Tryptophan 1 is
highlighted in yellow sticks. The residues proximal to the carboxylate moiety
of 1 that were targeted for reengineering the substrate selectivity of RebH are
shown in green space filling models.
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Substrate at 20 pM
-Trn Trnv*mmina
152F
152Y
P53F
P53G
P53W
F111L
F111W
F111Y
L113F
6% 6%
6% 6%
6% 6%
6% 6%
6% 6%
6% 6%
6% 6%
6% 6%
6% 6%
L113W x
L114F x x
L114G x x
L114W x x
Y455F x x
Y455L x x
Table 3.1: Summary of RebH WT and mutant assays. Only RebH L113G and RebH
Y455W retained activity for either substrate. Only RebH Y445W is selective for
tryptamine 2. Percent substrate conversions are shown in parentheses.
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accepts tryptamine 2 as opposed to the natural substrate L-tryptophan 1 (Figure
3.5). Only one other mutant, RebH L 113G, retained activity for either tryptophan
I or tryptamine 2 (Table 3.1). Since RebH L1 13G converted both L-Tryptophan 1
and tryptamine 2 to the respective chlorinated products, we subjected this mutant
to competition assays as described in Methods. RebH L 113G does not have the
desired selectivity, converting approximately 20% of both L-Tryptophan I and
tryptamine 2 to product after an incubation period of 16 hours in the competition
assay (Figure 3.6; Table 3.1). In contrast, RebH Y455W converts approximately
40% of tryptamine 2 to product, but less than 5% of L-Tryptophan 1 to product
(Figure 3.5B; Table 3.1).
Slow conversion to product in vitro prevented accurate measurement of
the steady-state enzyme kinetics parameters for WT RebH, RebH Y455W and
RebH Li 13G. Thus, to rigorously assess the substrate selectivity of RebH
Y455W-the mutant that preferentially chlorinates tryptamine 2 instead of
tryptophan 1-we utilized competition assays where either WT RebH or the
Y455W mutant was incubated with different ratios of L-Tryptohan 1 and
tryptamine 2. In total, we tested three different L-Tryptophan 1: tryptamine 2
ratios (500 pM:500 pM, 1000 pM:500 pM, and 500 pM:1000 pM). WT RebH
chlorinated both L-Tryptophan I and tryptamine 2 under these assay conditions
(Figure 3.7). However, we observed an approximately 30-fold higher
accumulation of 7-chlorotryptamine 2b than 7-chlorotryptophan lb in RebH
Y455W assays across all three substrate ratios (Figure 3.7). Relative to WT
RebH in these competition assays, the production of 7-chlorotryptophan I b was
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Figure 3.5: A. Extracted Ion Chromatograms for RebH WT competition assay
with tryptophan and tryptamine, each at 20 RM concentration. The top two
chromatograms display 7-chlorotryptophan and 7-chlorotryptamine
authentic standards. The third chromatogram displays the conversion of
tryptophan, where 80% of the substrate L-tryptophan is converted to product
after 16 hours. The bottom pane displays RebH WT tryptamine conversion in
the competition assay, with less than 5% of tryptamine converted to product
after 16 hours. B. Extracted Ion Chromatograms for RebH Y455W competition
assay with tryptophan and tryptamine, each at 20 [M concentration. The top
two chromatograms display 7-chlorotryptophan and 7-chlorotryptamine
authentic standards. The third chromatogram displays the RebH Y455W
tryptophan conversion, where less than 5% of the substrate L-tryptophan is
converted to product after 16 hours. The bottom pane displays RebH Y455W
tryptamine conversion, with approximately 40% of tryptamine converted to
product after 16 hours. These results illustrate that the substrate specificity of
RebH has been altered successfully.
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Figure 3.6: A. RebH L 13G competition assays with tryptophan and tryptamine
(tryptophan conversion). At concentrations of 20 [tM for both substrates, RebH Li 13
converts approximately 20% of tryptophan to product after an incubation period of 16
hours (bottom pane). Top and middle panes, respectively, display 7-chlorotryptophan
and L-tryptophan authentic standards. B. RebH Li 13G competition assays with
tryptophan and tryptamine (tryptamine conversion). At concentrations of 20 pLM for
both substrates, RebH Li 13 converts approximately 20% of tryptamine to product
after an incubation period of 16 hours (bottom pane). The top and middle panes,
respectively, display 7-chlorotryptamine and tryptamine authentic standards.
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Figure 3.7: RebH WT (wild type) and RebH Y455W competition assays with
tryptophan and 1 tryptamine 2. Both RebH WT (left) and RebH Y455W
(right) were incubated with three different ratios of tryptophan-to-
tryptamine. RebH Y455W has a 30-fold higher accumulation of 7-
chlorotryptamine (60 pM) over 7-chlorotryptophan (2 [iM), indicating that
this mutant is highly selective for 2.
diminished 10-fold while the production of 7-chlorotryptamine 2b was augmented
approximately 3-fold with RebH Y455W (Figure 3.7).
Mutational analyses in PyMol suggest that RebH Y455W partially
occludes L-tryptophan I from the redesigned active site while not impeding
access for tryptamine 2 (Figure 3.8). This mutational analysis is congruent with
the observation that the RebH Y455W mutant shows a clear preference for
tryptamine 2 as a substrate, even when L-Tryptophan I is present at initial
concentrations twice as high as tryptamine 2 (Figure 3.7). These results
demonstrate that we successfully altered the substrate specificity of RebH in vitro
to make it highly specific for tryptamine 2, a direct MIA precursor.
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A. B
L113
Y455
L-Trp
152
RebH WT model with L-Trp
PDB ID: 2E4G
RebH WT model with Tryptamine
modeled Into the active site
D.
L113 A**1113
Y455W
152
RebH Y45SW model with L-Trp
modeled Into the active site
152
RebH Y455W model with Tryptamine
modeled Into the active site
Figure 3.8. A. RebH WT model with L-tryptophan from the PDB code:
2E4G. B. Model of RebH WT with tryptamine. Tryptamine was modeled
into the RebH active site by removing the carboxylate moiety of the
tryptophan substrate of PDB code: 2E4G. C. RebH Y455 model with L-
tryptophan. L-Trp buttresses RebH Y455W. The mutant RebH Y455W
model was constructed via in silico mutational analysis from the PDB code:
2E4G in MacPyMOL. The right panel shows a model of RebH Y455W with
tryptamine. Tryptamine was modeled into the RebH Y455W active site by
removing the carboxylate moiety of the tryptophan substrate of the RebH
Y455W model with L-Tryptophan (left). Models were constructed in
MacPyMOL.
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C.
a.
Notably, H6lzer and co-workers demonstrated that PrnA, a tryptophan 7-
halogenase involved in pyrollnitrin biosynthesis (55% sequence identity to RebH)
does accept tryptamine analogues.16 However, PrnA was shown to install
chlorine atoms at the more nucleophilic 2-position of various analogues of
tryptamine 2, not at the 7-position, suggesting that the non-native substrates bind
differently to PrnA (Figure 3.9).16 To ensure that the regioselectivity of RebH
Y455W was unaltered, and also to determine whether WT RebH possesses the
same regioselectivity for the non-native substrate tryptamine 2, we compared the
tryptamine 2 enzymatic products of WT RebH and RebH Y455W with authentic
standards of all possible monochlorinated tryptamine isomers, namely,
tryptamine 2 chlorinated at the 2-, 4-, 5-, 6-, or 7-position of the indole ring. Using
LC-MS to monitor the retention times of the various chlorotryptamine isomers
(m/z 195), we noted that the WT RebH and RebH Y455W tryptamine enzymatic
products co-eluted exclusively with the 7-chlorotryptamine authentic standard
(Figure 3.10). Thus, WT RebH and RebH Y455W retained regioselectivity for the
7-position of the indole ring with tryptamine 2.
Though the mutant enzyme was sluggish in vitro, we rationalized that a
steady supply of fresh enzyme in the plant cell may allow the mutant enzyme to
function adequately over extended periods to yield isolable quantities of
chlorinated alkaloids. To test this reengineered enzyme in the context of a
biosynthetic pathway in vivo, we introduced RebH Y455W and RebF into
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periwinkle (C. roseus) via Agrobacterium rhizogenes to yield stably transformed
root cultures. To streamline the engineering process, neither gene was codon
A. Prod= Ky
POO
540 NH2
C1 2
6 N
7 H
Mono-chlorinated tryptamine Isomem
B. Pictet-Spengler Mechanism
R Cycdiztion 
+ N N
H H )HH
Base
Restore NH
Aromaticity 0 NRH
tetrahydro*carboUne
Figure 3.9: A. Chlorotryptamine product key. B. Proposed Pictet-Spengler
mechanism of strictosidine synthase. Holzer and co-workers demonstrated
that PrnA, a tryptophan 7 halogenase involved in pyrollnitrin biosynthesis
(55% sequence identity to RebH) does accept tryptamine analogues.1 6
However, PrnA was shown to install chlorine atoms at the more nucleophilic 2-
position of various analogues of tryptamine 2, not at the 7-position.
Chlorination at the 2 position of tryptamine 2 would preclude tetrahydro-P-
carboline formation via a Pictet-Spengler-type mechanism, a necessary step
in MIA biosynthesis.
optimized for expression in periwinkle. Each gene was placed into a
commercially available plant vector (pCAMBIA1305.1) and under the control of
the constituitive promoter CaMV 35S.
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Precursor-directed biosynthesis studies in periwinkle with 7-
chlorotrypamine 2b, as well as the prior studies in which periwinkle was
transformed with WT RebH and RebF, indicated that analogues of 19,20-
RebH WT Tryptamine Product
m/z 195
RebH Y4 W Tryptamine Product
r/z 195
7-chlo ptamine Standard
m/z 195
4.- 1 19 51 M
-v,,-chlo rptmine Standard
m/z 1954-chor i~ytmine Standard
m/Z 195
-chloR tptamine Standard m/Z 195
Regng o TIm a(M3n"wes)
dihydroakuammicine 5 are the major alkaloid analogue products when the 7-
position of the indole ring is modified. Notably, when the tryptamine precursor is
chlorinated at other positions of the indole ring and integrated into periwinkle
metabolism, the resulting chlorinated alkaloid profiles are drastically different,
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and chlorinated 19,20-dihydroakuammicine 5 is not a major product.8 Methanolic
extracts of the transformed roots were analyzed with selected ion monitoring for
12-chloro-19,20-dihydroakuammicine 5b (m/z 359) and 7-chlorotryptophan lb
(m/z 239). We observed several root lines harboring RebH Y455W and RebF
that produced 12-chloro-19,20-dihydroakuammicine 5b (Figure 3.11). RebH
Y455W/RebF (line 13), for example, accumulated 2.65±1.08 pg per gram fresh
weight of the product 12-chloro-19,20-dihydroakuammicine 5b (averaged across
three biological replicates) with no measured accumulation of 7-chlorotryptophan
Ib, indicating that RebH Y455W displays the desired substrate selectivity in
planta as well as in vitro (Figure 3.12; Tables 3.2 and 3.3). The accumulation of
12-chloro-19,20-dihydroakuammicine 5b (characterized by co-elution with an
authentic standard), the major metabolite expected from 7-chlorotryptamine 2b,
provides further confirmation that RebH Y455W installs chlorine regioselectively
at the 7-position of the indole ring of tryptamine 2. Chlorinated alkaloids aside
from 12-chloro-19,20-dihydroakuammicine 5b were not observed in this study, as
evidenced by selected ion monitoring. Moreover, chlorination at the 2-position of
the indole ring of tryptamine, as was observed in the study with Holzer and co-
workers,16 would preclude the formation of the tetrahydro-p-carboline via a
Pictet-Spengler mechanism, a necessary step in the biosynthesis of the
monoterpene indole alkaloids (Figure 3.9).)
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Line 13 12-chloro-1 9,20-dihydroakuammicine 7-chlorotryptophan
m/z 359 239
Subculture Accumulation (pg / g fresh weight) Accumulation (pg / g fresh weight)
Subculture 1 1.41 not detected
Subculture 2 3.23 not detected
Subculture 3 3.32 not detected
Average 2.65 not detected
Standard Deviation 1.08 not detected
Table 3.2: Metabolic analysis of RebH Y455W and RebF line 13 across 3
subcultures.
Line 74 12-chloro-1 9,20-dihydroakuammicine 7-chlorotryptophan
m/z 359 239
Subculture Accumulation (pg / g fresh weight) Accumulation (pg / g fresh weight)
Subculture 1 2.15 1.25
Subculture 2 2.24 not detected
Subculture 3 1.83 not detected
Average 2.07 0.415
Standard Deviation 0.215 0.722
Table 3.3: Metabolic analysis of RebH Y455W and RebF line 74 across 3
subcultures.
Figure 3.11: RebH Y455W and RebF lines 13 and 74 at 21 days.
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Figure 3.12: Metabolic analysis of lines harboring RebH Y455W and RebF. A.
Selected ion monitoring for 12-chloro-19,20-dihydroakuammicine 5b (m/z 359)
in transgenic root lines. This line accumulates 2.65 t 1.08 jg per gram fresh
weight of 5b B. The authentic standard of 5b.14 C. Selected ion monitoring of 7-
chlorotryptophan lb (m/z 239), D. Authentic standard of 1b." Lines expressing
RebH Y455W and RebF do not display a peak corresponding to 7-
chlorotryptophan 1b, but do produce alkaloid 5b.
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Notably, no 7-chlorotryptamine 2b accumulated in these transformed hairy
root lines, suggesting that 7-chlorotrypamine 2b is readily shuttled into the
alkaloid metabolism of periwinkle. Moreover, the lines harboring RebH Y455W
and RebF survived selection and grew more rapidly than lines over-expressing
tryptophan decarboxylase, RebH WT, and RebF (Figures 3.3A and 3.11),
demonstrating that reengineering the halogenase was the superior method of
alleviating the tryptophan decarboxylase bottleneck. However, the yield of
unnatural alkaloid 12-chloro-19,20-dihydroakuammicine 5b in this study
remained low (approximately 1% of the total alkaloid content),1 4 indicating that
this system is not yet at a stage where large-scale production of 12-chloro-1 9,20-
dihydroakuammicine 5b is practical.
We also transiently expressed RebH Y455W and RebF in leaf. Gene
constructs were separately transformed into Agrobacterium tumefacians, then
the two Agrobacterium strains were mixed in a 1:1 ratio just prior to transfection.
Perwinkle leaves were transfected via either vacuum infiltration or syringe
injection. We did not observe the accumulation of either 7-chlorotryptamine 2b or
halogenated alkaloids under these conditions, suggesting perhaps that MIA
biosynthesis-which is removed from primary metabolism-was not highly active
at that stage of growth. Alternatively, build up of halogenated alkaloids may
require an extended period of time, which in turn would require a constitutive
rather than transient expression system. Free tryptamine 2 levels in periwinkle
leaf were not measured in this study, but it is plausible that low levels of free
tryptamine 2 prevent the detection of the direct RebH Y455W and RebF product,
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7-chlorotryptamine 2b. Because we did not see formation of 7-chlorotryptamine
2b, we also screened for the accumulation of downstream alkaloids, specifically
12-chloro-19,20-dihydroakuammicine 5b, which we did not observe either.
Notably, 19,20-dihydroakuammicine 5 does not accumulate at detectable levels
in periwinkle plant leaf, presumably because the genes involved in 19,20-
dihydroakuammicine biosynthesis-which have not been identified as yet-are at
best only poorly expressed in leaf.
We hypothesize that as tractable heterologous hosts are developed to
produce plant-derived alkaloid pathways in high yields, incorporation of this
redesigned biosynthetic enzyme (along with selected downstream biosynthetic
enzymes that have also been engineered to favor chlorinated substrates) may
play a crucial role in improving the production of chlorinated alkaloids.
Il. Conclusions
Installing halogens onto natural products can generate compounds with
novel or improved properties.lA Notably, enzymatic halogenation is now possible
as a result of the discovery of several classes of halogenases;5 however,
applications are limited because of the narrow substrate specificity of these
enzymes. Here we demonstrate that the flavin-dependent halogenase RebH can
be engineered to install chlorine preferentially onto tryptamine 2 rather than the
native substrate L-Tryptophan 1. Tryptamine 2 is a direct precursor to many
alkaloid natural products, including approximately 3000 monoterpene indole
alkaloids. To validate the function of this engineered enzyme in vivo, we
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transformed the tryptamine-specific RebH mutant (Y455W) into the alkaloid-
producing plant Madagascar periwinkle (Catharanthus roseus) and observed the
de novo production of the halogenated alkaloid 12-chloro-1 9,20-
dihydroakuammicine 5b. While wild type RebH has been integrated into
periwinkle metabolism previously, the resulting tissue cultures accumulated
substantial levels of 7-chlorotryptophan lb-a metabolite that potentially disrupts
primary metabolism, including auxin (growth hormone) biosynthesis. Tryptophan
decarboxylase, the enzyme that converts L-Tryptophan I to tryptamine 2,
accepts 7-chlorotryptophan lb at only 3% of the efficiency of the native
substrate, thereby creating a bottleneck. 1 4 The RebH Y455W mutant circumvents
this bottleneck by installing chlorine directly onto tryptamine 2, a downstream
substrate. In comparison with cultures harboring RebH and RebF, tissue cultures
containing mutant RebH Y455W and RebF also accumulate microgram per gram
fresh-weight quantities of 12-chloro-19,20-dihydroakuammicine 5b but, in
contrast, do not accumulate 7-chlorotryptophan 1b, demonstrating the selectivity
and potential utility of this mutant in metabolic engineering applications.
Halogen moieties in natural products have been shown to confer potency
and modulate molecular bioactivity and pharmacokinetics.1,2,4,6,1 3 ,17 Additionally,
halogens offer unique, site-specific handles that can be utilized in cross-coupling
methodology for further derivatization.18 Notably, halogens appear in 25% of
pharmaceutical compounds.2 4 We have demonstrated the de novo biosynthesis
of a halogenated "unnatural" plant natural product by redesigning a halogenase
to preferentially install a chlorine atom onto a direct alkaloid precursor, tryptamine
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2, and subsequently integrating this redesigned enzyme into the alkaloid
biosynthesis of periwinkle. Interestingly, RebH can brominate the 7-position of L-
Tryptophan 1 in the presence of bromide ions.1 4'1 5 However, bromination does
not occur selectively in the presence of chloride sources (such as sodium
chloride), which to date has prevented selective formation of brominated
products using chlorinase enzymes in whole-cell systems.14
This mutant allows us to circumvent the metabolic bottleneck positioned at
tryptophan decarboxylase. Moreover, this work, along with other recently
reported studies19-for example, Payne et al. demonstrated the use of wild-type
RebH to halogenate an array of arenes regioselectively 20-highlights the
potential use of halogenases for more widespread applications. Notably, the work
presented in this chapter was conducted without a complete understanding of
MIA biosynthesis at the genetic level. One of the efforts to further elucidate MIA
biosynthesis is described in Chapter 2. Understanding the pathway completely
would potentially enable the efficient shuttling of chlorinated alkaloids into
different pathway branches through the reengineering of enzymes that do not
accept halogenated substrate analogs.
IV. Methods
A. The in planta Over-Expression of RebH WT, RebF and TDC
To over-express RebH WT, RebF and TDC in planta, we used the
pCAMBIA vector system. Specifically, the plant transformation vector harboring
codon optimized RebH WT and RebF (pCAMBIA1300-RebHRebF) and the plant
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TDCNcoI pCAM1305.1 5 ' -AAAAAACCATGGATGGGCAGCATTGA-3 '
TDCBsteII pCAM1305.1 5'-AAAAAAGGTGACCTCAAGCTTTTTG-3'
Table 3.4: Primers to clone Tryptophan Decarboxylase into pCAMBIA1305.1.
Restriction sites are underlined and bolded.
transformation vector harboring tryptophan decarboxylase (pCAMBIA1305.1-
TDC) were transformed separately into A. rhizogenes. pCAMBIA1 300-
RebHRebF was a gift from Runguphan and Qu. 4 C. roseus Tryptophan
decarboxylase (TDC) was amplified from TDC in pGEM (pGEM-TDC was a gift
from Runguphan) and flanked with Ncol and Bstell then placed into the vector
pCAMBIA1305.1 using the primers listed in Table 3.4. These vectors were used
to transform C. roseus according to Methods Section B. C. roseus roots
overexpressing Tryptophan Decarboxylase (TDC) along with codon optimized
RebH and RebF were grown, selected and propagated according to Methods
Section B. To ensure that transgenic TDC was integrated into the genome of C.
roseus, primers were designed to amplify from the CaMV 35S promoter of
pCAMBIA1305.1 to the middle of TDC to give an amplicon of 500 basepairs.
These primers are listed in Table 3.5. The amplicon from genomic DNA is shown
in Figure 3.13. Roots expressing RebH, RebF and transgenic TDC are shown in
Figure 3.3A. Control lines overexpressing TDC only are shown in Figure 3.3B.
TDC~transgenic forward 5'-CTCTTGACCATGGATGGGCAGC-3'
TDC transgenic reverse 5'-GTGGTGITTTGGATGACGCCGCC-3'
Table 3.5: Primers for 500-bp TDC amplicon from CaMV 35S promoter to center
of TDC gene.
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1000 bp
500 bp
Figure 3.13: Agarose electrophoresis gel (1%) of TDC amplicon from RebH, RebF
and TDC-overexpressing line. Lane 1: DNA ladder. Lane 2: TDC amplicon from
constitutive eukaryotic CaMV 35S promoter to middle of TDC gene (amplicon 500
base pairs).
B. Stable Transformation Protocol - RebH Y455W and RebF
C. roseus seedlings were germinated aseptically on solid Gamborg's B5
media (full strength basal salts, full strength vitamins, 30 g/L sucrose, 6 g/L agar,
pH 5.7) and grown for 4-6 weeks in a 16-hour light 8-hour dark cycle at 26 *C.
Liquid cultures of A. rhizogenes containing the plasmid of interest were grown in
Yeast Extract and Mannitol (YEM) media supplemented with kanamycin at 30 0C
for 48 hours just prior to infection. Seedlings were wounded at the stem tip using
forceps freshly dipped in the inoculant. Hairy roots formed on the seedlings at
approximately 3 weeks on approximately 80% of the punctured seedlings. Hairy
roots were grown on the seedlings for an additional 3 weeks then excised and
placed on solid Gamborg's B5 media (half strength basal salts, full strength
vitamins, 30 g/L sucrose, 6 g/L agar, pH 5.7) containing hygromycin (0.03
mg/mL) for selection and cefotaxime to a final concentration of 0.25 mg/mL to kill
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remaining A. rhizogenes. Cultures were grown in the dark for 1 month at 26 0C
during the selection process. Following the selection process, roots were
propagated by transferring actively growing portions of the root after 21 days
onto Gamborg's B5 media lacking hygromycin and cefotaxime.
C. RebH Mutant Design and Expression
The construct containing the RebH gene (pET28a-RebH) was expressed
in BL21 (DE3) pLysS and purified with Ni-NTA resin as previously described. 4
Single-thaw aliquots were stored at -80 OC for no more than 2 weeks. Primers to
introduce 17 mutations (152F, 152Y, P53F, P53G, P53W, F111L, F111W, F111Y,
L113F, L113G, L113W, L114F, L114G, L114W, Y455F, Y455L, Y455W) into the
pET28a-RebH construct were designed using the Stratagene (Agilent) online
site-directed mutagenesis tool
(http://www.genomics.agilent.com/CollectionSubpage.aspx?PageType=Tool&Su
bPageType=ToolQCPD&PagelD=15). Mutations to the pET28a-RebH construct
were made using the QuikChange Site-Directed Mutagenesis Kit according to
manual protocol specifications. The sequences of all vector constructs were
verified by DNA sequencing. Mutant genes were expressed and purified following
the same procedure for RebH wildtype.1 Primers to introduce mutations are listed
in Table 3.6.
Primer Name Primer Sequence (5'-3')
152FSENSE GGCGAGGCCACGTTCCCCAATCTGC
152FANTISENSE GCAGATTGGGGAACGTGGCCTCGCC
152YSENSE GTCGGCGAGGCCACGTATCCCAATCTGCAGACG
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152YANTISENSE CGTCTGCAGATTGGGATACGTGGCCTCGCCGAC
P53FSENSE GGCGAGGCCACGATCTTCAATCTGCAGACGGC
P53FANTISENSE GCCGTCTGCAGATTGAAGATCGTGGCCTCGCC
P53GSENSE GCGAGGCCACGATCGGCAATCTGCAGACGG
P53GANTISENSE CCGTCTGCAGATTGCCGATCGTGGCCTCGC
P53WSENSE GGCGAGGCCACGATCTGGAATCTGCAGACGGCG
P53WANTISENSE CGCCGTCTGCAGATTCCAGATCGTGGCCTCGCC
F11 L_SENSE CCACTTCTACCACTCCTTAGGTCTGCTCAAGTACC
Fl 11 L_ANTISENSE GGTACTTGAGCAGACCTAAGGAGTGGTAGAAGTGG
Fl 11W_SENSE ACCACTTCTACCACTCCTGGGGTCTGCTCAAGTACC
F111WANTISENSE GGTACTTGAGCAGACCCCAGGAGTGGTAGAAGTGGT
Fl 11 Y_SENSE GACCACTTCTACCACTCCTATGGTCTGCTCAAGTACCA
Fl 11 Y_ANTISENSE TGGTACTTGAGCAGACCATAGGAGTGGTAGAAGTGGTC
Li 13FSENSE CTACCACTCCTTCGGTTTCCTCAAGTACCACGAGC
Li 13FANTISENSE GCTCGTGGTACTTGAGGAAACCGAAGGAGTGGTAG
Li 13GSENSE CTTCTACCACTCCTTCGGTGGGCTCAAGTACCACGAG
Li 13GANTISENSE CTCGTGGTACTTGAGCCCACCGAAGGAGTGGTAGAAG
Li 13WSENSE CTTCTACCACTCCTTCGGTTGGCTCAAGTACCACGAG
Li 13WANTISENSE CTCGTGGTACTTGAGCCAACCGAAGGAGTGGTAGAAG
Li 14FSENSE CACTCCTTCGGTCTGTTCAAGTACCACGAGC
Li 14FANTISENSE GCTCGTGGTACTTGAACAGACCGAAGGAGTG
Li 14GSENSE CCACTCCTTCGGTCTGGGCAAGTACCACGAGCAG
Li 14GANTISENSE CTGCTCGTGGTACTTGCCCAGACCGAAGGAGTGG
Li 14WSENSE CTACCACTCCTTCGGTCTGTGGAAGTACCACGAGCAGATTC
Li 14WANTISENSE GAATCTGCTCGTGGTACTTCCACAGACCGAAGGAGTGGTAG
Y455FSENSE ACGACGCCCAGCTCTACTTCGGCAACTTC
Y455FANTISENSE GAAGTTGCCGAAGTAGAGCTGGGCGTCGT
Y455LSENSE GACGACGCCCAGCTCTACTTAGGCAACTTCGAGG
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Y455LANTISENSE CCTCGAAGTTGCCTAAGTAGAGCTGGGCGTCGTC
Y455WSENSE ACGACGCCCAGCTCTACTGGGGCAACTTCGAG
Y455WANTISENSE CTCGAAGTTGCCCCAGTAGAGCTGGGCGTCGT
Table 3.6: Primers to introduce 17 separate RebH mutations.
RebH WT and RebH Y455W expression are shown in Figure 3.13.
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Figure 3.14: A. RebH WT expression (expected molecular weight 62.3 kDa). B.
RebH Y455W expression (expected molecular weight 62.3 kDa).
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D. RebH Activity Assays
RebH or RebH mutant enzyme at a final concentration of 1 [tM (estimated
by Bradford assay) was incubated with 50 [tM Flavin Adenine Dinucleotide
(FAD), 50 mM NaCl, and substrate (either 20 [tM L-tryptophan, 20 [tM tryptamine
or 1250 [tM tryptamine), in 100 mM K2HPO4 buffer (pH 7.2) in a final volume of
100 pL. For ease of screening, dithiothreitol (20 mM) was added to all in vitro
assays as a reductant for FAD. The assay mixtures were incubated at 30 'C for
12 hours, after which aliquots (25 [tL) were quenched with methanol (975 tL)
and centrifuged at 13,000 rpm for 5 minutes to remove any particulates.
Liquid chromatography was performed on an Acquity Ultra Performance
BEH C18, 1.7 [tm, 2.1 x 100 mm column. The gradient was 10-90% acetonitrile
over 4.1 minutes with water and 0.1% formic acid as the second solvent. The
flow rate was 0.6 mL/min. Ionization was performed by ESI with a Micromass
LCT Premier TOF Mass Spectrometer in positive ionization V- mode. The
formation of 7-chlorotryptophan was monitored by selected ion monitoring at m/z
239. The identity of the product was characterized by co-elution with an authentic
standard.' The formation of 7-chlorotryptamine was monitored by selected ion
monitoring at m/z 195. The halogenated tryptamine product was characterized by
co-elution with an authentic 7-chlorotryptamine standard. 4 The following control
experiments were performed for both RebH WT and RebH Y455W: (1) boiled
enzyme control, where the enzyme was boiled to deactivate it, (2) no DTT
control, where 20 mM DTT was omitted from the assay and (3) no substrate
control, where tryamine was omitted from the assay mixture. Product formation
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was not observed for RebH WT (Figure 3.15) or RebH Y455W (Figure 3.16)
when active enzyme or reductant (20 mM DTT) was removed from the assay.
7-Chlorotryptamine 2b Standard
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Figure 3.15: RebH WT tryptamine product co-elutes with an authentic 7-
chlorotryptamine standard. The RebH tryptamine product is not observed in
any of the negative controls (boiled enzyme, no DTT, no tryptamine).
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Figure 3.16: RebH Y455W chlorotryptamnine product (m/z 195) co-elutes with
an authentic 7-chlorotryptahro tandard. The RebH Y455W tryptamine
product is not observed in any of the negative controls (boiled enzyme, no
DTT, no tryptamine).
For more rigorous characterization, we also used authentic standards of
each mono-chlorinated tryptamine isomer (2-chlorotryptamine, 4-
chlorotryptamine, 5-chlorotryptamine, 6-chlorotryptamine and 7-
chlorotryptamine). Chlorinated tryptamine isomers 4-chlorotryptamine and 6-
chlorotryptamine were a gift from Elizabeth McCoy.8 Weerawat Runguphan
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provided authentic standards of chlorinated tryptamine isomers 5-
chlorotryptamine and 7-chlorotryptamine that were previously described.14 The 2-
chlorotryptamine isomer was synthesized. ('HNMR, 500 MHz, DMSO: 7.51
(1H, d, J = 7.5 Hz), 7.24 (1H, d, J= 7.5 Hz), 7.07 (1H, t, J = 7.5 Hz), 7.02 (1H, t, J
= 7.5 Hz) 2.77 (multiplet s, 4H); 13CNMR, 125 MHz, DMSO: 134.6, 126.7, 121.7,
121.1, 119.4, 117.8, 110.9, 39.2, 22.9). The RebH WT and RebH Y455W
halogenated tryptamine product co-eluted exclusively with 7-chlorotryptamine.
E. RebH Wild Type, RebH Y455W and RebH L1 13G Competition Assay Screen
Slow conversion to product in vitro prevented accurate measurement of
the steady-state enzyme kinetics parameters for wild-type (WT) RebH, RebH
Y455W and RebH L113G. RebH, RebH Y455W and RebH L113G were
assessed by competition assay with a mixture of L-tryptophan and tryptamine.
These assays contained 1 [tM enzyme, 50 [tM FAD, 50 mM NaCl, 20 mM DTT,
20 [M L-tryptophan and 20 [tM tryptamine, in 100 mM K2HPO 4 buffer (pH 7.2) in
a final volume of 100 pL. Assays were quenched and analyzed by LC-MS as
described above in Methods Section D.
F. RebH WT and RebH Y455W Selectivity at Different Tryptophan-to-Tryptamine
Ratios
Further competition assays with different substrate concentrations, as
described in the main text, were also performed with RebH WT and RebH
Y455W. Enzyme at a final concentration of 2 [tM (estimated by Bradford Assay)
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was incubated with 20 mM DTT, 1 mM FAD, 50 mM NaCl, L-tryptophan,
tryptamine and 100 mM K2HPO 4 buffer (pH 7.2) at 30 0C for 16 hours. Ratios of
L-tryptophan:tryptamine were 500:500 pM, 500:1000 pM and 1000:500 pM. The
final assay volume was 100 [L. Aliquots (25 [tL) from enzyme assays were
quenched with 975 [tL methanol and then subjected to LC-MS analysis as
outlined in Methods Section D. Conversion of substrate to product was monitored
by simultaneous selected ion monitoring of both substrate and product masses
(L-Tryptophan m/z 205), 7-chlorotryptophan (m/z 239), tryptamine (m/z 161) and
7-chlorotryptamine (m/z 195).
G. The in planta Over-Expression of RebH Y455W and RebF
Approximately 350 C. roseus seedlings were germinated aseptically on
solid Gamborg's B5 media as described according to Methods Section B. The
plant transformation vectors pCAMBIA1305.1-RebHY455W and
pCAMBIA1305.1-RebF were separately transformed into Agrobacterium
rhizogenes ATCC 15834 via electroporation according to manual specifications
(BioRad electroporator). Liquid cultures of A. rhizogenes harboring
pCAMBIA1305.1RebHY455W and A. rhizogenes harboring
pCAMBIA1305.1RebF were mixed just prior to seedling infection.
All hairy root lines surviving hygromycin selection were macerated in
methanol (between 10 and 40 mL/g of fresh weight hairy roots) using a mortar
and pestle with 106 [tm acid washed glass beads. Crude product mixtures were
filtered through a 0.2 pm cellulose acetate membrane (VWR). Prior to analysis,
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samples were centrifuged at 13,000 rpm for 5 minutes to remove any
particulates. Alkaloid methanolic extracts (60 1tL) from hairy root tissues were
added to 700 tL HPLC grade methanol and subjected to LC-MS analysis as
follows. Liquid chromatography was performed on a single quadrupole Agilent
1100 HPLC-MS. A Phenomenex C18, 2.0 [tm, 2 x 50 mm column was employed.
The gradient was 10 to 90% acetonitrile over 8 minutes with water and 0.1%
formic acid as the second solvent. The solvent composition was returned to 10%
acetonitrile by 8.1 minutes, and the column was self-equilibrated at initial run
conditions until 12 minutes. The flow rate was 0.4 mL/min. Ionization was
performed by an 1100 MSD Mass Spectrometer in positive ionization mode. The
following specifications were employed: 4000 V capillary voltage, 350 0C drying
gas temperature, 30 psig nebulizer pressure. Single ion monitoring, 50% m/z 239
for 7-chlorotryptophan and 50% m/z 359 for 12-chloro-1 9,20-
dihydroakuammicine, was used. Each run injected 20 [tL.
No halogenated alkaloids (either 12-chloro-19,20-dihydroakuammicine or
7-chlorotryptophan) were detected in negative control lines [wild type hairy roots,
hairy roots with knocked down tryptophan decarboxylase (TDCi),
pCAMBIA1305.1 empty vector]. TDCi lines were a gift from Weerawat
Runguphan .14 An authentic standard of 12-chloro-19,20-dihydroakuammicine
was previously reported .14 Quantities of 12-chloro-19,20-dihydroakuammicine
and 7-chlorotryptophan (averaged across 3 subcultures) from two representative
lines harboring both RebHY455W and RebF are shown in Table 3.2 and Table
3.3.
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Two lines producing 12-chloro-19,20-dihydroakuammicine 5b (Lines 13
and 74) were subjected to isolation of genomic DNA following manual
specifications (Qiagen DNeasy kit). Both lines contained both RebH Y455W and
RebF. A 660 basepair amplicon was amplified in RebH Y455W. The primers for
the RebH Y455W amplicon are shown in Table 3.7. Full length RebF (503
basepairs) was amplified. The primers for the full-length RebF amplicon (513
basepairs) are provided in Weerawat et al.14 These lines co-migrated with the
corresponding amplicons from pET28aRebHY455W and pET28aRebF. The
negative control lines (TDCi) did not contain the amplicon (Figure 3.17).
Exposure was set at 040 ms. Contrast was set at 1.00.
RebHY455W gDNA forwardI5'-GTCT[ GATGGGGAGG CYG 3 -
RebHY455W gDNAreverse 5'-GTAGATGTGGATGTTGTCGG-3'
Table 3.7: Primers for RebH Y455W amplicon from genomic DNA (gDNA) extraction.
RebF Y455W
1000 bp
SO bp
13 74 TOI pET2Ba 13 74 TOI pET28a
RebF Rabh
Amplicon for RebF is full length (513 bp)
Amplicon for Y455W is 660 bp
Figure 3.17: Agarose gel (1%) of genomic DNA analysis of RebH Y455W and
RebF lines. RebF and RebH Y455W amplicons are shown in root lines and in
plasmid (positive control), but not in the TDCi line (negative control).
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H. Transient Expression of RebH Y455W and RebF
The plasmids pCAMBIA1305.1-RebHWT, pCAMBIA1305.1-RebHY455W
and pCAMBIA1305.1-RebF were each transformed separately into both
Agrobacterium tumefacians strain GV 3101 and A. tumefacians LB 4404 for a
total of 6 bacterial transformations. Liquid cultures (5 mL) of A. tumefacians
containing the plasmid of interest were grown in Yeast Extract and Mannitol
(YEM) media supplemented with kanamycin at 30 0C for 48 hours just prior to
infection. Since plasmids were transformed into separate A. tumefacians strains,
the cultures harboring them were mixed (either pCAMBIA1305.1-RebHWT and
pCAMBIA1305.1-RebF or pCAMBIA1305.1-RebHY455W and pCAMBIA1305.1-
RebF) just prior to plant transformation. (1) pCAMBIA1305.1-RebHWT and
pCAMBIA1305.1-RebF and (2) pCAMBIA1 305.1 -RebHY455W and
pCAMBIA1305.1-RebF were transiently expressed in planta via two different
methods (1) syringe injection (without a needle) and (2) vacuum infiltration for
each gene combination. Transformations were conducted also by testing both A.
tumefacians strains (GV3101 and LB 4404) using each infiltration method
(vacuum infiltration or syringe injection). All transiently transformed mature
leaves, each day for 3 days after transformation, were macerated in methanol
(between 10 and 40 mL/g of fresh weight hairy roots) using a mortar and pestle
with 106 m acid washed glass beads. Crude product mixtures were filtered
through a 0.2-[tm cellulose acetate membrane (VWR). Alkaloid methanolic
extracts (30 [tL) from mature leaves were diluted with 700 [tL HPLC grade
118
methanol and subjected to LC-MS analysis as outlined in Methods Section D.
Each run used 2 [tL of extract. No chlorinated alkaloids were detected in any
transient expressions under these conditions.
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Chapter 4
Redesign of a Dioxygenase Involved in Morphine Biosynthesis
Part of this chapter is published as a communication in
Runguphan W*, Glenn WS* and O'Connor SE. Chem Biol. 2012
Jun 22;19(6):674-8. (*equal contribution)
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I. Introduction
Opium poppy (Papaver somniferum) produces an array of medicinally
important benzylisoquinoline alkaloids, including the analgesics codeine 10 and
morphine 11 (Figure 4.1).1,2 The biosynthesis of these alkaloids commences with
the Pictet-Spengler condensation of dopamine 1 and 4-
hydroxyphenylacetaldehyde 2 to form (S)-norcoclaurine 3, which is further
modified to form (S)-reticuline 4, the pivotal biosynthetic intermediate of all
benzylisoquinoline alkaloids. (S)-reticuline 4 is subsequently converted to
thebaine 5, the intermediate at the entry point of the morphinan alkaloid pathway.
Two biosynthetic routes have been proposed for the conversion of
thebaine 5 to morphine 11. 3 In the first route (route A; see Figure 4.1), thebaine
6-0-demethylase (PsT60DM) demethylates thebaine 5 at the 6 position to form
neopinone 7, which spontaneously isomerizes to form codeinone 8. Codeinone 8
is then enzymatically reduced to yield codeine 10. Codeine O-demethylase
(PsCODM) demethylates codeine 10 at the 3 position to yield morphine 11.
Alternatively, in the second route (route B; see Figure 4.1), PsCODM
demethylates thebaine 5 at the 3 position to form oripavine 6. PsT60DM
catalyzes the second demethylation of oripavine 6-this time at the 6 position-
to form morphinone 9, which is then reduced to form morphine 11. Morphinan
alkaloids thebaine 5, oripavine 6, codeine 10, and morphine 11 all accumulate in
opium poppy, suggesting that both routes are operative in Vivo.12
The discovery of O-demethylases PsCODM and PsT60DM completed the
genetic characterization of the morphinan pathway.3 These genes were
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Figure 4.1: Biosynthesis of benzylisoquinoline alkaloids in P. somniferum.
The biosynthetic pathways leading to morphine 11 via morphine 9 and
codeine 10.
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discovered through a functional genomics approach by differentially comparing
transcripts found in native opium poppy (plants that accumulate morphine)
versus poppy mutant varieties that are devoid of morphinan alkaloids.4 The
differentially expressed genes (i.e. genes expressed in morphinan alkaloid-
containing plants that were not expressed in varieties lacking morphinan
alkaloids) could then be assayed for the desired demethylase activity.4'5
Surprisingly, non-heme iron [Fe(II)]- and a-ketoglutarate-dependent
dioxygenases (PsCODM and PsT60DM), were identified from this study. Notably,
PsCODM and PsT60DM are the only members of the non-heme iron- and cc-
ketoglutarate-dependent dioxygenase family capable of catalyzing 0-
demethylation; all others are P450s.4
The morphinan pathway provides a highly attractive reengineering target
at the enzyme and pathway levels because all late pathway genes are known.
Here we demonstrate how exploiting natural enzyme variation through
systematically mixing and matching the non-conserved amino acid regions of
these two recently discovered demethylases (PsCODM and PsT60DM) has led
to an enzyme with new specificity: a PsCODM mutant that is highly selective for
codeine. The unique selectivity of the reengineered demethylase enzyme may
allow us to explore how closing the metabolic valve to route B and redirecting
substrate exclusively through route A (Figure 4.1) will impact downstream
product yields in this branched natural product pathway.
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11. Results and Discussion
A clustal alignment of PsCODM, PsT60DM, and PsDIOX2 (a P.
somniferum 2-oxoglutarate/Fe(I)-dependent dioxygenase for which the native
substrate has not yet been identified, but which is known to be able to 0-
demethylate a number of protoberberine alkaloids) 4 revealed five specific regions
where these dioxygenases differ significantly at the amino acid level: A1
(residues 145-149), A2 (residues 150-152), B (residues 334-336), C, (residues
338- 342), and C2 (residues 343 - 152) (Figure 4.2). Lacking a crystal structure
of a P. somniferum dioxygenase, we built a homology model of PsCODM based
on the crystal structure of Arabidopsis thaliana anthocyanidin synthase (AtANS),
a structurally characterized 2-oxoglutarate/Fe(ii)-dependent dioxygenase with
moderate amino acid sequence similarity to PsCODM (32% identity at the amino
acid level).6 We employed SWISS-MODEL, an automated protein homology-
modeling server, to generate the model (Figure 4.3).7 Key residues likely to be
involved in Fe(ll)/2-oxoglutarate binding are highlighted in the (Figure 4.2). The
five regions-grouped as follows, A1 and A2 (residues 145-152); B (residues
334-336); and C1 and C2 (residues 338-346)-were then mapped on to this
homology model, where they appeared to be located proximal to the anthocyanin
binding site (Figure 4.3).
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DIOX1 MEKAKLMKLGNGEIPSVQELAKLTLAEISRYVCANENL:LGASVINDHETI ?VIDI 60
DIOX2 METAKLJKIGNGMSISVQELAKLTLAEISRYICTVENLQLVGASVIDDHETVJVIDI 60
DIOX3 METPILIKLNGLSIPSVQELAKLTLAEIPSRYTCTGESPLNNIGASVTDD-ETVVIDL 59
DIOX1 ENLLSPEPI IGKLELDRLHFACKENGFFQVVNHGVDASLVDSVKSEIQGFFNLSMDEKTK 120
DIOX2 ENLISSEPVTEKLELDRLMSACKENGFFQVVNHGVDTSLVDNVKSDIQGFFNLSMNEKIK 120
DIOX3 QNLLSPEFVVGKLELDKLHSACIEWGFFQLVNHIGVDALLMNIKSEIKGFFNLPMNEKTK 119
Region A
DIOX1 YEQEDGDVFQGFIESEDQTLIDADLnWTLPLLRKPLFSKLPVPLREIESYSS 180
DIOX2 YGQKDGDVEGFGQAEVASEDQTLDNADIFMILTLLRLRKPRLFSKLPLPLRETIESYSS 180
DIOX3 YGQQDGDFEGFGQFYIESEDRLDWTEVF3E.5LFLLRKPfLFFEL?LPFRETLESYLS 179
DIOX1 EMKLSMVLFNIMEKALCVQAAEIKGMSEVFIDGTQAMRMNYY??CQN:AIGLTSHSD 240
DIOX2 EOKLSMVLFEKOEKALVQAVEIKEISEVFKDMTQVMRMNYY??CQPEAIGLTPHSD 240
DIOX3 KMKLSTVVFMLKSLQL- -VEIKMT DLFEDGLQTIMRMNYYC?R?ELVLGLTSSD 237
DIOX1 FaGLTILLQINEVEGLQIKREGTNISVKLPNAFVVNVGDILEITNGIYHSVDRAVVN 300
DIOX2 FGGLTILLWLNEVEGLQIKNEGRWISVKLNAFVVNVGDVLEIMTNGYRSVDURAVVN 300
DIOX3 FSGLTI LLQLNEVEGLQIRKEERWISIKLPDAFIVNVDILEIMTNGIYRSVEHRAVVN 297
Region B Region C
DIOX1 STNERLSIATFHDPSLESVIGPISSLITPETPALEXAMMTYGLVZMrerRKLDGKSFLD 360
DIOX2 STKERLSIATFlDNLESEIGISSLITNTALFRSGSTYSELVEEFHSRKLDGKSFLD 360
DIOX3 STKERLSIATFHDSKLESEIGISSLVTETALFKM-RYEDXLXENLSRLDGKSFLD 356
DIOX1 SMRI- 364
DIOX2 SMRM- 364
DIOX3 YMRM- 360
Figure 4.2: Sequence alignment of PsDIOX1 (PsT60DM), PsDIOX2 and PsDIOX3
(PsCODM). * indicates residues that have been proposed to be important in 2-
oxoglutarate binding. * indicates residues that have been proposed to be
important in coordinating Fe(II).
127
Figure 4.3: Homology Models of PsT60DM and PsCODM Based on the Crystal
Structure of AtANS PsT60DM is indicated in green, and PsCODM is indicated in pink.
The models were created using SWISS-MODEL. Regions Al and A2 (residues 145-
152) are shown in red, B (residues 334-336) is in yellow, and C1 and C2 (residues
338-346) are in blue.
We hypothesized that the residues' proximity to the primary substrate
binding site implicated their involvement in dictating regioselectivity, which could
be readily reengineered through mutagenesis. Specifically, we envisioned using
site-directed mutagenesis to reverse the regioselectivity of PsCODM, which
demethylates the 3 position of morphinan alkaloids, and PsT60DM, which
demethylates the 6 position of morphinan alkaloids. Initial protein expression
screening revealed that all PsT60DM mutants are expressed at low levels.
Therefore, in this study, we focused our efforts on developing engineered
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PsCODM enzymes. We systematically replaced the native PsCODM sequence
with the corresponding sequence from PsT60DM at the five nonconserved
regions using standard site-directed mutagenesis. In total, we constructed 16
PsCODM mutants (Table 4.1).
Tested PsCODM Mutants
A, A 2  B C, C2 (wild type PsCODM)
1) At* A2* B C1* C2 *
2) A,* A, B C1* C2*
3) A,* A2* B C, C2 *
4) At* A,* B C1* C2
5) A,* A2* B C, C2
6) At* A2  B C, C2 *
7) At* A 2  B CI* C 2
8) A,* A 2  B C, C2
9) A1  A2* B C1 * C2*
10) At A2  B CI* C2 *
11) A1  A2* B C1  C2*
12) A, A2* B C1* C2
13) A, A2* B C1  C2
14) A1  A, B C1  C2*
15) A, A2  B C1* C,
16) A1  A 2  B* C, C2
Table 4.1: PsCODM mutants that were constructed in this study. * indicates that
the residues in that region were mutated to those of PsT60DM
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Plasmid Template used in SDM Primers used in SDM
pQECODM A,* A2 B C C2  pQECODM A, A2 B C, C2  Forward: 5'-ggaccaaagacttgattgggctgatgtgtttagcatgttaagtc-3'
Reverse: 5'-gacttaacatgctaaacacatcagcccaatcaagtctttggtcc-3'
Then perform the second round of SDM with the following primers
Forward: 5'-ccaaagacttgattgggctgatatatttagcatgttaagtcttcctc-3'
Reverse: 5'-gaggaagacttaacatgctaaatatatcagcccaatcaagtctttgg-3'
pQECODM AI* A2* B C, C2  pQECODM A,* A2 B C, C2  Forward: 5'-aaagacttgattgggctgatatatttatgatgttaagtcttcctctccatt-3'
Reverse: 5'-aatggagaggaagacttaacatcataaatatatcagcccaatcaagtcttt-3'
Then perform the second round of SDM with the following primers
Forward: 5'-cttgattgggctgatatatttatgatgttcactcttcctctccatttaagga-3'
Reverse: 5'-tccttaaatggagaggaagagtgaacatcataaatatatcagcccaatcaag-3'
pQECODM A, A2* B CI C2  pQECODM A, A2 B C, C2  Forward: 5'-caaagacttgattggactgaagtgtttatgatgttcactcttcctctccatttaaggaagcc-
3
'
Reverse: 5'-ggcttccttaaatggagaggaagagtgaacatcataaacacttcagtccaatcaagtctttg-3'
pQECODM A, A2 B* C, C2  pQECODM AI A2 B C, C2  Forward: 5'-gacacctgctttgttcaaaagtggatctacatatgaggatattttgaagg-3'
Reverse: 5'-ccttcaaaatatcctcatatgtagatccacttttgaacaaagcaggtgtc-3'
pQECODM A, A2 B C* C2  pQECODM A, A2 B C1 C2  Forward: 5'-tttgttcaaaagaggtaggtatggggatcttttgaaggaaaatctttcaagg- 3 '
Reverse: 5'-ccttgaaagattttccttcaaaagatccccatacctacctcttttgaacaaa-3'
Then perform the second round of SDM with the following primers
Forward: 5'-caaaagaggtaggtatggggatcttgtggaggaaaatctttcaagga- 3'
Reverse: 5'-tccttgaaagattttcctccacaagatccccatacctacctcttttg-3
pQECODM A, A2 B C,* C2* pQECODM A, A2 B C,* C2  Forward: 5'-gtatggggatcttgtggaggaatgtctttcaaggaagcttga- 3 '
Reverse: 5'-tcaagcttccttgaaagacattcctccacaagatccccatac-3'
Then perform the second round of SDM with the following primers
Forward: 5'-agaggtaggtatggggatcttgtggaggaatgtaagacgaggaagcttgatggaaa-3'
Reverse: 5'-tttccatcaagcttcctcgtcttacattcctccacaagatccccatacctacctct-3'
pQECODM AI A2 B C, C2* pQECODM AI A2 B C, C2  Forward: 5'-gacacctgctttgttcaaaagaggtaggtatgaggatattttgaa
ggaatgtaagacgaggaagcttgatggaaaatcatttct-3'
Reverse: 5'-agaaatgattttccatcaagcttcctcgtcttacattccttcaa
aatatcctcatacctacctcttttgaacaaagcaggtgtc-3'
pQECODM A,* A2 BCI* C2* pQECODM AI A2 B C,* C2* Forward: 5'-ggaccaaagacttgattgggctgatgtgtttagcatgttaagtc-3'
Reverse: 5'-gacttaacatgctaaacacatcagcccaatcaagtctttggtcc-3'
Then perform the second round of SDM with the following primers
Forward: 5'-ccaaagacttgattgggctgatatatttagcatgttaagtcttcctc- 3'
Reverse: 5'-gaggaagacttaacatgctaaatatatcagcccaatcaagtctttgg-3'
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Plasmid Template used in SDM Primers used in SDM
pQECODM A,*A 2* BC1 *C2* pQECODM A,* A2 BCI* C2* Forward: 5'-aaagacttgattgggctgatatatttatgatgttaagtcttcctctccatt-3'
Reverse: 5'-aatggagaggaagacttaacatcataaatatatcagcccaatcaagtcttt-3'
Then perform the second round of SDM with the following primers
Forward: 5'-cttgattgggctgatatatttatgatgttcactcttcctctccatttaagga-3'
Reverse: 5'-tccttaaatggagaggaagagtgaacatcataaatatatcagcccaatcaag-3'
pQECODM A, A2* B C1* C2  pQECODM A, A2 B C1 * C2  Forward: 5'-caaagacttgattggactgaagtgtttatgatgttcactcttcctctccatttaaggaagcc-3'
Reverse: 5'-ggcttccttaaatggagaggaagagtgaacatcataaacacttcagtcaatcaagttttg-3'
pQECODM AI* A2 B C1 C2* pQECODM A,* A2 B C C2  Forward: 5'-gacacctgctttgttcaaaagaggtaggtatgaggatattttgaa
ggaatgtaagacgaggaagcttgatggaaaatcatttct-3'
Reverse: 5'-agaaatgattttccatcaagcttcctcgtcttacattccttcaa
aatatcctcatacctacctcttttgaacaaagcaggtgtc-3'
pQECODM A, A2* B C, C2* pQECODM A, A2* B C, C2  Forward: 5'-gacacctgctttgttcaaaagaggtaggtatgaggatattttgaa
ggaatgtaagacgaggaagcttgatggaaaatcatttct-3'
Reverse: 5'-agaaatgattttccatcaagcttcctcgtcttacattccttcaa
aatatcctcatacctacctcttttgaacaaagcaggtgtc-3'
pQECODM AI* A2* BC C2* pQECODM AI* A2* B C, C2  Forward: 5'-gacacctgctttgttcaaaagaggtaggtatgaggatattttgaa
ggaatgtaagacgaggaagcttgatggaaaatcatttct-3'
Reverse: 5'-agaaatgattttccatcaagcttcctcgtcttacattccttcaa
aatatcctcatacctacctcttttgaacaaagcaggtgtc-3'
pQECODM A, A2* B CI*C2 * pQECODM A, A2 B Cj* C2* Forward: 5'-caaagacttgattggactgaagtgtttatgatgttcactcttccttccatttaaggaagcc- 3'
Reverse: 5'-ggcttccttaaatggagaggaagagtgaacatcataaacacttcagtcaatcaagtCtttg- 3 '
pQECODM AI* A2* BC,* C2  pQECODM AI* A2* B C, C2  Forward: 5'-tttgttcaaaagaggtaggtatggggatcttttgaaggaaaatctttcaagg- 3'
Reverse: 5'-ccttgaaagattttecttcaaaagatccccatacctacctcttttgaacaaa-3'
Then perform the second round of SDM with the following primers
Forward: 5'-caaaagaggtaggtatggggatcttgtggaggaaaatctttcaagga-3'
Reverse: 5'-tccttgaaagattttcctccacaagatccccatacctacctcttttg-3'
pQECODM AI* A2 B C,* C, pQECODM A,* A2 B C1 C2  Forward: 5'-tttgttcaaaagaggtaggtatggggatcttttgaaggaaaatctttcaagg- 3 '
Reverse: 5'-ccttgaaagattttccttcaaaagatccccatacctacctcttttgaacaaa-3'
Then perform the second round of SDM with the following primers
Forward: 5'-caaaagaggtaggtatggggatcttgtggaggaaaatctttcaagga-3'
Reverse: 5'-tccttgaaagattttcctccacaagatccccatacctacctcttttg-3'
Dr. Jillian Hagel and Professor Peter Facchini (University of Calgary,
Calgary, Alberta, Canada) provided Escherichia coli expression plasmids
pQEDIOX1 and pQEDIOX3, which contain the open reading frames of P.
somniferum T60DM and CODM, respectively. Primers to design the mutant
constructs are listed in Table 4.2. We adapted heterologous expression
conditions for E. coli from a previously reported protocol.3 Protein expression of
the majority of PsCODM mutants was robust (Figure 4.4). Only the A1A 2*BC1C 2
mutant (S149M L151F S152T mutant; the asterisk designates the mutated
region) was expressed at low levels, perhaps due to improper folding. We
screened each of the mutant enzymes with substrates thebaine 5 and codeine 10
at a concentration of 0.25 mM. Assay conditions are provided in Methods.
Product formation was monitored using liquid chromatography-mass
spectrometry (LC-MS). LC-MS chromatograms of representative in vitro
enzymatic assays of wild type and mutant PsCODM enzymes are shown in
Figures 4.5 and 4.6, respectively. These endpoint assays indicated that the
majority of the mutants lost 0-demethylase activity toward both thebaine 5 and
codeine 10. Out of the total of 16 mutants, only two, A1A 2 BC1*C 2 (E338G 1340L
L341V K342E) and A1A2B*C1C 2 (R334S R336S+T), retained O-demethylase
activity toward either thebaine 5 or codeine 10 (Figure 4.5). The A1A 2B*C1C 2
mutant was similar to the wild type enzyme in that it turned over both thebaine 5
and codeine 10 to yield oripavine 6 and morphine 11, respectively.
The co-elution of the wild type PsCODM and PsCODM A1A2B*C 1C2 mutant
thebaine 5 demethylation products suggests that the A1A2B*C1C 2 mutant
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Figure 44: SDS-PAGE of purified wild type and mutant PsCODM enzymes
from Talon colbalt affinity column (Clontech). Arrow indicates band
corresponding to the correct molecular weight.
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retained regiospecificity for the 3 position of thebaine 5 (Figure 4.5). In contrast,
the AiA2 BC1*C 2 mutant displayed only negligible 0-demethylation activity for
thebaine 5 but selectively turned over codeine 10 (Figure 4.5). Since codeine 10
only contains a methoxy group at the 3 position, the C3 regioselectivity of the
AiA2 BC1*C 2 mutant is also clearly unchanged from the wild type PsCODM.
Competitive assay conditions with both thebaine 5 (0.25 mM) and codeine 10
(0.25 mM) were also employed to assess the activity of PsCODM mutants
(Figure 4.5). Morphine 11 and oripavine 6 products formed at a 4:1 ratio when
wild type PsCODM was subjected to these assay conditions. Similarly, the
A1A 2B*C1 C2 mutant also yielded morphine 11 and oripavine 6 at approximately a
4:1 ratio, though notably at lower concentrations than the wild type enzyme,
HO
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Figure 4.5: PsCODM and representative PsCODM mutants with codeine 10. Only
A1B 2B*C1C2 and AiA 2BC1*C 2 retain activity for codeine 10. qE30 is empty vector.
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Figure 4.6: PsCODM wild type and representative PsCODM mutants with thebaine
5. Only A1B 2B*C1 C2 and A1A2BC1*C 2 (negligible) retain activity for thebaine 5.
qE30 is the empty vector control.
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Figure 4.7: PsCODM wild type and representative PsCODM mutants in a
competition assay with both codeine 10 and thebaine 5. Only A1B 2B*C1C 2 and
AiA 2BCI*C 2 retain activity for either substrate; AiA 2 BC1*C 2 is specific for
codeine 10. qE30 is the empty vector control.
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indicating lower catalytic efficiency for the mutated enzyme. However, while the
AiA2BC1*C 2 mutant produced only negligible amounts of oripavine 6, morphine
11 was produced at levels similar to those observed with wild type enzyme,
confirming the stringent selectivity of the A1A 2BC1*C 2 mutant.
We measured the steady-state kinetic parameters of wild type PsCODM
and mutant PsCODM AiA2 BC1*C 2 by monitoring the rate of product formation. In
total, we measured kinetic parameters for the following combinations: (1) wild
type PsCODM with codeine (kcat/KM = 9.54 x10-7s-1 tM-1 and KM = 72.3 ± 33.4
tM); (2) wild type PsCODM with thebaine (kcat/KM = 1.52 x 10-8 s-'iM- and KM =
216 ± 76.2 [M); and (3) PsCODM mutant A1A 2BC1*C 2 with codeine (kcat/KM =
3.62x10-7 s-1 M~1 and KM = 99.0 ± 22.4 [M). Notably, the mutant enzyme formed
only negligible amounts of the thebaine 5 demethylation product after 4 hr even
when substrate concentrations were as high as 2,000 [M. Steady-state kinetic
data are shown in Figures 4.8-4.10; Table 4.3).
Although structural information is not yet available for these demethylases,
we could build a homology model for both wild type and A1A 2BC1*C 2 mutant
PsCODM based on the anthocyanidin synthase enzyme docked with thebaine 5.
While these computational results must be interpreted with caution, docking
studies suggest that the binding orientation of thebaine differs substantially
between the wild type enzyme and the A1A 2 BC1*C 2 mutant (Figures 4.10 and
4.11). Specifically, in the model of the mutant with thebaine 5, the
histidine/asparate facial triad seemingly anchors the iron-oxo complex away from
the 0-methyl moiety. It is interesting that the homology model (Figure 4.2) also
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predicts that the C1 region switches from an alpha helix in the wild type enzyme
to a random coil in the codeine-specific mutant, suggesting that the mutation in
the C1 region introduces changes to the PsCODM secondary structure.
Parameters WT with AIA 2BC,*C 2  WT with AA 2 BC,*C2
Codeine with Codeine Thebaine with Thebaine
Vmax (gM/min) 0.299 ± 0.044 0.213 ± 0.015 0.043 ± 0.001 ND
Km ([M) 72.2 ± 33.4 99.0 ± 22.4 216.1 ±76.2 ND
kcat (s-) 6.90 x 10-s 3.58 x 10- 3.28 x 10-6 ND
kcat/KM (s- pM-) 9.54 x 10-7 3.62 x 10-7 1.52 x 10-8 ND
r2 0.92 0.97 0.96 ND
replicates 2 3 2 3
Table 4.3:Summary of kinetic parameters for PsCODM and Mutant
AA 2BC,*C 2with codeine 10 and thebaine 5.
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Figure 4.8: Michaelis-Menten curve of WT PsCODM with codeine 10.
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Figure 4.10: Michaelis-Menten curve of Mutant A1A 2BC 1*C2 with codeine 10.
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Figure 4.12: Thebaine docked into wild type PsCODM (DIOX3).
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Figure 4.14 Codeine docked into wild type PsCODM (DIOX3).
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Figure 4.15: Codeine docked into PsCODM (DIOX3) Mutant AA 2BCI*C 2.
The mutation in the Ci* region appears to prevent productive binding of the
thebaine 5 substrate without greatly altering the catalytic efficiency for codeine 10
(kat/Km = 9.54 x10-7s- M-1 for wild-type, kat/KM = 3.62 X10 ~7S~ M- for mutant).
In the models, the binding orientation of codeine 10 does not appear to differ
substantially between the wild type enzyme and the A1A 2 BC1*C 2 mutant.
At the outset of this study, we hypothesized that the amino acid differences
between PsCODM, a C3 O-demethylase, and PsT60DM, a C6 O-demethylase,
would control the distinct regioselectivity of the demethylation reactions.
Therefore, we expected that swapping the non-conserved amino acid regions of
these two enzymes would alter the regioselectivity of the mutated enzymes.
Instead, the mutations altered the substrate selectivity in an unpredictable
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manner. Moreover, the A1A 2 BC1*C 2 PsCODM mutant retained C3
regioselectivity.
Notably, PsT60DM turns over thebaine 5 and oripavine 6, and PsCODM
turns over thebaine 5 and codeine 10. Despite both wild type enzymes accepting
thebaine 5, the introduction of residues from PsT60DM into PsCODM at the C1
position (Figure 4.3) yields a mutant PsCODM enzyme that is selective for
codeine 10. This change in substrate specificity does not readily correlate with
the substrate specificity of the parent wild type enzymes. Particularly in the
absence of experimental structural data, it is difficult to rationalize what structural
changes these mutations confer to PsCODM and how these changes impact
substrate specificity. Nevertheless, while this work highlights the difficulty of
rational, structure-based protein design, we successfully demonstrate how
sequence alignment of enzymes with subtle differences in specificity can be used
to readily generate swapped sequences that are functionally distinct from
naturally occurring wild-type variations.
One goal of metabolic engineering is the removal of shunt or redundant
pathways that adversely impact production yields of a desired compound.8 This
A1A2BC1*C 2 PsCODM mutant may fulfill an engineering function by providing a
means to shut off a redundant route (route B in Figure 1) in morphinan
biosynthesis. Because A1A 2BC1*C 2 PsCODM fails to demethylate thebaine 5 to
form oripavine 6, the first committed step of route B, replacement of wild-type
PsCODM with the A1A 2 BC1*C 2 mutant would presumably force the morphine
pathway to proceed via route A.
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Notably, growers in India, a major cultivator of licit opium, inadvertently
counter-selected for P. somniferum cultivars low in oripavine 6 when selecting for
the highest seed quality and opium yields, suggesting that low oripavine 6
production levels may correlate with economically desirable traits.9 Therefore, in
addition to assessing how knock-outs of wild type PsCODM and PsT60DM affect
flux into morphine production, it will be of interest to observe how using the
PsCODM A1A2 BC 1*C2 mutant-which effectively sidesteps oripavine 6
production by committing thebaine 5 to route A-instead of the wild type
PsCODM enzyme would impact titers of codeine 10 and morphine 11. 9
Moreover, substantial interest lies in reconstituting morphinan alkaloid
biosynthesis in yeast and E. coli.' 0 12 Mutants with altered specificity such as
PsCODM A1A 2BC1*C 2 could provide important building blocks for these synthetic
biology efforts.
III. Conclusions
We have altered the substrate specificity of a morphinan pathway enzyme
codeine O-demethylase (PsCODM). One PsCODM mutant, mutant A1A2BC1*C 2
(E338G 1340L L341V K342E), exhibits demethylase activity exclusively toward
codeine 10, whereas the wild type PsCODM exhibits demethylase activity with
both codeine 10 and thebaine 5. These results provide a starting point for
rationalizing how PsCODM and PsT60DM, two enzymes involved in morphinan
biosynthesis with 73% identity at the amino acid level, facilitate O-demethylation
regioselectivity on separate sets of substrates. In addition to providing insight into
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O-demethylase substrate selectivity, this mutant could also be useful in
biotechnological efforts to provide P. somniferum strains with augmented yields
of codeine 10 and morphine 11 and diminished titers of oripavine 6, an
intermediate in a redundant pathway branch that has been associated with poor
seed quality and low opium yields.9 In short, mutants with enhanced enzyme
selectivity will allow us to explore how the targeted disruption of a redundant
pathway branch affects downstream product yields and may enable more
efficient production of these high value compounds. In addition to the potential
biotechnological applications of this enzyme, these protein engineering efforts
also provide a starting point for understanding how the subtle sequence
differences of highly similar enzymes can impact substrate and regioselectivity.
IV. Methods
A. Construction of PsCODM Mutant Expression Plasmids
pQEDIOX1 (pQET60DM) and pQEDIOX3 (pQECODM), which contain the
open reading frames of PsT60DM and PsCODM, respectively, were provided by
Professor Peter Facchini and Dr. Jillian Hagel (University of Calgary). To obtain
the 16 CODM mutants (Table 4.1), site-directed mutagenesis (SDM) was per-
formed using the Stratagene QuikChange Site-Directed Mutagenesis kit. SDM
primers are listed in the Supplemental Information (Table 4.1). The PsCODM
mutant constructs were sequenced to verify the DNA sequence and were
subsequently transformed for expression into E. coli strain SG13009 (QIAGEN)
via electroporation using standard protocols.
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B. Heterologous Expression of PsCODM Mutants
A single transformed E. coli colony (strain SG13009 [QIAGEN]) was
inoculated in 10 ml Luria-Bertani (LB) media supplemented with kanamycin (0.05
g/l) and ampicillin (0.1 g/l) and incubated overnight at 370C with shaking at 225
rpm. Subsequently, 800 ml LB media supplemented with kanamycin (0.05 g/l)
and ampicillin (0.1 g/l) was inoculated with an overnight culture (8 ml) and incu-
bated at 370C with shaking at 225 rpm until reaching an optical density 600
(ODoo) of 0.6. Protein expression was induced by the addition of isopropyl-P-D-
galactopyranoside (IPTG; final concentration 0.3 mM). Following induction, cells
were incubated at 60C with shaking at 225 rpm for 24 hr. Cells were harvested by
centrifugation and lysed by sonication. The hexa-histidine-tagged PsCODM
mutants were purified using Talon colbalt affinity column (Clontech) using the
manufacturer's protocols. Eluted enzyme was subsequently buffer-exchanged
into Tris buffer (100 mM Tris-HCI, pH 7.4, 10% [v/v] glycerol, and 14 mM 2-
mercaptoethanol) and immediately assayed for activity. These enzymes were not
stable upon extended storage.
C. In Vitro Activity Assay of PsCODM Mutants
The in vitro activity assay protocol was adapted from a previous report
(Hagel and Facchini, 2010). Briefly, the assay for 2-oxoglutarate/Fe(ll)-
dependent dioxygenase activity was performed using a 100 ml reaction mixture
of 100 mM Tris-HCI (pH 7.4), 10% (v/v) glycerol, 14 mM 2-mercaptoethanol, 0.25
145
mM alkaloid(s), 10 mM 2-oxoglutarate, 10 mM sodium ascorbate, 0.5 mM
FeSO4, and 1 mM purified enzyme. Assays were carried out for 4 hr at 30 C.
Aliquots (25 ml) were quenched in 1 ml methanol containing yohimbine (500 nM)
as an internal standard. The samples were centrifuged in a microcen- trifuge
(13,000 rpm, 5 min) to remove particulates and then analyzed by LC-MS.
Samples were ionized by ESI with a Micromass LCT Premier TOF Mass
Spectrometer. The LC was performed on an Acquity Ultra Performance BEH
C18, 1.7 [tM, 2.1 x 100 mm column on a gradient of 10%-90% acetoni-
trile/water (0.1% formic acid) over 5 min at a flow rate of 0.6 ml/min. The
appearance of morphine 11 and oripavine 6 was monitored by peak integration
and normalized to the internal standard. All chemicals were obtained from a
commercial source (Sigma Aldrich).
D. Steady-State Kinetic Assay of Wild-Type CODM and AjA2BCi*C 2 Mutant
Assay components were used in the following final concentrations: pH 7.4
Tris-HCI (67 mM) containing 10% (v/v) glycerol and 14 mM 2-mercaptoethanol,
o-ketoglutarate (6.7 mM), sodium ascorbate (6.7 mM), iron (11) sulfate (333 mM),
and enzyme wild type (4.1 mg/ml) or enzyme mutant (18 mg/ml), in an assay
volume of 150 ml. The enzyme concentrations were estimated by Bradford
assay. Assays were initiated by addition of iron (II) sulfate and conducted at
300C. Aliquots (25 ml) were quenched every 30 min from 1 to 3 hr with 975 ml
methanol containing 500 nM ajmaline as an internal standard. Prior to analysis,
methanol quenched samples were centrifuged in a microcentrifuge at 13,000 rpm
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for 5 min to remove any particulates. Liquid chromatography was performed on
an Acquity Ultra Performance BEH C18, 1.7 [tM, 2.1 x 100 mm column. The
gradient was 10%-90% acetonitrile over 4 min with water and 0.1% formic acid
in water as the second solvent. The flow rate was 0.5 mI/min. We performed
electrospray ionization (ESI) with a Micromass LCT Premier TOF Mass
Spectrometer in positive ionization V-mode.
Product accumulation was measured to determine the kinetic parameters. A
standard curve for morphine 11, the demethylation product of codeine 10, was
constructed to determine the kinetic parameters of codeine 10 demethylation.
However, oripavine 6, the demethylation product of thebaine 5, was unavailable;
therefore, hydromorphonone, which was available, was used as a surrogate.
Plotted experimental data were fit to a Michaelis-Menten curve using SigmaPlot
version 9.0. Experiments were duplicated or triplicated to ensure reproducibility.
E. Computational modeling
Both wild type and mutant PsCODM homology models were built using A.
thaliana anthocyanadin synthase (AtANS) as a template in SWISS MODEL.
Primary substrates were docked into the active site at the lowest catalytically
competent conformation. The location of the iron-oxo species was postulated
based on the position of histidine/aspartate facial triad.
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Chapter 5
Conclusions and Future Work: The Alkaloids and Beyond
I. Conclusions
Chapter 1 opens the thesis by discussing current work in the
understanding and manipulation of plant natural product biosynthesis.
Specifically, chapter 1 surveys current research regarding monoterpene indole
alkaloids, benzylisoquinoline alkaloids and the glucosinolates. These classes of
compounds have been witness to heroic efforts aimed at enzyme discovery and
engineering. These efforts have undoubtedly been energized by the desire to
harness and improve yields of these highly bioactive compounds.
While many pathway segments of benzylisoquinoline biosynthesis-most
notably the morphinan pathway'-have been completely characterized,
monoterpene indole alkaloid biosynthesis has not been fully elucidated in any
organism. Fully elucidated pathways are more amenable to various engineering
strategies. Moreover, we also have an impetus to study missing pathway steps
because they may possess unique and interesting chemistry. Approximately
three steps are missing in the biosynthesis of secologanin, a direct monoterpene
indole alkaloid precursor in Madagascar periwinkle (Figure 5.1). Chapter 2
chronicles our efforts to discover 10-hydroxygeraniol oxidoreductase activity in
periwinkle (Figure 5.1). This enzyme is positioned at the seat of iridoid
biosynthesis and produces the substrate for the iridoid synthase, which
assembles the characteristic iridoid molecular scaffold.
Despite having an incomplete understanding of monoterpene indole
alkaloid biosynthesis, our lab has demonstrated several successful engineering
strategies for this pathway, most notably the incorporation of halogens.4-6
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Figure 5.1: Proposed biosynthesis of secologanin 13. Chapter 2 focuses on the
discovery of 10-hydroxygeraniol oxidoreductase activity in C. roseus. 10-
hydroxygeraniol reductase oxidizes both hydroxyl moieties of 10-hydroxygeraniol 5
to form 10-oxogeranial 6 (dotted line box), which is the substrate for Iridoid
Synthase-the enzyme that assembles the iridoid scaffold. Approximately 4 steps are
missing in the biosynthesis of secologanin 13.
Runguphan et al. provides a seminal study on the de novo production of halogenated
alkaloids by introducing prokaryotic genes that code for tryptophan halogenases into
periwinkle, a terrestrial plant.5 This is the first example of de novo combinatorial
biosynthesis in plants. In this study, Runguphan et al. produced 12-chloro-19,20-
dihydroakuammicine 13 at a titer of 25 [tg per gram fresh weight.5 However, because of
the metabolic bottleneck situated at tryptophan decarboxylase (TDC), the plant also
accumulated 7-chlorotryptophan-the RebH/F product-at 50 tig per gram fresh weight
(twice as high as the chlorinated alkaloid titer).5 We posited that the accumulation of 7-
chlorotryptophan-an analog to a canonical, proteinogenic amino acid that is structurally
similar to an auxin growth hormone-caused the slow growth and browning morphology
observed in Runguphan et aI.'s intial study. Therefore, as highlighted in chapter 3, we
explored two strategies to alleviate the metabolic bottleneck: (1) over-expressing
endogenous TDC and (2) reengineering RebH to preferentially chlorinate tryptamine, a
downstream and direct alkaloid precursor, instead of the native substrate L-tryptophan
(Figure 5.2).6 While over-expressing endogenous TDC failed to fracture the metabolic
bottleneck, we successfully circumnavigated the bottleneck by reengineering RebH to
preferentially accept tryptamine (Figure 5.2).6 The tryptamine specific mutant RebH
Y455W along with flavin reductase RebF was incorporated into periwinkle's metabolism,
and we observed de novo production of 12-chloro-19,20-dihydroakuammicine 13. In
contrast to Runguphan et al., no 7-chlorotryptophan was observed when this mutant was
employed, demonstrating its desired substrate selectivity (Figure 5.2).6
Pathways are more amenable to sophisticated engineering strategies (or only
plausible) when the targeted pathway is completely characterized. The morphinan
pathway, whose elucidation was completed in 2010 with the discovered of the two
dioxygenases Codeine O-Demethylase (PsCODM) and Thebaine 6-0-Demethylase
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Figure 5.2: RebH was reengineered to preferentially chlorinate tryptamine 11 instead of
native L-tryptophan. This strategy successfully alleviated the metabolic bottleneck by
circumventing it altogether. Incorporation of this mutant into the MIA metabolism of C.
roseus (Madagascar periwinkle) led to the de novo production of halogenated metabolite
12-chloro-19,20-dihydroakuammicine 13, without the accumulation of 7-
chlorotryptophan, highlighting the reengineered specificity of the enzyme.
(PsT60DM) from Papaver somniferum, is particularly attractive as it produces codeine
and morphine.' The pathway utilizes two separate routes to convert thebaine into
morphine.' Chapter 4 archives our serendipitous discovery of a PsCODM mutant that
would presumably selectively disable one pathway-adventitiously, the pathway
associated with poor licit opium and seed quality-while simultaneously committing
thebaine to the route with more medicinally valuable compounds.7
The PsCODM project began by attempting to switch the regioselectivity of
PsCODM (which selectively demethylates the 3 position of thebaine 18 and codeine 21)
and PsT60DM (which selectively demethyltes the 6 position of thebaine 18 and
oripavine 22). The enzymes' primary structures are highly similar, but sequence analysis
pinpointed five regions of dissimilarity. We hypothesized that mixing-and-matching the
regions of dissimilarity between the two sequences would alter the enzymes'
regioselectivity and, in turn, offer some insight into how regioselectivity is controlled in
this class of enzyme.
PsT60DM mutants were only poorly expressed; therefore, we focused our efforts
on PsCODM mutants. While most of the 16 mutants were inactive for either thebaine or
codeine, one PsCODM mutant (E338G 1340L L341V K342E) selectivity demethylates
codeine. This switch in selectivity does not readily correlate to the selectivities of the
parent enzymes. Nonetheless, this mutant could fulfill a pivotal role in morphinan
pathway reconstitution (Figure 5.3).
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Figure 5.3: PsCODM mutant E338G 1340L L314V K342E selectively demethylates
thebaine 14. This mutant disables route B, which has been associated with poor licit
opium and seed quality and instead commits thebaine 14 to the more medicinally
useful pathway that produces codeine 17 and leads to morphine 20.
II. Future Directions - The Alkaloids and Beyond
Historically, altering metabolic pathways in plants to achieve a given end has
been difficult. Metabolic engineering in plants is still in its infancy and until very recently
has largely been confined to single-gene expression or silencing events in the
background of endogenous plant cell metabolism. The complexity of the plant host's
metabolism has been shown, in many cases, to effectively mute the engineering effort or
lead to unpredictable results (Table 1.1). However, in recent years, a wealth of new
approaches has expanded the capabilities of multi-gene pathway expression in both
plants and microbes and has highlighted our increasing ability to engineer the production
of plant natural products in both plants and heterologous systems. The increase in
available and reliable sequencing and expression data enables the (relatively) facile
discovery of gene, transporter and regulatory elements, the identification of which is
often a prerequisite for multi-step metabolic engineering efforts. The three case studies
described in Chapter 1 (MIAs, BIAs and glucosinolates) exemplify the challenges and
progress in metabolically engineering plant-derived natural products. While we have
made a special effort to highlight the advantages and pitfalls of individual techniques and
efforts throughout this thesis, a number of grand challenges for plant metabolic
engineering remain to be tackled in the coming years.
A. Effective Mining Strategies
Effective mining strategies, such as those employed by Giddings et al.,8 Hagel et
al.,' Winzer et al.,9 Liscombe et al.,10 and Geu-Flores et al.,' are required to sift through
the mounting data of the sequencing age. Hanson et al. provides a recent
comprehensive review of effective mining strategies and phylogenetic analyses.
Traditionally, plant enzyme discovery methods have relied heavily upon time-intensive
reverse genetics based strategies. Bioinformatic techniques that engage co-expression
analyses and comparative metabolite profiling to limit the gene space to be investigated
are greatly accelerating the discovery process in plant systems. Moreover, a suite of
new silencing tools, including VIGS,1 2 RNAi13 and the IL-60 system,14 can provide rapid
insight into the physiological function of plant enzymes.
B. Metabolic Engineering in Native Versus Non-Native Hosts
Many efforts aimed at improving the yield of alkaloids in native hosts have
focused on feeding precursors and over-expressing transcription factors or enzymes
positioned at metabolic bottlenecks. While these efforts often result in modest
improvements to yield (Table 1.1), many are often accompanied by adverse
morphological effects that may significantly stunt the growth of plant and tissue cultures,
highlighting the tight regulation of metabolic processes within highly organized plant cells
and tissues. In native systems especially, the slow growth phenotypes may result from
the depletion of cellular resources used in synthesizing a surfeit of transcripts and
enzymes or from the accumulation of toxic intermediates that negatively impact growth
and development. Engineering in native hosts or heterologous plant species is attractive
because not having to build the starting substrates and supply the co-factors greatly
simplifies engineering efforts. However, with this strategy, maintaining the balance
between primary metabolism and the engineered metabolism-a feat that will likely
improve growth morphologies-is complicated precisely because endogenous primary
metabolite pools are expropriated for the overproduction of selected metabolites. Also,
despite the advantage of minimal gene stacking, the often uncharacterized and
unanticipated complex metabolism and regulatory elements of native systems can lead
to engineering outcomes that are particularly difficult to control and predict. The
industrial scale production of plant natural products will likely require more
comprehensive engineering efforts than single-gene over-expression or silencing events
in the context of native plant hosts. Engineering in faster-growing and "chemically silent"
heterologous hosts may increase biomass accumulation and simplify purification.
C. Controlling Metabolic Flux through New Expression Constructs, Scaffolds and
Tunable Regulatory Elements
The intricate relationship between primary metabolism (i.e. glycolysis, the TCA
cycle) and the native or heterologous secondary metabolism (i.e. isoprenoid and alkaloid
pathways) must be considered. In plants, Park et al. alluded to this interplay by
demonstrating that BBE expression levels vastly affect amino acid levels.15'16 As
metabolic engineering strategies in plants become more sophisticated, we should also
begin to consider flux analyses, taking into account that natural product pathways are
evolutionarily optimized to channel intermediates toward product through a highly
choreographed system of protein-protein interactions, localization and regulation .7 The
overall goal is to maximally channel metabolic resources to the desired products without
over taxing the host system.
Co-localization through scaffolding is a proven way to channel metabolites in E.
coli. These systems attempt to mock natural megasynthases, which efficiently shuttle
metabolites between adjacent active sites. Essentially, scaffolding increases the local
metabolite and enzyme concentrations and effectively lowers the Km of the substrate.
These systems are widely modular and are known to improve titers, alleviate metabolic
bottlenecks and reduce metabolic loads by preventing carbon from exiting the pathway.
Under conditions of low enzyme expression (decreased metabolic load), Dueber et al.
successfully achieved a 77-fold enhancement in mevalonate production by building a
scaffold based on the protein-protein interactions of GBD, SH3 and PDZ domains and
their cognate ligands.18 They built the scaffold on hydroxymethylglutaryl-CoA reductase,
the enzymatic bottleneck of mevalonate production.18 Notably, these scaffolding systems
require that the enzyme at the metabolic bottleneck, the subsequent enzyme and the
substrate be co-localized,18 underscoring why they may be untenable for some highly
compartmentalized systems. Nonetheless, the prospect of engineering metabolons into
plants is exciting.
The effective metabolic engineering of plant natural products will inevitably
require advanced, but easy-to-use, gene stacking techniques. Traditionally, multi-gene
expression in plants has been plagued with inadvertent silencing events, the incomplete
incorporation of all genes and lengthy and technically challenging procedures.19 A
number of new technologies, however, are being developed to assemble and transplant
large fragments of DNA.19 Golden Gate cloning and USER fusion have been used to
clone multiple pathway elements. 1 9,20 Additionally, synthetic plant chromosomes and the
universal expression and silencing IL-60 platform both have the demonstrated capability
of introducing multiple plant pathway elements into plants.1921 For example, under the
transformation-free IL-60 platform, Mozes-Koch et al. expressed an entire bacterial
operon in tomato and produced pyrollinitrin, which they observed after only two days.
A number of RNA-based silencing systems, including RNAi, have also been
engineered and applied to medicinal plants.22 Notably, RNAi, which provides a
permanent pheno- or chemotype, has been employed to block shunt pathways and
channel metabolic resources toward a desired product, enhancing our ability to engineer
in multiple dimensions.22
Lastly, promoter libraries, engineered untranslated regions (i.e. 5' untranslated
regions and intergenic regions), genetic circuit designs and biosensor regulators have
been tremendously helpful in microbial engineering. Applying these design principles to
the metabolic engineering of plants may greatly enrich our efforts to produce valuable
and chemically diverse alkaloids. Notably, a variety of constitutive and inducible plant
promoters and expression systems are now widely available. Synthetic RNA elements,
ribosome binding site elements and a combination of different strength promoters
strategically placed in front of stacked pathway genes could theoretically enable tunable
protein expression.2 24 These elements could potentially limit the expression of toxic
activities or the accumulation of toxic metabolites until the stationary phase (or an
appropriate stage) of growth, thereby absolving the system of unsustainable metabolic
burden.
D. Localization and Transport - Engineering in Multiple Dimensions
Many alkaloid biosynthetic pathways are highly compartmentalized at both the
inter- and intracellular levels. For example, at least three cell types are required for the
biosynthesis of many MIAs.25 The impact that localization has on product yields is not
currently well understood. The forward engineering of plant natural products will require
sifting through the increasing amount of available sequencing and expression data and
untangling the complexity of the plant cell and different tissue types. In addition to the
linear design and channeling of metabolic pathways, the successful metabolic
engineering of plant natural products will require engineering in the "third dimension,"
namely at the level of localization and cell type.
E. Physiological Relevance of Alkaloids
It is not entirely clear what role the alkaloids have evolved to fulfill, though it is
commonly postulated that the alkaloids are defense compounds that protect the plant.
Certainly that is a sensible hypothesis given that most alkaloids exhibit some degree of
bioactivity. This hypothesis could potentially be tested first by studying how generalist
herbivores feed on alkaloid-containing plants versus engineered plants devoid of
alkaloids (e.g. the C. roseus tryptophan decarboxylase RNA interference line).27
Increased feeding on lines devoid of alkaloids would suggest that the alkaloids are plant
defense compounds. Secondly, introducing a non-canonical amino acid or radio-labeled
tag into the plant may permit the direct study of what proteins are expressed in response
to insect feeding. Notably, this strategy may also require that the plant's amino acyl
tRNA synthetases be reengineered to accommodate these non-canonical amino acids.
Therefore, comparative transcriptomic, proteomic and metabolomic analyses may be
cheaper, faster and easier, but potentially less direct. Up-regulation of known alkaloid
biosynthetic enzymes and alkaloid production would strongly implicate alkaloids in plant
defense strategies.
F. Combinatorial Biosynthesis in Plants - Mixing and Matching Pathways and
Engineering New Enzyme Specificities
De novo combinatorial biosynthesis in plant systems has gone largely
underexplored. Most of the few efforts to engineer unnatural natural products have
utilized precursor feeding or mutasynthesis-based approaches, which can be costly and
time intensive., 27 The de novo biosynthesis of unnatural natural products will require
that constituent enzymes have reengineered or broad specificity. Notably, directed
evolution has been successfully used to alter enzyme specificity. However, enzyme-
engineering efforts are greatly enhanced if protein structure is known and the
mechanism is well understood. Then, the enzyme can be subjected to structure-guided
techniques, such as site-directed mutagenesis and domain swapping, which create
smaller protein libraries enriched with functional mutants.
Halogenation-particularly fluorination-is a typical lead editing strategy 28
Despite its value, chemical halogenation often suffers from low regio- and
stereospecificity and is oftentimes non-catalytic. 27 Moreover, these reactions require
harsh, anhydrous reactions conditions.27 Notably, however, Halex reactions can be
performed at room temperature, but still require anhydrous reaction conditions. For
these reasons, enzymatic fluorination is highly attractive as it presumably would require
only the addition of simple salts, and the reaction can be run under aqueous
conditions.27,28 Though fluoride ions are potent nucleophiles, they are tightly solvated by
water, which makes them effectively inert in aqueous media.29 The binding of substrate
SAM in the fluorinase (5'-fluoro-5'-deoxyadenosine synthase) from Streptomyces
cattleya-the only as yet characterized fluorinase-is predicted to desolvate fluoride and
enable fluoride's SN2 displacement of methionine on the SAM substrate.
No nucleophilic aromatic fluorinase has yet been reported. To the best of our
knowledge, no naturally occurring aromatic fluorometabolites have been reported either,
suggesting that the enzymatic repertoire for nucleophilic aromatic fluorination either does
not exist in nature or is very rare. Because of our interest in medicinally useful MIAs, we
include as a future challenge the development of a nucleophilic aromatic fluorinase that
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Figure 5.4: A. Design of Substrate Activated for Nucleophilic Aromatic Fluorination.
The Sigma complex suggests that electron withdrawing groups should be placed at
positions 6 and 4, which are ortho and para to position 7, respectively. Position 7 has
been selected as the position of fluorination because RebH-the well-characterized
enzyme we propose to reengineer-regioselectively chlorinates at that position,
though notably through an electrophilic aromatic substitution mechanism. B.
Enzymatic nucleophilic aromatic fluorination mechanism. The first step is
nucleophilic attack followed by a restoration of aromaticity. X represents a good
leaving group whereas A and B represent electron withdrawing groups.
accepts tryptamine 11, a direct MIA precursor. It is likely that if such an enzyme can be
engineered, early engineered versions would require tryptamine analogs strongly
activated for nucleophilic aromatic substitution (Figure 5.4). Therefore, we propose as
one possible strategy the synthesis of a tryptamine analog with a good leaving group at
position 7 (the proposed site of fluoride substitution), and strong electron withdrawing
groups at positions 6 and 4, which are para and ortho to position 7, respectively, to help
distribute the negative charge upon nucleoplhilic attack (Figure 5.4). After synthesizing a
library of activated tryptamine analogs, RebH-a 7-tryptophan chlorinase that operates
via electrophilic aromatic substitution-would need to be reengineered to function
instead via nucleophilic aromatic substitution to accept these substrates. Alternatively,
since the structure and mechanism of 5'-fluoro-5'-deoxyadenosine synthase are known
and relatively well understood, it may be plausible to reengineer this fluorinase to accept
non-native, aromatic substrates.
As we seek further to convert plants and microbes into the chemical factories to
meet our medicinal needs, we should remember that, although many plant natural
products are bioactive and serve as important lead compounds, they often require
modification before making it to the clinic. Therefore, the forward engineering of
"unnatural" or "new-to-nature" natural products must also be a grand challenge if plant
natural products are to be shuttled from the annals of human tradition into the drug
development programs and clinics of tomorrow.
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Candidate 1786 open reading frame sequence from clone
ATGCAGATCATAACTTGCAAGGCTGTGGTGTGCTGGGCGGCCGGAGAGCCACCGGTGGT
TGAGGAGATACTGGTAGAACCTCCGAGGTCAGGCGAAGTCAGGATTAAGATTTTGTTTG
CTAGTCTTTGCCACACTGATGTCCTCGCCTGCAAGGGCTTCCCAACGCCCATGTTTCCT
CGAGTTCTGGGACATGAAGGTGTCGGCGTGGTGGAGTGTGTGGGTGAAGGAGTTTCAGA
ACTGAGAGAGGGAGACGTGGTGATCCCCACATACTTGGGAGAATGCGGAGAATGTGAGA
ATTGTGAGTCAGGAAGAACGAATCTATGCCGAACTTACCCTTTGCAAGCATTCACAGGC
TTAATGCCTGATGGTTCCTCAAGAATGTCTTCCGCCAAAGGAGGGGAAATGTTGTACCA
ATTCCTTAGCTGCTCCACTTGGTCTGAGTATACTGTTATTGACGCCAACTATGCCGTGA
AGATAGACTCCAGAATACCTCTGCCCCATGCTAGCTTCCTTTCTTGCGGCTTCACCACT
GGGTTTGGGGCAACCTGGAAGGAAGCCAAGCTTCAAGAGGGATCCAGCACCGTTGCTGT
TCTGGGTCTTGGGGCAGTTGGACTTGGAGCTGTGGAGGGAGCTCGAGTGCAGGGAGTAA
CTCAAATAATAGGAATAGACATTAACGACAACAAACGTGAGAAAGGAGAAGCCTTCGGA
ATGACTCATTTCATCAACCCCAAAAAAGATAATAATAAATCCATTTCAGAATTAGTTAA
AGAGTTAACAAAAGGACAAGGTGTGGACGTCTGTTTTGAATGCACGGGAGTCCCTGACT
TGGTTAATGAAGCTCTTGAATCCACAAAGATCGGAACAGGAAATATGATAATGCTAGGA
GCAGGAACCCAGAAAAGCATGACCATAAACTTCGTTTCACTATTGGGCTGCAGAACTTT
CAAGTATTCTGTTTTCGGCGGGGTTAAGGTCCAATCCGACCTTCCTCTCATTATTCAGA
AATGCTTAAATAAGGAAATACAGAAAATTGAGCAGCTTTTAACTCATCAAGTTCAACTG
GAAGACATAAATAGAGCCTTTGAGCTGCTTAAGGAACCTGATTGCGTGAAGGTTCTCAT
CACATTGTGA
Candidate 1786 protein sequence
M Q I I T C K A V V C W A AGE PPVVEE I LVEPPRS
G E V R I K I L F A S L C H T D V L A C K G F P T P M F P R
V L G HE G V G VV E CV GE G VS EL RE GD V VIP T Y
LGECGECENCESGR TNL CR TY P LQ AFTGLM
P D G S S R M S S A K G G E M L Y Q F L S C S T W S E Y T V
I D A N Y A V K I D S R I P L P H A S F L S C G F T T G F G
A T W K E A K L Q E G S S T V A V L G L G A V G L G A V E G
A R V Q G V T Q I I G I D I N D N K R E K G E A F G M T H F
I N P K K D N N K S I S E L V K E L T K G Q G V D V C F E C
T G V P D L V N E A L E S T K I G T G N M I M L G A G T Q K
S M T I N F V S L L G C R T F K Y S V F G G V K V Q S D L P
166
L I I Q K C L N K E I Q K I E Q L L T H Q V Q L E D I N R A
F E L L K E P D C V K V L I T L Stop
Residues predicted to be involved in zinc binding are shown in red, bolded and
underlined.
Candidate 26 open reading frame sequence from clone
ATGGCCGCCATGGGTACCTCGGAAAAATATGCAGTTGTTACGGGATCAAACAAAGGTAT
TGGATTTGAAACCTGCAAGAAATTGGCTTCTCAAGGGATCACTGTGGTCCTTACTGCTA
GAGATGAAAAAAGAGGGCTCGATGCTCTTGAGAAGCTCAAAGAATTGGGTCTCTCTGGT
AAGGTGCTATTTCATCAGCTTGATGTGACCGATTCATCCAGCGTTGCTTCCCTTGCAGA
ATTTGTCAAGAAACAATTTGGAAGACTTGATATCTTGGTAAACAATGCAGGGGTTAATG
GAGTGATTACTGATGTTGAAGCTGTGAAAAAGCTAAATCCTGCAGAAGATCCGGCCGAT
GTCGACTTTAGCAAGATATACAAGGAAACATATGAGTTGGCTGAAGAATGCATTCAAAT
TAACTACTTTGGAACAAAAAGAACCACTGATGCACTTCTTCCTCTTCTCCAATTATCTG
CATCACCAAGAATCGTAAATATTTCCTCCATCATGGGACAGTTAAAGAACATACCAAGT
GAATGGGCTAAAGGAATCCTGGGAGATGCTAGCAACCTCACAGAAGATAGATTGGATGA
GGTGATCAATAACTTCTTGAAGGACTTCAAGGAAGGATCCCTTGCAGCTAAGGGATGGC
CTCCATCCTTTTCAGCTTATATAGTCTCAAAAGTTGTGGTGAATGCCTACACAAGAATT
CTGGCCAAGAAGTATCCCAATTTCAAGATCAATTGTGTTTGTCCAGGGTTTGCCAAGAC
AGATTTGAATCATGGCTTAGGCTTATTAACTGCAGAAGAAGCTGCTGAAAACCCTGTGA
AACTCGCTTTGCTGCCTGATGATGGTCCTTCGGGTTTGTTCTTTGATCGCAGCGAGGAG
TCATCGTTTGAATGA
Candidate 26 protein sequence
M A A M G T S E K Y A V V T G S N K G I G F E T C K K L A S
Q G I T V V L T A R D E K R G L D A L E K L K E L G L S G K
V L F H Q L D V T D S S S V A S L A E F V K K Q F G R L D I
L V N N A G V N G V I T D V E A V K K L N P A E D P A D V D
F S K I Y K E T Y E L A E E C I Q I N Y F G T K R T T D A L
L P L L Q L S A S P R I V N I S S I M G Q L K N I P S E W A
K G I L G D A S N L T E D R L D E V I N N F L K D F K E G S
L A A K G W P P S F S A Y I V S K V V V N A Y T R I L A K K
Y P N F K I N C V C P G F A K T D L N H G L G L L T A E E A
A E N P V K L A L L P D D G P S G L F F D R S E E S S F E
Stop
Candidate 4319 open reading frame sequence from clone
ATGGCCAGAAAATCACCAGAAGATGAACATCCCGTGAAGGCTTACGGATGGGCCGTCAA
AGATGGAACAACTGGAATTCTTTCTCCCTTCAAATTTTCCATAAGGGCAACAGGTGATA
ATGATGTTCGAATCAAGATCCTCTATTGTGGAGTTTGTCGTACCGATCTTGCGGCAACC
AAGAACGCATTCGGGTTTCTTTCTTATCCTCTTGTGCCTGGTAGAGAGATCGTGGGAAT
167
AGTGAGCGAGATAGGGAAAAATGTGAAAAAAGTTAAAGTTGGAGAAAAAGTTGGAGTAG
CCCCGCATGTGGGTAGCTGTGGCAAATGCAAGAGTTGTGTGAATGAGGTGGAGAATTTC
TGTCCGAAACTGATCATCCCTTATGGCACCCCATACCACGATGGTACTATTTGCTACGG
TGGTTTCTCCAACGAGACTGTCAGAGATGAACGCTTTGTTTTTCGTTTTCCTGAAAATC
TTTCGCTGCCTGGCGGAGCTCCCTTGGTTAGTGCTGGGGTTACCACGTACGGTGCATTG
AGAAATAATGGCCTCGACAAGCCCGGATTACACGTGGGAGTCGTCGGTCTAGGTGGACT
AGGTCATCTGGCTGTTAAATTTGCTAAGGCTTTAGGCGTCAAAGTAACTGTTATTAGTA
CCAATCCTAGCAAGGAGCATGATGCTATAAATGGTTTCGGTGCTGATGCCTTCATCCTC
ACCCACCATGAGGAACAAATGAAGGCTGCCATGGGAACTTTAGATGGAATTCTTTATAC
AGTGCCTGTTGTTCATGCCATTGCACCATTACTTAGTCTACTGGGAAGTCAAGGGAAAT
TTGTGTTGATTGGGGCACCATCTCAATTACTTGAGGTGCCACCTATTCAATTATTATTT
GGTGGAAAATCTATTATTGGAAGTGCGGCTGGAAATGTGAAGCAAATCCAAGAAATGCT
TGAATTTGCAGCAAAACATGATATAATTGCGAATGTTGAGATTATCCAAATGGATTATA
TAAATACTGCAATGGAACGTCTAGACAAAGGTGATGTTAGATATCGATTTGTAATTGAT
ATCGAAAACTCTCTCACTCTTCCATCAGAGGTGTGA
Candidate 4319 protein sequence
MARKS PE DEHPVK A Y G W A V K D G T T G I L S P F
K F S I R A T G D N D V R I K I L Y C G V C R T D L A A T K
N A F G F L S Y P L V P G R E I V G I V S E I G K N V K K V
K V G E K V G V A P H V G S C G K C K S C V N E V E N F C P
K L I I P Y G T P Y H D G T I C Y G G F S N E T V R D E R F
V F R F P E N L S L P G G A P L V S A G V T T Y G A L R N N
G L D K P G L H V G V V G L G G L G H L A V K F A K A L G V
K V T V I S T N P S K E H D A I N G F G A D A F I L T H H E
E Q M K A A M G T L D G I L Y T V P V V H A I A P L L S L L
G S Q G K F V L I G A P S Q L L E V P P I Q L L F G G K S I
I G S A A G N V K Q I Q E M L E F A A K H D I I A N V E I I
Q M D Y I N T A M E R L D K G D V R Y R F V I D I E N S L T
L P S E V Stop
Candidate 5743 open reading frame sequence from clone
ATGACCAAGACCAATTCCCCTGCTCCTTCTGTCATCACTTGCAAAGCTGCTGTGGTATG
GAAATCAGGGGAGCCACCAAAGGTGGAAGAGATACAAGTTGATCCACCAAAGGCCTCAG
AAGTTAGGATTAAGATGCTTTGTGCCAGTTTGTGCCACACTGATTTCCTTGCCTGCAAT
GGCCTTCCTGTTCCATTGTTCCCTCGCATTCCTGGACACGAAGGAGTCGGAATGATCGA
GAGCGTTGGAGAAAATGTTACGAACCTAAAAGAAGGAGACATAGTGATGCCACTTTACT
TGGGAGAATGTGGGGAATGCTTGAATTGCAAATCAGGAAGGACAAATTTGTGCCACAAA
TATCCTTTAGGTTTTAGTGGATTATTGCTTGATGGAACATCAAGAATGTCAATTGGAGA
GCAAAAAGTATATCACCATTTCAGCTGTTCGACATGGTCAGAGTATATAGTGATTGAAG
CAGCTTATGCAGTGAAGGTAGATCCAAGGGTTTCTCTTCCACATGCTAGCTTTCTTTGC
TGTGGATTCACCACTGGTTTTGGTGCTACTTGGAGAGATGTCAATGTTGTCAAGGGCTC
TACTGTGGCTGTTCTAGGCCTTGGTGCTGTTGGACTTGGGGCTGTGCAAGGAGCTAAAT
CACAAGGAGCATCAAGAATTATAGGTTTGGATATCAACGACAAGAAACGTGAAAAGGGA
GAAGCATTTGGAATGACTGAATTTATAAATCCAAAAGGTTCAAACAAATCAATTTCTGA
168
ACTAATAAATGAAGCAACTGGTGGATTAGGACTTGACTATGTCTACGAATGCACTGGAG
TTCCAGCTTTACTCAATGAAGCCATTGAATCCTCTAAAGTGGGACTTGGAACTGCAGTA
TTGATTGGGGCAGGACTTGAAACAAGTGGAGAAATCAAATTCATTCCTCTTCTGTGTGG
TAGAACTGTTAAAGGTTCAATTTATGGTGGAGTAAGACCTAAATCAGACCTCCCCACTT
TAATTGAAAAGTGCATAAACAAGGAAATTCCAATGGATGAACTAATGACTCATGAAGTT
TCATTGTCTGAGATAAACAAAGGATTTGAGTACCTTAAGCATCCTGATTGTGTCAAAGT
TGTTATCAAGTTCTAA
Candidate 5743 protein sequence
M T K T N S P A P S V I T C K A A V V W K S G E P P K V E E
IQ VDP PKASEVRIKML CASL CH TDFL ACNG
L P V P L F P R I P G H E G V G M I E S V G E N V T N L K E
GD I VMP L Y L GE C GE CL N C K S G R TN L C HK Y P
L G F S G L L L D G T S R M S I G E Q K V Y H H F S C S T W
S E Y I V I E A A Y A V K V D P R V S L P H A S F L C C G F
T T G F G A T W R D V N V V K G S T V A V L G L G A V G L G
A V Q G A K S Q G A S R I I G L D I N D K K R E K G E A F G
M T E F I N P K G S N K S I S E L I N E A T G G L G L D Y V
Y E C T G V P A L L N E A I E S S K V G L G T A V L I G A G
L E T S G E I K F I P L L C G R T V K G S I Y G G V R P K S
D L P T L I E K C I N K E I P M D E L M T H E V S L S E I N
K G F E Y L K H P D C V K V V I K F Stop
Residues predicted to be involved in zinc-binding are shown in red, bolded and
underlined.
Candidate 7220 open reading frame from clone
ATGGAGATTAATGTTGAAGTTGCTCCAGTAAGGTATGCAGTCGTTACTGGAGCAAACAA
GGGCATTGGTCTTGAGACTGTCCAACAGCTAGCAGCCTCAGGTGTGACTGTCGTGTTAA
CAGCTCGAAATGAGAAGAGAGGCATGGAGGCCACTTCTTTGCTGCATGAATCAGGTTTG
TCAAATGTAATTTTCCATCAGCTTGATGTTCAAGACAAAGAAAGCATCAAATCATTGGC
CGAGTTTATACAAAAAGAGTTTGGAAGACTTGACATTTTGGTAAATAATGCCGGTGCTT
CAGGAGTGGCAGTTGACAAAGATGGACTAAGGGCCTTAAATATAGACACTGCATCTTGG
TTAGCCGGAAAGGTTGTTAATGTGGTAGCTGATGTAATCAAAACTACATATGAAAAAGC
CAAAGAATGTCTGGAGACCAACTATTATGGTGTTAAGGATGTAACCGAAGCTCTTCTTC
CACTGCTGCAACTTTCAACTTCAGGAGCAAGGATTGTAAACGTCTCTTCTCTAAGGAGT
GAATTAAGTAGGATCCCTAACGAGCAAAGAAGAAAAGTACTAGCGGATATTGAGACTCT
AACAGAAAACAAAATCAATGAGATTCTTCAACAGTTTTTGCATGATCTGAAGCATGATG
CTTTAGAAGCAAACGGATGGCAAAAGATGTTGCCGGCCTACAGCATATCAAAAGCAACA
CTTAATGCTTATACAAGAATTCTTGCAAAGAAGTATCCTCATATGTGTATAAACTGTGT
TCATCCGGGATATGTTAACACAGACATCAATTGGCATACAGGACCATTGCCGGTGGAAG
AGGGAGCTGCCGGACCTGTTATGCTGGCTCTTCTACCAGAAGGAGGTCCTACTGGTTGC
TACTTTGATCAGACAAAACTATCCGAGTTTTGA
Candidate 7220 protein sequence
169
M E I N V E V A P V R Y A V V T G A N K G I G L E T V Q Q L
A A S G V T V V L T A R N E K R G M E A T S L L H E S G L S
N V I F H Q L D V Q D K E S I K S L A E F I Q K E F G R L D
I L V N N A G A S G V A V D K D G L R A L N I D T A S W L A
G K V V N V V A D V I K T T Y E K A K E C L E T N Y Y G V K
DV TE AL L P L L Q L ST S GA RI VN V S S L R SE L S
R I P N E Q R R K V L A D I E T L T E N K I N E I L Q Q F L
H D L K H D A L E A N G W Q K M L P A Y S I S K A T L N A Y
T R I L A K K Y P H M C I N C V H P G Y V N T D I N W H T G
P L P V E E G A A G P V M L A L L P E G G P T G C Y F D Q T
K L S E F Stop
Candidate 8694 open reading frame from clone
ATGACGTCGTCATCCTCGCCGTCGCCGTCGCCGTTGAAGGGAAAAGCTGTGGATAAAGA
CGGCGATCACAAGGTGAAGAAGAAAGAGGCATTAGGATGGATGGAGTGGCTTAGAGGAT
GGATGTATATAGTGTACGAAATGCTGTTCCAGCGGATCATGGCCAGTCATTTATCTAAT
CCAATGCCTCTTCCGCCTCTGAATGAGCTTACTTTTGTAGTCACCGGCTCCACCAGCGG
TATTGGCCGCGAAATCGCCCGTCAATTGGCAGAGTCCGGCGGGCACGTGATAATGGCTG
TTAGAAATACCAAGGCAGCTAATGAATTAATTCGCAAATGGCAAGAGGAATGGTCTGGT
CGCGGACTACCTCTTAATATTGAGGTGATGGAGCTGGATCTTCTATCATTGGATTCGGT
TGTGAGATTTGCTGAGGCATTTAACGCACGTTCCGGACCTTTGAATGTGCTCATTAACA
ATGCTGGCATATTTTCAATCGGAGAACCACAGAGGTTTTCAAAGGATGGTTATGAAGAA
CACCTGCAAGTGAATCATCTAGCTCCAGCACTGTTGTCTATATTGCTCTTACCTTCTCT
TATTAGAGGCTCTCCAAGCCGAATAGTTAATGTGAACTCTATAATGCATTATGTTGGAT
TTGTTGATACGGAAGATATGAATGTTACATCTGGGAGAAGAAAGTACAGCAGTTTAGTT
GGATACTCTGGCAGCAAACTGGCAGAGGTGATGTTCAGTAGTGTCCTGCACAAACGGCT
GCCTGCCGAATCTGGCATAAGTGTACTATGCGTATCGCCTGGAATAGTACACACAAATG
TGGCTAGGGATCTTTCAAAAATTGTTCAAGCTGCTTATCATCTAATTCCCTATTTTATT
TTTAGTCCTGAAGAAGGCTCTAGAAGCGCACTTTTTGCAGCTACAGATCCACAAGTTCC
GGAGTACACTGAGATGTTAAAAGCAGATGAGTGGCCAGTTTGTGCTTTCATATCTCAAG
ATTGCCGTCCAACAAATCCATCTGAAGAAGCACATAATGTTGAAACTTCTTACAAAGTC
TGGGAGAAGACCTTGGAAATGGTTGGACTTCCATCAGATGTTGTGGAGAAGCTTATAGA
AGGGGAAGAAGTTAAATGCAGATATGGGGCTTCTCAAGAGTAA
Candidate 8694 protein sequence
M T S S S S P S P S P L K G K A V D K D G D H K V K K K E A
L G W M E W L R G W M Y I V Y E M L F Q R I M A S H L S N P
M P L P P L N E L T F V V T G S T S G I G R E I A R Q L A E
S G G H V I M A V R N T K A A N E L I R K W Q E E W S G R G
L P L N I E V M E L D L L S L D S V V R F A E A F N A R S G
P L N V L I N N A G I F S I G E P Q R F S K D G Y E E H L Q
V N H L A P A L L S I L L L P S L I R G S P S R I V N V N S
I M H Y V G F V D T E D M N V T S G R R K Y S S L V G Y S G
S K L A E V M F S S V L H K R L P A E S G I S V L C V S P G
I V H T N V A R D L S K I V Q A A Y H L I P Y F I F S P E E
G S R S A L F A A T D P Q V P E Y T E M L K A D E W P V C A
170
F I S Q D C R P T N P S E E A H N V E T S Y K V W E K T L E
M V G L P S D V V E K L I E G E E V K C R Y G A S Q E Stop
Candidate 2041 open reading frame from clone
ATGGGATACTACCATTATTATATTAGACAACCACTCACCACTGACCAATTGGTTTTATC
TCTTCCTTCTATAATGGCAGTTCCATCGGCAGAAACAGCAAAGACAATCGAGGCCTATG
GATGGGCAGCCAGAGACTCATCTGGGCTTCTCTCTCCCTTCAAGTTCCAGAGACGGGCC
ACAACGGAGCATGATGTCCAGCTCAAAATATTGTATTGTGGGATGTGCGATTGGGATCT
ACATGTAGTCAAGAATTGGTTTGGCACCACCAACTATCCCATTGTACCTGGGCACGAGG
CAGTGGGCGTGGTGACTGAAATCGGCAACAAGGTACAGAAATTCAAGATTGGGGACATA
GTAGGCGTTAGTACTTACATTCGAACATGTCGGAGCTGCGAGAGATGTAAAGAAGGTGA
AGACAGTTACTGTCCCAGCTTAATAACAGGAGATGGAACTTCATTTAGTGATGGAAAAG
ATGCATTTTTCTATGATCCAAATGATGATAATACAAAAGAGACAACAAAAACATATGGC
TCATATTCCAATTTCACAGTTGTGGATGAATATTACGTTATTCGTTGGCCAGAAAACTT
TCCTTTGGCTGCTGGAGTACCTCTTCTTTGTGCTGGTACAGTTCCTTATAGTCCAATGA
GGCACTTTGGATTTGATAAACCTGGAATTCATATTGGTGTGGTTGGATTTGGTGGGATT
GGCAAATTAGTTGTTAAATTTGCTAAGGCTTTTGGAGTTAAAGTAACAGTGATTAGTAC
CTCCATTGATAAGAAGCATGAAGCTATTCATGAATATGGTGCTCATGGATTCTTACTCA
GCAAAGAACCTCAGCAGCTTCAGGCTGCTATTAATACTATGGAAGGTATAGTTGATACA
GTTCCTAAAGTTCACCCTATTCTTCCATTGATCAAATTGTTGAAATTCGATGGTACCCT
TCTTATGCTCGGAGCACCGCCGGAGCCATATGAGTTTCCAATCTCCACATTGCTTATGG
GGAGGAAGAGGGTGGTGGGAAGTGCTGGAGCGAGCATGAAGGAAACACAAGAAATGATG
GATTTTGCAGCGAAGCACAACATAGTTGCAGATGTTGAATTAAACCTCAGCAAGCTTGC
GGCCGCACTCGAGCACCACCACCACCAACCACTGAGATCCGGCTGCTAA
Candidate 2041 protein sequence
M G Y Y H Y Y I R Q P L T T D Q L V L S L P S I M A V P S A
E T A K T I E A Y G W A A R D S S G L L S P F K F Q R R A T
T E H D V Q L K I L Y C G M C D W D L H V V K N W F G T T N
Y P I V P G H E A V G V V T E I G N K V Q K F K I G D I V G
V S T Y I R T C R S C E R C K E G E D S Y C P S L I T G D G
T S F S D G K D A F F Y D P N D D N T K E T T K T Y G S Y S
N F T V V D E Y Y V I R W P E N F P L A A G V P L L C A G T
V P Y S P M R H F G F D K P G I H I G V V G F G G I G K L V
V K F A K A F G V K V T V I S T S I D K K H E A I H E Y G A
H G F L L S K E P Q Q L Q A A I N T M E G I V D T V P K V H
P I L P L I K L L K F D G T L L M L G A P P E P Y E F P I S
T L L M G R K R V V G S A G A S M K E T Q E M M D F A A K H
N I V A D V E L N L S K L A A A L E H H H H Q P L R S G C
Stop
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0 Substrate
Hexanes: EtOAc (1:1)
Figure A.1 - No NAD(P)+ and no enzyme controls. No product formation is
observed when either enzyme or NAD(P)+ is missing from the assay mixture.
Candidates
Product
Substrate
Hexanes: EtOAc (1:1)
Figure A.2 - No zinc controls. Product formation is still observed when zinc is
omitted from the reaction, suggesting zinc binds during protein folding.
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Candidates
Product
4- Substrate
Hexanes: EtOAc (1:1)
Figure A.3 - Chelator controls. 1 mM EDTA was added to the assay mixture and
zinc was omitted. Product formation is only quelled with the Candidate 1786-
NADP+ assay, suggesting the zinc binds less tightly under those conditions.
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Figure A.4: Authentic standard of 10-hydroxygeraniol oxidoreductase substrate
10-hydroxygeraniol 8.
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Figure A.5: GC-MS chromatogram of 10-hydroxygeraniol authentic standard. 10-hydroxgeraniol is the substrate
for 10-hydroxygeraniol oxidoreductase.
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Figure A.6: Mass spectrum of 10-hydroxygeraniol authentic standard.
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Figure A.7: GC-MS chromatogram of 10-oxogeranial authentic standard. 10-oxogeranial is the enzymatic product of 10-
hydroxygeraniol oxidoreductase.
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Figure A.8: Mass spectrum of 10-oxogeranial authentic standard.
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Figure A.9: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 1786 and
cofactor NAD+. The peak that co-elutes with the authentic 10-oxogeranial standard is highlighted in purple.
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Figure A.10: Mass spectrum of highlighted peak from Candidate 1786
spectrum of authentic 10-oxogeranial enables positive assignment.
and cofactor NAD+ assay. Similarity to the mass
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Figure A.11: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 1786 and
cofactor NAD+ without the addition of ZnCl2 to the assay mixture. The peak that co-elutes with the authentic 10-
oxogeranial standard is highlighted in purple.
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Figure A.12: Mass spectrum of highlighted peak from Candidate 1786 and cofactor NAD+ assay when ZnCl2 is omitted from
the assay mixture. Similarity to the mass spectrum of authentic 10-oxogeranial enables positive assignment
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Figure A.13: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 1786 and
cofactor NAD+ when EDTA to a final concentration of 1 mM was added to the reaction mixture and ZnCl2 was omitted.
The peak that co-elutes with the authentic 10-oxogeranial standard is highlighted in purple.
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Figure A.14: Mass spectrum of highlighted peak from Candidate 1786 and cofactor NAD+ assay when EDTA is
added to a final concentration of 1 mM in the assay mixture and ZnCl2 is omitted. Similarity to the mass spectrum
of authentic 10-oxogeranial enables positive assignment.
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Figure A.15: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 1786 and
cofactor NADP+. The peak that co-elutes with the authentic 10-oxogeranial standard is highlighted in purple.
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Figure A.16: Mass spectrum of highlighted peak from Candidate 1786 and cofactor NADP+ assay. Similarity to the
mass spectrum of authentic 10-oxogeranial enables positive assignment.
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Figure A.17: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 1786 and
cofactor NADP+ without the addition of ZnCl2 to the assay mixture. The peak that co-elutes with the authentic 10-
oxogeranial standard is highlighted in purple.
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Figure A.18: Mass spectrum of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 1786+ and cofactor
NAD when ZnCl2 was omitted from the reaction. The peak that co-elutes with the authentic 10-oxogeranial standard is
highlighted in purple.
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Figure A.19: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screening with Candidate 1786 and
cofactor NADP+ when EDTA to a final concentration of 1 mM was added to the reaction mixture and ZnCI2 was omitted. The
peak that co-elutes with the authentic 10-oxogeranial standard is highlighted in purple.
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Figure A.20: Mass spectrum of highlighted peak from Candidate 1786 and cofactor NAD+ assay when EDTA is added to
a final concentration of 1 mM and ZnCl2 is omitted. Similarity to the mass spectrum of authentic 10-hydroxygeraniol
enables positive assignment as starting substrate, not product.
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Figure A.21: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 1786 in the absence of
either NAD+ or NADP+. No peak co-elutes with the authentic 10-oxogeranial standard; the region of 10-oxogeranial elution is
highlighted in purple.
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Figure A.22: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 26 and
cofactor NAD+. No peak co-elutes with the authentic 10-oxogeranial standard; the region of 10-oxogeranial elution is
highlighted in purple.
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Figure A.23: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 26 and cofactor
NADP+. The peak that co-elutes with the authentic 10-oxogeranial standard is highlighted in purple.
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Figure A.24: Mass spectrum of highlighted peak from Candidate 1786 and cofactor NADP+ assay. Similarity to the
mass spectrum of authentic 10-oxogeranial enables positive assignment.
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Figure A.25: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 26 and cofactor
NADP+ without the addition of ZnCl2 to the assay mixture. The peak that co-elutes with the authentic 10-oxogeranial standard
is highlighted in purple.
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Figure A.26: Mass spectrum of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 26 and cofactor NADP+
when ZnCl2 was omitted from the assay mixture. Similarity to the mass spectrum of authentic 10-oxogeranial enables positive
assignment.
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Figure A.27: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 26 and cofactor
NADP+ when EDTA to a final concentration of 1 mM was added to the reaction mixture and ZnCl2 was omitted. The peak
that co-elutes with the authentic 10-oxogeranial standard is highlighted in purple.
r77#1
C
10000
10'? logo 1085 109D 1 1100 11, 1110 Ills
2Candidate 26 - NADP
EDTA + No ZnCl Control
(highlighted peak)
712
10-oxogeranial
M/z
Figure A.28: Mass spectrum of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 26 and cofactor
NADP+ when ZnCl2 was omitted from the assay mixture. Similarity to the mass spectrum of authentic 10-
oxogeranial enables positive assignment.
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Figure A.29: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 26 in
the absence of either NAD+ or NADP+. No peak co-elutes with the authentic 10-oxogeranial standard; the region
of 10-oxogeranial elution is highlighted in purple.
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Figure A.30: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 4319 and
cofactor NAD+. No peak co-elutes with the authentic 10-oxogeranial standard; the region of 10-oxogeranial elution is
highlighted in purple.
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Figure A.31: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 4319 and
cofactor NADP+. No peak co-elutes with the authentic 10-oxogeranial standard; the region of 10-oxogeranial elution is
highlighted in purple.
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Figure A.32: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 5743 and
cofactor NAD+. The peak that co-elutes with the authentic 10-oxogeranial standard is highlighted in purple.
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Figure A.33: Mass spectrum of highlighted peak from Candidate 5743 and cofactor NADP+ assay. Similarity to the mass
spectrum of authentic 10-oxogeranial enables positive assignment.
I
8
C
'U
A
0
10-oxogeranial
ill
II
I I
1
02
1 V, IIIa 1 1
'It
7 IL IRII i1LV l~2~*2 ~
Is - --- - -
I
llt?,111
lb -lb- - - -,&- - - - lk it - JO--- - -, , Ito * ' , , '06
,rn
6I
C
1"
Candidate 5743 - NAD
No ZnCl 2 control
ve 14,15 fn M
Time (min)
Figure A.34: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 5743 and
cofactor NAD+ without the addition of ZnCl2 to the assay mixture. The peak that co-elutes with the authentic 10-
oxogeranial standard is highlighted in purple.
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Figure A.35: Mass spectrum of highlighted peak from Candidate 5743 and cofactor NAD+ assay when ZnCl2 is
omitted from the assay mixture. Similarity to the mass spectrum of authentic 10-oxogeranial enables positive
assignment.
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Figure A.36: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 5743 and
cofactor NAD+ when EDTA is added to a final concentration of 1 mM and ZnCl2 is omitted from assay mixture. The peak that
co-elutes with the authentic 10-oxogeranial standard is highlighted in purple.
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Figure A.37: Mass spectrum of highlighted peak from Candidate 5743 and cofactor NAD+ assay when EDTA is added to a
final concentration of 1 mM and ZnCl2 is omitted from the assay mixture. Similarity to the mass spectrum of authentic 10-
oxogeranial enables positive assignment.
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Figure A.38: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 5743 and
cofactor NADP+. The peak that co-elutes with the authentic 10-oxogeranial standard is highlighted in purple.
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Figure A.39: Mass spectrum of highlighted peak from Candidate 5743 and cofactor NADP+ assay. Similarity to the mass
spectrum of authentic 10-oxogeranial enables positive assignment.
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Figure A.40: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 5743 and
cofactor NADP+ when ZnC12 is omitted from the assay mixture. The peak that co-elutes with the authentic 10-
oxogeranial standard is highlighted in purple.
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Figure A.41: Mass spectrum of highlighted peak from Candidate 5743 and cofactor NADP+ assay when ZnC12 is omitted
from the assay mixture. Similarity to the mass spectrum of authentic 10-oxogeranial enables positive assignment.
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Figure A.42: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 5743 and
cofactor NADP+ when EDTA is added to a final assay concentration of 1 mM and ZnCI2 is omited. The peak that co-elutes
with the authentic 10-oxogeranial standard is highlighted in purple.
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Figure A.43: Mass spectrum of highlighted peak from Candidate 5743 and cofactor NADP+ assay when EDTA is added to
the assay mixture to a final concentration of 1 mM and ZnCl2 is omitted. Similarity to the mass spectrum of authentic 10-
oxoeeranial enables nositive assignment.
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Figure A.44: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 5743 in the
absence of either NAD+ or NADP+. No peak co-elutes with the authentic 10-oxogeranial standard; the region of 10-
oxogeranial elution is highlighted in purple.
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Figure A.45: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screen with Candidate 7220 and
cofactor NAD+. No peak co-elutes with the authentic 10-oxogeranial standard; the region of 10-oxogeranial elution is
highlighted in purple.
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Figure A.46: GC-MS chromatogram of 10-hydroxygeraniol oxidoreductase candidate screening with Candidate 7220 and
cofactor NADP+. The peak that co-elutes with the authentic 10-oxogeranial standard is highlighted in purple.
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Figure A.47: Mass spectrum of highlighted peak from Candidate 7220 and cofactor NADP+ assay. Similarity to the
mass spectrum of authentic 10-hydroxygeraniol enables positive assignment as starting substrate, not product.
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Figure A.48: No enzyme control with NAD+ cofactor. No 10-oxogeranial product is observed. The single peak shown
co-elutes with substrate 10-hydroxygeraniol.
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Figure A.49: Mass spectrum of no enzyme control with cofactor NAD+. Averaging of the single peak in the GC-MS
chromatogram displays a mass spectrum signature consistent with 10-hydroxgeraniol, the substrate.
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Figure A.50: No enzyme control with NADP+ cofactor. No 10-oxogeranial product is observed. The single peak
shown co-elutes with substrate 10-hydroxygeraniol.
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Figure A.51: Mass spectrum of no enzyme control with cofactor NADP+. Averaging of the single peak in the GC-MS
chromatogram displays a mass spectrum signature consistent with 10-hydroxgeraniol, the substrate.
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Certificate in Teaching College Science and Engineering
Teaching and Learning Laboratory (MIT)
Diversity training - Reducing Stereotype Threat
Professor Catherine Drennan's Howard Hughes Medical Institute
Professor's Program
Middle School Counselor
Office of Engineering Outreach Programs (MIT)
General Chemistry (5.111) Teaching Assistant
Hampton University
6/2008-7/2008
6/2008-7/2008
6/2008-7/2008
9/2005-8/2008
9/2005-12/2005
Mentor to High School Science Student
Laboratory of Professor Shanthi Paranawithana
Organic Chemistry Laboratory Teaching Assistant
Middle school counselor for the "Young Doctors' Program"
General Chemistry and Organic Chemistry Tutor
Elementary School Tutor
Read: For the Future
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